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ABSTRACT 
Prostate cancer is the most rampant diagnosed cancer and the second leading cause 
of cancer related death in men between middle age and old age. There is a need to 
identify the molecular genetic processes that underpin prostate cancer and to search 
for new treatments. Alternative splicing affects over 94% of human genes and aberrant 
splicing is implicated in prostate cancer. Splicing is regulated by splice factors and 
protein kinases (the latter including SRPK1 and CLK1). The CLK1 protein kinase 
specifically regulates alternative splicing by phosphorylation of SR proteins within the 
nucleus, particularly in nuclear speckles (splice factor storage sites). CLK1 is also 
found to be overexpressed during malignant prostate cell transformation-; therefore 
targeting the splice factor kinase CLK1 by its specific chemical inhibitor (TG003) could 
be therapeutically useful. We confirm that CLK1 expression is itself regulated through 
alternative splicing: skipping of exon 4 or retention of intron 4 results in truncated, 
inactive CLK1. The aims of this project are to study CLK1 alternative splicing and to 
explore the effects of targeting the splice factor kinase CLK1 in prostate cancer. 
Prostate cancer cell lines (androgen independent PC3 and DU145 cells) were treated 
independently for 24, 48 and 72hrs with varying concentrations (10nM -100µM) of the 
benzothiazole compound (TG003) a specific inhibitor of CLK1. Results suggest that 
chemical inhibition of CLK1 with TG003 treatment suppressed growth and induced 
apoptosis in prostate cancer cell lines, as well as causing decreased cell migration 
and invasion. Similar effects were observed when CLK1 expression was reduced with 
an siRNA. There was also increased E-cadherin expression with TG003 treatment; in 
contrast, vimentin expression was reduced suggesting reversal of endothelial- 
mesenchymal transition following TG003 treatment. RT-PCR analysis revealed that 
TG003 treatment altered CLK1’s own splicing by altering exon 4 skipping rates in a 
iv 
 
dose dependent manner, suggesting that a feedback loop mechanism contributes to 
the regulation of CLK1 expression. In vivo mouse work with PC3 cell line xenografts 
showed a highly significant reduction in tumour growth and volume following 
intraperitoneal TG003 administration (10 and 50µM). In conclusion, the findings 
presented in this thesis suggest that targeting CLK1 may bring considerable 
anticancer benefits.   
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Introduction 
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1.1 Prostate cancer 
There are different forms of cancer including prostate cancer arising from several 
factors such as chemical, environmental, genetic, immunological, or factors of viral 
origin (David and Manley, 2010; Ghigna et al., 2008). Genetic and epigenetic changes 
that promote cancer also accumulate over a period of time (Lapuk et al., 2014). 
However, the causes of several forms of cancer (including prostate cancer) are still 
unclear (Kandoth et al., 2013; Augello et al., 2013). Prostate cancer incidence has 
increased dramatically. Apart from family history, one of the notable and strongest 
prostate cancer risk factors is age and ethnicity including African-American related 
races (Gann, 2002). These are discussed in detail in other sections. Prostate cancer 
is an increasing, devastating, deleterious and disastrous pathologic disorder affecting 
men with over twenty-nine thousand seven hundred and twenty death per annum in 
the western word (Siegel et al., 2013).  
Apart from skin cancer, in men between middle and old age, prostate cancer (PCa) is 
the most rampant diagnosed cancer and the second leading cause of cancer related 
mortality among men in the U.K and USA (Aragon and Dahut, 2009). In 2013, Siegel 
and her research team estimated that 238,590 men in the United States are likely to 
develop prostate cancer per annum and 29,720 will die from the disease (Siegel et al., 
2013). Prostate cancer is an age-dependent disorder manifesting generally from 
middle to older age (Watson and Watson, 2010). Other etiological factors that could 
contribute to prostate cancer risk are dietary fat intake, androgens, race, 
environmental (such as chemical exposure) and genetic factors (Watson and Watson, 
2010). These are further explained in subsequent sections. 
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Prostate cancer is usually confined to the prostate at the early stage of development. 
Surgery or radiation therapy could provide treatment at this stage. (Narla et al., 2005; 
Aragon et al., 2009; Drake et al., 2014), but the disease becomes too devastating and 
difficult to manage or cure at later metastatic stages. Prostate cancer in most cases 
grows very slowly at the initial stage of manifestation. At this stage it relies on androgen 
(male reproductive hormone that seem to fuel prostate cancer growth) to grow, that is 
why androgen deprivation/depletion therapy (castration) is beneficial for the treatment 
of early stage androgen dependent prostate cancer (Sha et al., 2013). However, the 
disease at the later stage transforms to androgen independent (castration resistance) 
impeding effective treatment (Wozney et al., 2014). Greater precision and accuracy in 
the diagnosis, detection and staging of the prostate cancer would help to ameliorate 
the devastating and deleterious effect of the disease (Aragon et al., 2009; Drake et al., 
2014).  
In the U.K. and other parts of the world, prostate cancer is frequently diagnosed when 
a patient is presenting with lower urinary tract symptoms (LUTS). However, there is 
possibility of a man suffering from detrusor instability (inability of the bladder muscles 
to control contraction) or Benign Prostatic Hyperplasia (BPH) resulting in presentation 
with poor urinary stream, hesitancy and urinary frequency (Verhamme et al., 2002). 
Prostate cancer is mostly asymptomatic at early stages as most of the prostate 
malignancies stem from the peripheral zone farther from the prostatic urethra. 
Symptomatic presentation is in most cases associated with prostate metastatic 
extension to the urethra, bladder neck, neighbouring tissues and glands (Pentyala et 
al., 2016; Litwin and Tan, 2017). Intermittent urinary flow, hesitancy, urinary stream 
slowing are the obstructive voiding symptoms of prostate malignancy especially during 
extension to the urethra and bladder neck (Litwin and Tan, 2017; Verhamme et al., 
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2002). Urgent and frequent urination pose the uncomfortable voiding symptoms 
though not specific to prostate cancer. With cancer progression, due to obstruction of 
the ejaculatory duct, sexual symptoms such as slow and low ejaculating volume, and 
haematospermia may be present. Extension of the prostate metastasis to the 
neurovascular bundles may lead to erectile dysfunction (Hamilton and Sharp, 2004). 
Furthermore, metastatic invasion of the skeleton may result to symptomatic bony 
pains, however, Gohiji et al., (2003) reported that osteoblastic metastases is frequently 
observed in majority of prostate cancer cases. Other possible symptoms are; vein and 
lymphatic vessel occlusion causing edema and anaemia due to bone marrow 
metastatic involvement. 
Due to the unprecedented prostate cancer increase across the world, prostate cancer 
researchers have focused their effort towards valuable and relevant research leading 
to new prostate cancer therapies. Prostate cancer survival rate has increased thanks 
to prostate cancer research. However, efforts need to be intensified towards 
developing new treatment options that could tackle prostate cancer metastases and 
progression with minimal or no adverse effect.  
There is a need to understand the molecular genetic principles that underpin prostate 
cancer in order to generate molecular minimal toxicity treatment to keep men safe from 
the devastating effect of prostate cancer. Before now, prostate cancer treatment 
options include, radiation therapy, surgery, chemotherapy, cryosurgery, hormonal 
therapy, dietary therapies such as tomatoes, low fat diets and others. These are 
discussed in subsequent sections. However, apart from dietary therapies, some of 
these treatment options possess some form of hazardous and cytotoxic effect (Chen 
and Zhao, 2013). For instance, radical prostatectomy, which is the surgical removal of 
the cancer affected prostate often goes with the surgery of the surrounding lymph 
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nodes such as pelvic lymphadenectomy which makes surgery a multimodal (non-
monotherapy) strategy with numerous associated side effect such as high PSA levels, 
risk of lymph node malignancy and exaggerated positive surgical margins 
(Lawrentschuk et al., 2010; Donnelly et al., 2010; chen and Zhao, 2013). Hormone 
therapy for prostate cancer treatment implies the starving of prostate cancer by 
withdrawal of androgen as androgen presence typically fuels the growth and 
metastases of prostate cancer. Androgen deprivation therapy (ADT) in combination 
with surgery seem to be effective and beneficial in the initial treatment of androgen 
dependent prostate cancer (Perlmutter and Lepor, 2007). Androgen deprivation 
therapy is a treatment for primary prostate cancer treatment but does not cure cancer 
when used as a monotherapy (Johnson et al., 2010). Commonly applied and combined 
chemotherapy for the treatment of advanced metastatic prostate cancer include 
doxorubicin, mitoxantrone, vinblastine, docetaxel, paclitaxel and others. Combination 
of these therapies has improved survival rate in most cases, but the adverse cytotoxic 
effect has not been overlooked (Tannock et al., 2004). Dietary modification is a double-
edged sword, while some diets could help to reduce prostate cancer risk, others could 
lead to increased risk of developing prostate cancer. For instance, high risks of 
prostate cancer can be averted by abstaining from high fat diets (Llaverias et al., 
2010).  
Current strategies for prostate cancer treatment also include immunotherapy; for the 
past few years immunotherapy has remained an essential strategic modality for 
prostate cancer treatment especially in combination with other strategies for optimal 
synergistic effect. Studies have reported optimal beneficial synergic effect of 
immunotherapies with cancer vaccines with minimal or no side effect. One of such 
benefits is the induction of immune response with huge long-lasting clinical outcome 
6 
 
without significant toxicity (Bilusic et al., 2017). In 2010, the U. S. Food and drug 
authority (FDA) approved the use of an immunotherapeutic drug- Sipuleucel-T 
(Dendreon Corp) for the treatment of mild symptomatic or asymptomatic castration 
resistant prostate cancer (Kantoff et al., 2010). Another improved treatment option is 
the use of high-intensity focused ultrasound (HIFU) for prostate cancer treatment. With 
HIFU average life expectancy and quality of life of men with prostate cancer has 
dramatically improved with a reduction in prostate cancer age detection and early 
diagnosis at the stage where curative treatment is possible (Chaussy and thuroff, 
2017). High-intensity focused ultrasound is a non-invasive strategy that employs 
accurate delivery of ultrasound energy to achieve tumour cell death in the absence of 
surgical excision or radiation. 
Furthermore, kinase inhibitors has been suggested to possess effective prostate 
cancer therapeutic strategy as demonstrated in xenografts. For instance. Wise et al., 
2017 demonstrated that loss of PTEN (tumour suppressor gene) function which leads 
to phosphoinositide 3-kinase (PI3K) dysregulation is associated with aggressive 
metastatic prostate cancer development thereby making PTEN a valuable prognostic 
prostate cancer biomarker to differentiate indolent tumour from the more likely 
prostatic tumours. BKM120 which is a pan-PI3K inhibitor has been used by Maira et 
al., (2012) to reduce in vivo prostate cancer (PC3) growth. SPHINX, an SRPK1 
inhibitor has been used by Mavrou et al., (2014) to drastically reduce tumour volume 
in prostate cancer induced nude mice. 
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1.1.1 Structure and function of the prostate gland 
The prostate is a male reproductive exocrine gland situated below the urinary bladder 
posterior to the rectum at the base of the penis (Gupta and McVary, 2017). The 
prostate gland secrets prostatic fluid stimulated by seminal vesicles which forms part 
of the semen that nourishes and protects the sperm cells during ejaculation (Levin, 
2018). The prostate gland also secretes a special protein PSA (Prostate Specific 
Antigen) which maintains the liquid state of the semen and is detectable in large 
amount in the blood stream after recent ejaculation and in disease conditions. One of 
such disease conditions is prostate cancer and BPH (Fung et al., 2004). By definition, 
prostate cancer is an uncontrolled continuous proliferative growth of the prostate gland 
(Torre et al., 2015).  
The prostate gland is a component of male urinary and reproductive system, spherical 
in shape and measuring about three centimetres thick and four centimetres in 
diameter. The prostate comprises of two lobes that winds around the urethra. During 
excretion, the urethra transports urine from the bladder to the penis through the 
prostate (Ayala et al., 1989; Wilson, 2014). Structurally, the prostate gland is made up 
of prostatic capsule which is a layer of connective tissue covering the prostate. Fibrous 
cells, muscle cells and gland cells constitute the cells of the prostate gland and are 
known to provide the gland’s structural support, control of ejaculation and urine flow 
and produce part of the semen fluid respectively. Other structures around the prostate 
are the seminal vesicles responsible for semen production, nerve bundles located on 
both sides of the prostate responsible for erectile function control, the vas deferens 
transports sperm to the seminal vesicles from the testes (Wilson, 2014). 
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There are three zones of the prostate gland which include the peripheral, transition 
and the central zones. At birth the peripheral zone is the largest zone of the prostate 
where about 75 percent of prostate tumours are localised, it is the site usually felt by 
clinicians during digital rectal examination (DRE) due to its proximity to the rectum. 
The transition zone is located in between the central and the peripheral zones at the 
middle of the prostate. Before the age of 40, the transition zone makes up about one-
fifth of the prostrate and enlarges proportionally with age until eventually becomes the 
largest part of the prostate at old age leading to benign prostatic hyperplasia (BPH) 
(Lee et al., 2011; Yacoub and Oto, 2018). The peripheral zone is being pushed to the 
rectum by this enlargement. The central zone is located frontal to the transition zone 
of the prostrate far from the rectum. Tumours in this zone cannot be diagnosed by 
DRE because of its distance from the rectum (Yacoub and Oto, 2018). 
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Figure 1.1. Skeletal diagram of the prostate gland. The peripheral zone (PZ), the transition zone 
(TZ) and the central zone (CZ) of the prostate are duly represented. The prostate gland is located at 
the base of the bladder. The urethra passes through the prostate. The peripheral zone is the largest 
zone of the prostate and constitute the site for digital rectal examination. Most prostate cancers are 
localised at the peripheral zone. The transition zone enlarges with age and later becomes the largest 
zone at old age. The central zone is located far from the rectum, tumours at the central zone cannot be 
diagnosed by digital rectal examination due to its distance from the rectum. 
 
1.1.2 Benign prostate hyperplaxia (BPH) and prostate cancer  
BPH is a non-metastatic enlargement of the prostate due to prostate cell hyperplasia 
(Dai et al., 2016). This is a rampant disorder of older and frail male population with 
significant effect on the lower urinary tract (LUT) with or without symptoms (Gupa et 
al., 2015; Wu and Kapoor. 2013). It is the most common diagnosed disease of men 
over 50 years of age due to prostatic cell proliferation resulting to enlarged prostate 
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gland, LUT symptoms and urethral occlusion (Homma et al., 2011; Skinder et al., 
2016). Indeed, when men over 50 present with LUT symptoms, BPH becomes a 
diagnosis of exclusion (Skinder et al., 2016). Mobley et al., (2015) estimated that one 
–fourth of male population aged 50 to 65 years are prone to or already have lower 
urinary tract symptoms. Pathophysiological examinations have described the 
association of UTI, hormonal dysregulation, genetic predisposition, and inflammation, 
release of prostate growth factors and pro-proliferative mediators with the 
development of BPH. In 2018, Chaitoff et al., proposed a combination therapy of 5-
alpha reductase inhibitor and alphablocker as a potent synergic regimen against BPH 
(Chaitoff, 2018). Anti- muscarinic drugs (such as cholinolytics), trans urethral resection 
of prostate, laser therapy and phosphodiesterase-5-inhibitors are also recommended 
as the current effective therapeutic measures of targeting BPH though most patients 
do not respond positively to treatment (Rahman, 2016). BPH common risk factors 
include: advancing age, diabetes, obesity, functioning testicles, family history, race 
and metabolic syndrome (Sarma et al., 2012). 
Furthermore, the aetiology of prostate cancer and BPH disorders are yet to be fully 
understood. Anatomical studies revealed that BPH originates from the prostate 
transition zone while prostate cancer is an adenocarcinoma which originate from the 
peripheral epithelial zone of the prostate gland and rarely arise from the transition 
prostate zone (McNeal, 1998; Miah and Catto, 2014). Autopsy study revealed that 
about 83.3% of prostate cancer cases occurs concurrently with BPH (Bostwick et al., 
1992). BPH affects more than 70% of men as they grow older as it is the most common 
disease of aging men, while prostate cancer is the rampant form of cancer among 
middle aged and elderly men in UK. It has been statistically proven that the most 
common cause of lower urinary tract symptom (LUTS) is BPH and not prostate cancer. 
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However, only few male patients can develop prostate cancer related LUTS. 
Furthermore, combined results of DRE, PSA and biopsy can serve as a clinical 
differential diagnosis of BPH and prostate cancer (Konwar et al., 2008). 
1.1.3 Epidemiology of prostate cancer 
In previous centuries, prostate cancer was seen as a very low frequently occurring 
disorder (Carlsson and Vickers, 2015). Now it is the most common cancer of men all 
over the globe. In the United States and Europe for instance, prostate cancer is the 
second most frequent cause of cancer related mortality (with 220,800 estimated new 
cases and 27, 540 death in 2015) (Siegel et al., 2015). In 2018, prostate cancer 
estimated new cases was 164,690 and 29,430 death (Siegel et al., 2018) It is one of 
the major devastating public health problems of men in developed and developing 
countries including United Kingdom and United States (Siegel et al., 2013; Farlay et 
al., 2013). Autopsy results reveal that approximately 29% of men population already 
have microscopic evidence of prostate cancer between the age of 30-39 which 
increases to about 65% at the age of 70 (Chodak and Warren, 2006). 
Furthermore, prostate cancer incidence rate varies greatly around the globe probably 
due to variations in healthcare access, screening potentials and policies. Globally, 
prostate cancer is the most common third male cancer in the world with about five 
hundred thousand new cases per annum (Parkin et al., 2005; Parkin et al., 2001). 
However, while prostate cancer mortality rate is decreasing in industrial nations such 
as UK, Canada, Australia, Germany, Italy, France and Spain, its incidence rate is on 
the increase in the above countries. It has been proposed that the incidence rate of 
prostate cancer is one in six men, but the mortality rate is one in thirty- six (Gulati et 
al., 2011). This accounts for the age dependency of the disease, occurring between 
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middle age and the end of life. In most cases symptoms develop before death (Jemal 
et al., 2010; Gulati et al., 2011). Therefore, prostate cancer is at times a symptomless 
progressive disorder. Furthermore, in a global cancer statistics, 2012, Torrre et al., 
(2015) critically analysed the worldwide statistical incidence of prostate cancer as 
follows: worldwide estimated new cases and prostate cancer mortality as of 2012 are 
1,111,700 and 307,500 respectively. In developed countries, the estimated new 
prostate cancer cases and mortalities are 758,700 and 142,000 respectively. While in 
developing countries the estimated new cases and death are 353,000 and 165,500 
respectively. Diet and environmental exposures account for the higher incident cases 
in developed countries while in developing countries, the incident is attributed to 
infections (Torrre et al., 2015). 
Some researchers have identified genetic and environmental changes as possible 
cause of worldwide increasing prostate cancer incidence. In USA, the prostate cancer 
incidence analysis reveals that the prostate cancer incidences of US born Japanese, 
Chinese and Filipino is little above that of their native immigrants (Shimizu et al., 1990). 
They discovered that the native immigrants’ incidences of prostate cancer were about 
half that of US-born Japanese, Chinese and Filipino. Nomura et al., (1991) speculated 
that prostate cancer disease becomes increasingly common when groups of people 
migrate from the region of low incidence to the region of high incidence. This correlates 
the role of genetic and environmental factors. 
There is a difference between statistical prevalence and statistical incidence. 
Statistical incidence provides information of the number of new cases of prostate 
cancer in a population diagnosed in a specified period, while statistical prevalence 
gives information of the number or population of people who have prostate cancer in 
a specific period. However, epidemiological studies of a disease are based on its 
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incidence (diagnosed new cases) but due to the asymptomatic and latent feature of 
prostate cancer, many cases of prostate cancer are undetected at the time of 
diagnosis leading to misleading and untrue prevalence of prostate cancer in a 
population (Haas et al., 2008). This was confirmed by autopsy studies which has 
reported several latent cancers of the prostate that diagnostic test could not detect 
(Sakr et al., 1994). However, accurate prevalence of prostate cancer disease can be 
achieved by continuous advances in prostate cancer diagnosis and detection. 
Furthermore, the term prevalence also applies to the number of incidence of a known 
disease condition existing in a given population comprising of diagnosed and visibly 
present cases. Prevalence of prostate cancer can be evaluated from different sources. 
Several years ago, transurethral prostatectomy pathological examination was the only 
means of prostate cancer detection in suspected patients with BPH, on the contrary 
up to one-fourth of the patients operated for BPH were discovered to have prostate 
malignancy (Armenian et al., 1974; Bostwick et al., 1992). However, with the 
introduction of prostatic specific antigen (PSA) the frequency of such misleading 
incidence is drastically reduced as most patients booked for BPH operation are tested 
for PSA (Chou and LeFevre, 2011). 
Other sources evaluated the prostate cancer prevalence from the cystoprostatectomy 
(operation due to invasive bladder cancer) point of view. However, about one-fourth 
to two-fifth of this category were discovered to suffer prostate cancer and not bladder 
cancer though it has been investigated that both prostate and bladder cancer share a 
common route of carcinogenesis (Chun 1997; Abbas et al., 1992; Montie et al., 1989; 
Troncoso et al., 1989).  
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In a cancer statistics study published by Siegel et al., 2013, the estimated new prostate 
cancer cases and mortalities in United State is 238,590 and 29,720 respectively. In 
United Kingdom, in 2015, the incident case was 47,700 and 11,500 deaths per year 
(Cancer research UK). It has been estimated that above two million men presently 
living in the United States have prostate cancer and about 16.48% of the entire male 
population will be diagnosed of the disease in the near future (Jemal et al., 2010; 
Siegel et al., 2011). In 2011, over 240,000 men were diagnosed with prostate cancer 
(Howlader et al., 2011). In 2006, about 234,460 new cases of prostate cancer was 
predicted in the USA which is about three times higher than the number of prostate 
cancer cases that occurred in 1985 (Jemal et al., 2006: American Cancer society, 
2010). Between 1976 and 1994 prostate cancer mortality increase by 20% but the 
death rate stabilized and then reduced since 2000 (Ries et al., 1997; Oliver et al., 
1993). Many researchers have proposed possible causes of prostate cancer incidence 
which include the availability of modern diagnostic and early detecting techniques 
(PSA and systemic biopsy), increased life expectancy and increased environmental 
carcinogens (Pienta et al., 1993; Pack et al., 1993). 
The cause of decreased prostate cancer death is still unclear but can be attributed to 
early detection though the relationship has not been proven, because increased death 
rate is observed in Australia despite high PSA screening while declined mortality is 
observed in United Kingdom despite a relatively low screening rate (Smith et al., 1998; 
Oliver et al., 2000). However, the impact of early detection is largely attributed and 
responsible to a great extent for the diminishing rate of advanced prostate cancer 
(Hankey et al., 1999; Hoedemaeker et al., 2000). Nevertheless, researches have 
suggested that improved advanced prostate cancer treatment, radiotherapy and 
radical prostatectomy are few factors that could explain decline in prostate cancer 
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related mortality (Master et al., 2005; Galper et al., 2006). In the trial by the European 
prostate cancer screening randomized study to determine if screening has an effect 
on prostate cancer mortality, out of 38,350 men that were randomly selected and 
screened based on their DRE and PSA levels 1.4% of the men were actually 
diagnosed with prostate cancer while others had clinically confined prostate cancer 
(Andriole et al., 2005; Schroder, 2005). 
 
1.1.4 Prostate cancer risk factors 
Several factors have been queried as contributing to the development of prostate 
carcinogenesis. However, epidemiological studies suggest that age, race, family 
history and lifestyle are the core etiological factors of prostate carcinogenesis (Jemal 
et al., 2002; Carter et al., 1993). 
Family history: the genetic correlation of prostate cancer with family history has not 
been well elucidated. However, what was formerly defined as hereditary prostate 
cancer is a diagnosed prostate cancer in the family that fulfils at least one of the 
following criteria; prostate cancer affecting at least three relatives, prostate cancer 
diagnosed in two relatives below or at the age of 55, thirdly, prostate cancer identified 
in each of three successive generations (Carter et al., 1993). Scientists suggest that 
this definition of hereditary prostate cancer tends to exclude some families with X-
linked or autosomal recessive transmission (Schaid, 2004). It has been reported that 
about 5% to 6% of prostate cancer diseases occur ten years earlier than sporadic 
prostate cancer comprises hereditary prostate cancer (Carter et al., 1993). Hereditary 
prostate cancer also comprises of about one-third of prostate cancer incidences 
diagnosed prior to 60years of age (Bratt et al., 1999). Based on its earlier onset, 
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hereditary prostate cancer is accountable to greater prostate cancer mortality in male 
population than sporadic prostate cancer. 
In 1996, genetically related prostate cancer was first linked to chromosome 1q23–25 
during which hereditary prostate cancer 1 (HPC1) was identified on chromosome 
1(susceptibility locus for prostate Cancer) (Smith et al., 1996). Other genes such as 
RNASEL (gene responsible for prostate hereditary carcinogenesis) were discovered 
and studied within this chromosomal region (Schaid, 2004). Other regions of 
chromosome such as chromosome X have also been linked to play a role in hereditary 
prostate cancer. Furthermore, prostate cancer incidence variances between regions 
and populations could be partially attributed or linked to the susceptibility genes and 
environmental factors heterogeneity. However, research has to be intensified to 
identify and determine the role and relevance of susceptibility genes in prostate 
carcinogenesis (Schaid, 2004; Bratt et al., 1999). 
Age: prostate cancer has been described as an elderly men disorder. It is a disease 
of middle men and above with rare diagnosis at ages below fifty and high exponential 
incidence at fifty years and above (Haas and Sakr, 1997). However, the role of age in 
prostate carcinogenesis is not yet clear but can be linked to age-dependent sclerotic 
atrophy of the prostate gland which is considered to be a precancerous alteration 
(Franks, 1954). However, researchers have proven that cancer of the prostate 
originates from the glandular active epithelium of the prostate rather than the atrophic 
glands (Michael, 1969). Other research conducted in African countries suggested the 
absence of histological correlation between prostate carcinoma and aging (Kovi et al., 
1982). Other studies suggested that prostate cancer is stimulated from accumulation 
of cellular events and environmental insults leading to neoplasia and the role of aging 
in cancer is to provide adequate time for the accumulation (Miller, 1980). This 
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suggestion explains why prostate cancer incidence increases with increased life 
expectancy. 
Race: prostate cancer age-matched studies confirmed the greater frequency and 
higher grading stage of prostate cancer disease in African American men over their 
white counterparts (Brawley, 1998; Littrup, 1997). At the time of diagnosis, African 
American men are younger in age and have low rate of survival probably due to 
socioeconomic status (Austin et al., 1990; Tewari et al., 2005). It has been difficult to 
understand the cause of the higher incidence of prostate cancer in the black African 
race. Though not yet proven, a researcher has traced the cause to a combination of 
genetic and environmental factors since elevated levels of androgen metabolites has 
been reported in black men over their white counterparts (Elis and Nyborg, 1992). 
Furthermore, several studies have investigated the impact of vitamin D3 in cellular 
growth, differentiation and regulation of oncogenes. Therefore, studies suggest that 
the black race have limited ultraviolet induced vitamin D3 production than whites 
probably due to huge access to sunlight (Schwartz and Hulka, 1990; Buttyan et al., 
1987). Reduced ultraviolet induced vitamin D3 production is found in black people than 
the whites (Gerland et al., 2006). Diminished serum level of 25-hydroxyvitamin D 
(25(OH)D) is significant evidence of lack of vitamin D which is predominantly high in 
all races especially in black American people (Looker et al., 2002; Arya et al., 2004). 
Another suggested reason for early development of prostate cancer in blacks more 
than the whites is attributed to discrepancies and variations in nutrition as the blacks 
prefer food richer in animal fats (Mettlin et al., 1989). 
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1.1.5 Genetic and other factors in prostate cancer predisposition  
A wide range of genetic factors have been implicated in the aetiology of prostate 
cancer. For instance, metabolic and androgen related genes have been linked to 
functional prostate growth (Stanford et al., 2002). Steroid hormones have been 
reported to play a role and deeply involved in the regulation of gene involved in 
prostate oncogenesis, while oestrogen plays a modulatory function, the androgen is 
responsible for prostate growth and development. Studies also report that decreased 
oestrogen level could be a risk factor of prostate cancer. Due to its involvement in the 
stimulation and synthesis of sex steroid hormone (testosterone), cytochrome P-450 
steroid 17, a hydroxylase (CYP17) has been seen as a prostate cancer marker (Sobti 
et al., 2008; Niino et al., 2000). Relatives of men with BPH early onset pose about 
66% risk of BPH related prostatectomy, while relatives of men who have had 
prostatectomy possess a four- fold increase in age related prostatectomy for BPH and 
probably prostate cancer. However, first degree relatives of the above scenarios have 
a six-fold increased risk. Studies of genetic polymorphism of numerous genes 
associated with metabolic pathway of steroids have been linked with prostate cancer 
increased risk (Park and Choi, 2014). 
There is rapidly growing research suggesting the association of bladder cancer with 
prostate cancer. In a study by Chun et al., (1997), the incidence of prostate cancer in 
men with bladder cancer is far higher than prostate cancer patients without bladder 
cancer. Furthermore, compared to control population, greater number of bladder 
cancer patients are also diagnosed with prostate cancer (Chun, 1997). The role of 
some genetic factors in the development of disease could explain this association as 
RB and TP53 tumour suppressor genes have been linked to both bladder and prostate 
cancer development (Singh et al., 1999).  
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There is also evidence of overexpression of stem cell antigen in human cell 
carcinomas (Amara and Palapattus, 2001). There could be possibilities of 
immunologic response or induced elevated androgen level with high risk of prostate 
cancer following vasectomy (Giovannucci et al., 1993). There are conflicting studies 
about induction of prostate cancer by early sexual relationship, numerous sexual 
partners and sexually transmitted diseases (Oishi et al., 1990). 
The role of cigarette/tobacco smoking in the development of prostate cancer is not yet 
fully understood. Studies have linked prostate cancer to a known carcinogen 
(cadmium) found in tobacco or cigarette (Matzkin and Soloway, 1993: Waalkes and 
Rehm, 1994). 
In a cytokine molecular study by Robbert et al., 2009, 81% of 283 of samples 
suspected of prostate cancer were stained positive for CD3 inflammatory T-cell marker 
and larger prostate volume and symptoms correlate with patients with higher levels of 
inflammation (Robbert et al., 2009). Studies also suggest that CD8+ T-cells are 
recruited by BPH or PCa epithelial cells due to low level of prostatic 
dihydrotestosterone (DHT), therefore CD8+ T-cell fuels proliferation of BPH epithelial 
cells under diminished androgen level (Yang et al., 2017). Numerous studies have 
also linked the association between prostate cancer development and inflammatory 
infiltrates, these infiltrates are usually found in prostate specimen of men with prostatic 
disorder and the degree of inflammation correlate with the prostate weight and volume 
thereby suggesting that chronic inflammation is a contributing factor to prostatic 
disorders including prostate cancer (Gandaglia et al., 2013; Fibbi et al., 2010; Kramer 
et al., 2007). During inflammation, angiogenesis and growth factor production by the 
inflammatory cytokines are affecting prostate tissue. Furthermore, prostate 
hyperplasia has been described as an immune inflammatory disorder (Dobrian et al., 
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2001) due to T- cell increased production of ROS whose deleterious effect is 
associated with DNA damage, tissue injury, aberrant growth, proliferation and 
neoplasia (Farooqui et al., 2011) 
Diabetes has been linked with increased risk of LUTS, BPH and prostate cancer 
(Tseng, 2011). Epidemiological studies have identified obesity, meat and fat 
consumption as lifestyle factors that could aggravate risk of LUTS, BPH and PCa, 
while decreased risks are associated with physical exercise and vegetable 
consumption (Hsing et al., 2011; Porter et al., 2005). Obesity itself has been known to 
potentially weaken the potency of 5α-reductase inhibitors (5-ARI). Studies have 
confirmed the role of vitamin D in prostate volume reduction and decreased prostate 
cell proliferation especially when induced by testosterone, dihydrotestosterone and 
growth stimulating molecules such as IL-8, Des (1-3) IGF-1. Therefore, daily intake of 
6000 iu of vitamin D supplement is highly recommended (Tuohimaa et al., 2007).  
Zinc is a metal ion with reference range of 9.6 - 31.6 µmol/L (Ghasemi et al., 2012) 
required for normal enzymatic activities and transcription factors needed for normal 
growth and development (Iguchi et al., 2004). Studies revealed that highest 
concentration of zinc is found in the normal prostate with much lower concentration in 
prostate carcinoma and BPH (Franz et al., 2013; Prasad et al., 2010; Murakami and 
Hirano, 2008). However, Zhao et al., (2016) reported that highest zinc level was found 
in BPH than normal cells with much lower concentration in malignant prostate cell. The 
mechanism by which zinc is gradually lost in progressive prostate cancer is yet 
unknown (Zhao et al., 2016). Zinc in the form of ZnCl2 was reported to inhibit androgen-
responsive cell growth which also slowed down prostate cancer growth and 
proliferation (Liang et al., 1999; To et al., 2018). Research has examined the effect of 
zinc on prostatic lesion. Progressive high levels of serum zinc was identified in benign 
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and malignant prostatic lesions of patients compared to normal and healthy subjects 
(Zhao et al., 2016). 
It has been reported that abdominal accumulation of fat is associated with urological 
disorders such as erectile dysfunction, urinary incontinence, BPH and prostate cancer 
(Kolonel et al., 1999). Fatty acids and prostate disorders have been linked to lipids 
peroxidation, inflammatory mechanisms, oxidative stress, 8-hydroxy-2’–
deoxyguanosine accumulation and increased androgen synthesis stimulating prostate 
growth and enlargement (Kolonel et al., 1999; Khandrika et al., 2009). It has been 
reported that high fat diet is responsible for metabolically triggered inflammation 
though the process is still unclear but thought to be through oxidative stress resulting 
to increased vulnerability of the prostate to several diseases including prostate 
disorders (Rahman, 2016). 
1.1.6 Diagnosis of prostate cancer 
Between 1960s and 70s, Dr. Donald Gleason in a prospective study involving 2,900 
patients, pioneered the invention of grading and staging of prostate adenocarcinoma 
based on histological growth patterns in comparison with prognosis and clinical data 
(Gleason, 1977). In 2004, the world health organisation (WHO), adopted this grading 
pattern and it was named “Gleason” after the inventor (Eble et al., 2004). The Gleason 
(grading) pattern (figure 1.2) ranges from 1 to 5 which denotes the best differentiation 
(better prognosis) and the poor differentiation (poor prognosis) respectively. The term 
Gleason score was developed to facilitate proper, efficient and accurate calculation of 
the grading (Gleason). The Gleason score is the summation of the Gleason patterns 
harboured by primary and secondary prostate adenocarcinoma. Where only one 
histological grading exists, for instance, if the primary Gleason is 3 it is assumed that 
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both primary and secondary Gleason are same. In this case the Gleason score is 6 
(i.e 3+3) (Gleason, 1977; Chen and Zhou 2016; Amin et al., 2004). 
From the original Gleason classification pattern of Dr. Donald Gleason based on 
haematoxylin and eosin staining, the following features are linked with Gleason pattern 
1: separate, single, uniform round, closely packed glands in a well circumscribed 
nodular borders (figure 1.2) (Eble et al., 2004). However, this pattern is very rare and 
the features was later discovered to be mistaken features of adenosis, otherwise 
called atypical adenomatous hyperplasia (AAH) and not prostate cancer (Eble et al., 
2004). Features of Gleason 2 are almost same as 1 but with less peripheral 
circumscription, more separated stromal glands (figure 1.2), no stromal infiltration and 
more variable glandular shapes (Eble et al., 2004). This pattern was also suggested 
to be rare as in 1 above (Humphrey, 2004; Berney, 2007). Gleason grade 3 consists 
of a poorly differentiated edge with some structures still circumscribed, irregularly 
separated, closely packed, single and many variable glands, slight infiltration with 
more loosed nodules, angulated or compressed glands, pseudo atrophic appearance 
of large glands or undulating luminal contours in minimal sized glands. Gleason grade 
3 is the most common Gleason score (McKenney et al., 2011; Humphrey, 2004). 
Features of grade 4 Gleason are as follows: fused glands due to non-existing 
intervening stroma in adjacent glands, predominant presence of acinar structures with 
or without formed lumina, presence of papillary tumours with invasive irregular edges, 
abnormally enlarged cribriformed gland nodules without supporting stroma (Dong et 
al., 2013; Kweldam et al., 2015; Amin et al., 2004). Gleason grade 5 possesses the 
following features; presence of comedonecrosis which comprises intraluminal central 
necrotic cells with papillary spaces, cord formation with vacuoles generally referred to 
as signet ring cells with absence of glandular lumens and presence of single cells 
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(Shah et al., 2015; Amin et al., 2004, Chen and Zhou, 2016). Some of these grading 
features are depicted in figure 1.2. 
The original Gleason pattern has been modified and updated due to results obtained 
from new testing and diagnostic modalities such as needle biopsy, PSA and surgical 
procedures. For instance, results from multiple radical prostatectomies and needle 
biopsies from multiple sites need to be taken into consideration by pathologists and 
incorporated in the Gleason grading system (Chen and Zhou, 2016). One of the major 
consensus reached by two-third majority of 70 leading urologist/pathologist during 
2005 international society of urologic pathology (ISUP) consensus is that Gleason 
score 1+1 equals 2 diagnosed by needle biopsy should be stopped, as this is a typical 
diagnosis for adenosis (Eptein et al., 2006; Osunkoya, 2012). Needle biopsy Gleason 
scores of 3 and 4 from various combinations of primary and secondary Gleason such 
as 2+2, 1+2 and 2+1 is considered controversial due to their non-correspondence and 
poor reproducibility with the grading of prostatectomy samples, more so the edge of 
the nodule from needle biopsies made from the transition zone is difficult to assess. 
Therefore, the ISUP 2005 recommends that diagnosis involving Gleason score 3 and 
4 from needle biopsy be performed in conjunction with expert urologic-pathologist. On 
occasions where there is moderately or minor irregular nodule edge on Gleason score 
2+3 equals 5 or vice versa, diagnosis can only be made by experts (Epstein et al., 
2005). 
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Figure 1.2 Gleason grading of prostate cancer. This depicts some of the features of the various 
Gleason grading patterns of prostate cancer  
Prostatic specific antigen (PSA), otherwise known as human kallikrein 3 (hK3) with 
molecular weight of 33KDa. It is called (hK3) because it is a serine‑protease of 
kallikrein tissue identified in 1970s from human prostatic extracts and are involved in 
seminal fluid synthesis (Ablin et al., 1970). In 1979, Wang et al. discovered PSA in 
human sera, followed by its isolation from prostate tissue in 1980 by Papsidero et al 
(Papsidero et al., 1980) confirming its relevance as a biomarker of PCa that could be 
used in a screening test (Potosky et al., 1995; Stephenson et al., 1996). The acinar 
cells, the ductal cells and the periurethral gland of the prostatic epithelium produce 
PSA. Produced PSA is subsequently transported into the seminal fluid where it 
liquefies seminal coagulum during ejaculation as its primary physiological function 
(Robert et al., 1997). 
There have been increases in the detection of prostate cancer following the 
introduction of the PSA test and efforts have been geared towards its improvement as 
a prostate cancer screening test. However, PSA is not a specific prostate cancer 
marker since its serum levels are elevated in other conditions such as recent 
ejaculation, prostatitis, prostate hyperplasia, cigarette/tobacco smoking, digital rectal 
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examination (DRE), urologic manipulations and medication such as finasteride (Guess 
et al., 1993). 
Furthermore, Stamey and research colleagues demonstrated in 2004 that PSA 
measurement is an accurate biomarker in detection of prostate diseases including 
prostatitis, prostate cancer and BPH, but not necessarily prostate cancer (Stamey et 
al., 2004). In 2005, Thompson et al demonstrated that PSA screening is very sensitive 
in prostate disease detection (detecting both mortal and non-mortal cancers) but not 
specific to prostate malignancies (Thompson et al., 2005). Notwithstanding these 
limitations PSA screening has aided the early detection of the disease as it is often 
diagnosed late due to its asymptomatic during development (Chodak et al., 1989). In 
1987, there was a substantial increase in PSA screening tests which resulted in a 
dramatic increase in prostate cancer detection and therefore treatment (Ries et al., 
1999; Ellison et al., 1999). Prostate cancer specific deaths reduced in 1993 as more 
cancers were detected early and treated (Hankey et al., 1999). The improved early 
detection and screening of prostate cancer resulted in intensified research on prostate 
cancer chemoprevention and chemotherapy. 
Initial evaluation of PSA as a screening test reveals that the best predictive value clear 
cut off is 4ng/ml. This cut off allows for detection of still confined and curable prostate 
cancer and reduces rates of unnecessary biopsies in non- prostate cancer patients 
(Catalona et al., 1991). Based on research, this 4ng/ml bench mark is recently in doubt 
as 48% of patients with PSA Level ˂4ng/ml suddenly measured ˃4ng/ml within a 
space of four years and 13% of these patients were diagnosed of prostate cancer 
(Smith et al., 1996). In similar research, prostate cancer was detected in 15.2% of 
2,950 men with normal DRE and PSA level ˂4ng/ml (Thompson et al., 2004). Based 
on these reports, researchers recommend PSA cut off of 2.6ng/ml as an ideal 
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reference (Smith et al., 1996). However, some authors suggest adjustment of PSA cut 
off for frail and younger men since serum PSA levels increase with increase in prostate 
volume and age thereby resulting in low specificity and sensitivity PSA screening 
values in frail and younger men respectively (Partin et al., 1996). 
PSA use in prostate cancer screening has gained global preference to TRUS and DRE 
for economic, specificity, and effectiveness reasons. Therefore, PSA is the most 
widely recognised prostate cancer screening parameter; but it is also the most 
controversial prostate cancer marker due to misleading impression of either absence 
or presence of prostate cancer at varying PSA levels (Shan et al., 2017). Researchers 
have intensified efforts to authenticate the relevance of PSA in early prostate cancer 
detection. However, it is recommended that its combination with other diagnostic 
measures for prostate cancer screening will give more specific, efficient and reliable 
results. Babaian and Camps, (1991) suggested that a PSA value of 4ng/ml in 
conjunction with positive DRE is diagnostic of prostate cancer. A study also suggested 
that to maintain accuracy and precision in the use of PSA for prostate cancer 
screening, men with increased PSA levels should be subjected to at least four 
kallikrein markers screening test to guide biopsy decisions (Ferro et al., 2016). 
However, Ferro et al., 2016 suggested that prostate cancer screening with PSA should 
be ideally carried out two or three times in a life time between the age of 55 and 59 as 
over diagnosis is possible at age 63 and above.HK2 is closely related to PSA with 
80% conservation in amino acid sequence. Like PSA, elevated levels of HK2 are most 
frequently seen in the prostatic tissue (Kumar et al., 1997; Yousef and Diamandis, 
2001). HK2 is otherwise called free PSA (fPSA) because it is free and unbound in the 
serum. It is predominantly used to differentiate between normal and cancerous 
prostate cells (including BPH and prostate cancer) (Kwiatkowski et al., 1998; Nam et 
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al., 2000). Elevated levels of free PSA in a total PSA is an indication of BPH, not cancer 
(Catalona et al., 1995). However, it has also been reported that increased total PSA 
with minimal elevated values of fPSA is suggestive of prostate cancer. In 1999, Partin 
and his research colleagues reported that prostate cancer is better diagnosed, 
identified and confirmed when there is elevated levels of HK2 in combination with 
lower levels of PSA (less than 25%) and when the HK2/PSA ratio is less than 0.18 
(Partin et al., 1999; Hong, 2014). A comparative study of HK2 and PSA levels in 
preoperative prostatectomy patients (Haese et al., 2000), revealed that the 37% 
sensitivity and 100% specificity of HK2 in detection of organ confined prostate 
diseases compared to 14 and 100% sensitivity and specificity (respectively) for total 
PSA. 
In a recent study, Lee et al., (2015) reported serum levels of total HK2 detection 
through effective silicon antibody immunoassay which improves prostate cancer 
detection with or without PSA. However, Mao et al., (2018) suggested that the 
combination of biomarkers such as HK2, PSA and prostate cancer gene 3 (PCA3) 
provides a greater beneficial effect in prostate cancer detection and diagnosis. 
It has been clear for some time that some cases of prostate cancer (latent prostate 
cancer) are undetected or misdiagnosed. Pathologically, the term latent prostate 
cancer applies to hidden prostate cancer that can only be identified through post-
mortem examination of prostate specimen (Sakr et al., 1994).  Denton et al., (1965) 
reported about 25% of patients diagnosed and treated for BPH actually had prostate 
cancer after transurethral surgery and examination of their specimen (Denton et al., 
1965). This also implies that the true prevalence and epidemiological studies of 
prostate cancer is difficult to measure with such dormant/hidden form of prostate 
cancer. This has declined the use of PSA as the only screening test. Therefore true 
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prevalence of prostate cancer can only be measured by combining the results of PSA 
tests, transuretheral examination, crystoprostatectomy, biopsy and autopsy (Draisma 
et al., 2003).TRU is very unspecific to prostate cancer since it has been found that 
minimal percentage of hypoechoic ultrasound images correlate with prostate cancer 
(Norberg et al., 1993), and one- fifth of normal ultrasound images of the prostate gland 
are positive for prostate malignancy after biopsies (El-Gabry et al., 2001). Because 
TRU guides systemic biopsies, it is also called guided biopsy. Several studies suggest 
that far lateral zone prostate biopsy should replace systemic sextant biopsy which had 
remain the gold standard of prostate biopsies for several years until about 31% false 
negative results was reported (Epstein et al., 1997). Eskew et al., reported about 34% 
increased detection of prostate cancer in far lateral zone which was previously missed 
by sextant TRU (Eskew et al., 1997). Eskew et al., 1997 also conclusively reported 
that the lateral zone TRU involving systematic five region prostate biopsy detects more 
tumours than the sextant ultrasound, due to its efficacy of prostate cancer detection at 
significant early stage. 
Kong and Byun, (2013 and 2015) reported the relevance of prostatic acid phosphatase 
(PAP) in prostate cancer prognosis and diagnosis. They reported that PAP levels 
increase proportionately with increasing prostate cancer progression, thereby making 
PAP a good prognostic tool in prostate cancer management. Kong and Byun also 
proposed that prostate cancer progression could be arrested by introducing molecules 
such as an RNA ligand aptamer that specifically binds to PAP (Kong and Byun, 2015).  
PAP was the first biochemical marker employed for prostate cancer staging and 
diagnosis. Inorganic phosphates are produced in a hydrolization reaction of esters by 
PAP in acidic medium. PAP is not a specific prostatic marker as it is being synthesized 
in other organs such as the brain, liver and lungs, but majority of it is secreted from 
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the prostate epithelia cells and transported into the glandular lumen (Kong and Byun, 
2013).  
Earlier studies have reported increased levels of PAP in patients with BPH and more 
elevated levels in patients with metastatic prostate cancer (Gytman et al., 1938, 
Pentyala et al., 2016). Another study reports that 84% of 102 patients with increased 
levels of PAP were diagnosed of various degrees of prostate metastases (Bahnson et 
al., 1987). Lowe et al., (1993) suggested that surgically curable prostate cancer is 
difficult in patients with elevated PAP. However, the introduction of PSA has drastically 
reduced the use of PAP in prostate cancer diagnosis and staging. 
In patients with different forms of malignancies such as breast, lung, colon and 
prostate cancers, insulin-like growth factor-1 (IGF-1) and insulin-like growth factor 
binding proteins (IGFPBs) are important markers for tumour progression and 
prognosis (Yu and Rohan, 2000). These factors also play vital roles in both malignant 
and normal cell proliferation and transformation (Zumkeller, 2001). In an earlier study 
(Djavan et al., 1999) detected IGF-1 in prostate cancer patients and recommends the 
use of IGF-1 with PSA in early prostate cancer detection. However, this was disputed 
in a study by (Shariat et al., 2000) who suggested that there was no correlation 
between prostate cancer and IGF-1 levels. However, serum concentrations of IGFBP-
2 and IGFBP-3 are examined in the assessment of disease progression. For instance, 
lowest levels of IGFBP-3 were found in bony metastatic patients, relatively higher in 
confined diseases and highest in healthy individuals (Shariat et al., 2002). On the other 
hand, IGFBP-2 is higher in organ confined diseases and lower in disease progression 
(Yu and Rohan, 2000). Furthermore, Chan et al., (1998) reported that increased levels 
of IGF-1 is majorly associated with high prostate cancer risk. Harman et al., (2000) 
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also reported that elevated serum levels of IGF-1 and low IGF-II are independently 
linked with high prostate cancer risk 
Furthermore, transforming growth factor-β1 (TGF-β1), TGF-β1 cytokines have been 
implicated in many stages of tumorigeneses and TGF-β1 elevation have been 
identified in many cancer patients including patients with prostate malignancies (Blobe 
et al., 2000). TGF-β1 is reported to be involved in numerous cancers (including 
prostate cancer) progression, proliferation and aggressive malignancies (Fuxe et al., 
2012). Normally, elevated presence of TGF-β1 in disease is an indication of 
progressive deterioration and poor prognosis (Wu et al., 2015; Drabsch and ten Dijke, 
2012). Immunohistochemical studies have been used to differentiate normal prostate 
tissue from neoplastic prostatic epithelium due to increased expression of TGF-β1 in 
cancer (Perry et al., 1997). Shariat et al., (2001) and Adler et al., (1999) have 
confirmed the positive association between TGF-β1 plasma concentrations and 
prostate cancer progression. However, this assumed correlation was refuted by Perry 
et al., (1997), but rather uphold a strong correlation between urinary levels of TGF-β1 
and prostate cancer progression. Shariat et al., (2004) reported plasma TGF-β1 
elevation in extra prostatic (spread to vesicle and lymph nodes) pre and postoperative 
patients. In 2015, Wu et al conclusively reported TGF-β1 as a potential biomarker and 
could be targeted suggesting a future potential prostate cancer therapy (Wu et al., 
2015). 
Interleukin-6 (IL-6) is also a prostate cancer biomarker as some studies propose that 
there are signs of inflammatory response in most prostate cancers and that there is 
an association between stromal proliferation and T-cell infiltration, suggesting the 
involvement of IL-6 and IL-8 (Drabsch et al., 2012; Handisurya et al., 2001). 
Abbasabad et al., (2018) also proposed a strong relationship between inflammation 
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and the presence of malignant prostate cells. IL-6 is recognised as an inflammatory 
molecule synthesized and released by malignant cells (Abbasabad et al., 2018). IL-6 
is an immunological factor that regulates numerous cellular activities such as bone 
turn over and immune function. Comparative studies have shown 18 and 8-fold 
increased concentration of IL-6 protein and receptors respectively in confined prostate 
cancer than normal prostate tissues (Giri et al., 2001). Furthermore, Shariat et al., 
(2001) reported elevated plasma IL-6 in metastatic prostate cancer patients and 
increased IL-6 soluble receptor levels in patients with prostatic bone metastases 
followed by patients with lymph nodes involvement. Shariat et al., (2001) also carried 
out a research on 309 prostate localized disease patients and reported increased IL-
6 and its receptor levels in preoperative patients which drastically decreased after 
prostatectomy irrespective curative achievement. Giri et al., (2001) and Adler et al., 
(1999) detected elevated levels of IL-6 in both human prostate cancer and BPH and 
suggest that overexpression of IL-6 could be a serious sign of malignant prostate cells. 
In Northwest population of Iran, Abbasabad et al., (2018) identified a mutation (single 
nucleotide polymorphism-SNP) in interlukin-6 gene (IL-6 -174G>C (rs1800795) and 
its association with prostate cancer metastasis.   
Magita et al., (2009) observed that fatty acid synthase gene (FASN) is a prostate 
cancer oncogene which exerts its oncogenic properties by inhibiting the intrinsic 
apoptotic pathway. Apart from adipose tissues and liver, FASN is hardly expressed in 
normal tissues but highly expressed in tumour cells and its overexpression in tumour 
is an indication of poor prognosis (Kusakabe et al., 2000; Carvalho et al., 2008). In 
2006, it was discovered through fluorescent in situ hybridization that 25% of human 
prostate cancer tissues are highly positive for FAS protein (Shah et al., 2006). 
Oncoantigen 519 (OA-519) immunohistochemical staining in combination with FAS 
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was first used by Epstein et al to study the pathological stages of prostatectomy 
specimens (Epstien et al., 1995). They confirmed that QA-519 immunohistochemical 
staining provides excellent predictive information of the pathological grades and 
progression of prostate cancer than Gleason scores. Furthermore, Swinnen et al., 
(2002) identified increased FAS signalling from a low to high grade prostatic 
intraepithelial neoplasia (PIN) in frozen needle prostate biopsies. The study suggests 
that higher FAS signalling correlates with higher prostate cancer proliferative index 
and FAS expression is an indicative of early prostate cancer development (Swinnen 
et al., 2002). 
Early prostate cancer antigen (EPCA): numerous cancers are clinically diagnosed by 
critically observing the cell nuclear matrix to determine the shape and the texture of 
the nucleus under microscope, the nuclear matrix protein of the prostate otherwise 
known as early prostate cancer antigen (EPCA) has been identified as a potential 
prostate cancer biomarker. However, the nuclear matrix protein of other cancers 
constitute their respective specific early cancer antigens (Zhao et al., 2010; Leman et 
al., 2008). Immunohistochemistry has been used to identify a nuclear protein linked 
with prostate cancer (Ohir et al., 2004). Ohir et al., (2004) also studied the efficacy of 
EPCA in prostate cancer biopsy specimens and found that EPCA staining possesses 
84 and 85% sensitivity and specificity respectively in prostate cancer detection. The 
study also reports that EPCA immunohistochemistry may provide the opportunity to 
detect PCa five years earlier than PSA and drastically reduce the number of biopsies 
due to misleading increased PSA levels (Ohir et al., 2004). 
Use of urinary secretory markers for prostate cancer detection (USM): the prostate 
secretes prostasomes and exosomes as two forms of microvesicles; the prostasomes 
are secreted from the normal prostatic duct which form part of the semen and are 
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important for male fertility (Burden et al., 2006). The exosomes are nanovescicles 
secreted by both tumour and normal cells. However, exosomes have been found to 
be over-secreted in urine, effusion and serum of prostate cancer patients (Mitchell et 
al., 2009; Wilkosz et al., 2011). 
Numerous studies have identified a novel protein called PCA3 as a useful marker that 
can be used with DRE and PSA due to its specificity to enhance accuracy of prostate 
cancer diagnosis and grading (Tinzl et al., 2004). Number of biopsies performed on 
patients suspected of prostate cancer have been lowered by the introduction of PCA3 
urine test due to its potentials of specific prostate cancer detection (Nakanishi et al., 
2008). Other conventional prostate cancer urine markers are: 8-hydroxy-2’-
deoxyguanosine (8-OHdG), Annexin A3 (ANXA3), δ-Catenin, Endoglin, Oestrogen 
metabolites, GOLM1, LOH (loss of heterozygosity), Met, Alpha-methylacyl CoA 
racemase (AMACR) etcetera (Wilkosz et al., 2011).  
Cancer cells tend to resist therapy due to the expression of numerous splice variants 
associated with poor survival rate. Research suggest that cancer cells specific splice 
variants expression are good prognostic and diagnostic markers of cancer including 
prostate cancer (Pal et al., 2012). More so, prostate cancer specific variants of crucial 
genes such as CCND1 (a gene whose overexpression is associated with cancer 
chemo resistance (Noel et al., 2010) could be used as a therapeutic measure to target 
proteins of non-healthy cells. It was suggested that it might be helpful to reduce 
prostate tumour growth by developing a compound or tool that will preferentially and 
specifically modulate transcript variants expression of prostate cancer cells at the 
expense of healthy cells. Zhang et al., (2006) was able to differentially separate 
prostate cancer cell lines from other organ’s cancer cell lines using splicing-sensitive 
microarray that is made up of selected splice variants and genes subset. Using a 
34 
 
splicing-sensitive microarray in biopsy sample, it was possible to specifically 
distinguish between splicing signatures of neoplastic prostate and normal prostate 
cells. However, this suggests that during prostate tumorigenesis, there is evidence of 
splicing changes thereby presenting splicing variants important and precise prostate 
cancer biomarkers. Numerous groups have performed a comparative analysis 
comparing cancerous prostate and normal prostate. In general, there would appear to 
be consistent, changes in the expression of alternative splice variants in prostate 
cancer (Hagen and Ladomery, 2012; Lapuk et al., 2014; Hagen et al., 2013; Venables 
et al., 2006).  
Li et al. (2006) using exon arrays validated by RT-PCR established splicing changes 
in prostate cancer. About one thousand five hundred mRNA variants from prostate 
cancer genes were examined using splicing arrays. This approach could help to 
differentiate prostate cancer cell lines from cell lines of other tumours based on 
differences in splicing patterns. 
Prostate cancer progression has been linked with many specific splicing patterns 
(Watson and Watson, 2010; David and Manley, 2010). For instance, in prostate 
cancer, prostate-specific membrane antigen (PSMA) is up-regulated (Watson and 
Watson, 2010). Four specific splice PSMA isoforms exist which are useful prognostic 
indicators for PCa. They include: PSM, PSM-C, PSM-D and PSM-E (Watson and 
Watson, 2010; Chen and Miller, 2013). The progressively increased expression of 
these antigens (for instance, from PSM to PSM-E) is associated with the highest grade 
of prostate cancer. The preferential expression of specific isoforms also creates 
opportunities for detection of prostate tumour grades using immunological techniques 
(Williams and Kole, 2006; Watson and Watson, 2010; Cao et al., 2012). 
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1.1.7 Established treatments of prostate cancer 
Prostate cancer screening and diagnoses has led to early detection of the disease and 
higher prevention of prostate cancer related death. However increased screening has 
resulted in prostate cancer over diagnosis and treatment of indolent tumours with the 
associated chemotherapy toxicity and other side effects (Gulati et al., 2011; Etzioni et 
al., 2002). Therefore, instead of chemotherapy, radiotherapy or prostatectomy, active 
surveillance and monitoring/watchful waiting has become a viable corrective option for 
patients who have still confined prostate cancer (Lund et al., 2014). It is an indirect 
way to delay aggressive treatment in low risk PCa patients who are unlikely to develop 
symptoms in a life time. The patients are followed up by PSA, DREs and biopsies and 
about one-third of the patients out of psychology, anxiety and distress switch to active 
therapy especially when symptoms are likely to develop following biopsy results 
(Dall’Era et al., 2012). In the 80s active surveillance and watchful waiting are useful 
approaches to monitor progress of prostate cancer.  The former is a situation where 
suspected confined prostate cancer patients are not treated but monitored until 
evidence of local metastasis is established, here frequent tests are required to monitor 
cancer growth. While the later is otherwise called watch and wait, a situation where 
time is allowed before medical intervention is needed (Bill-Axelson et al., 2008). 
However, Klotz suggested that nowadays due to multiple co-morbidities watchful 
waiting can only be offered to prostate cancer patients with at most five years life 
expectancy (Klotz, 2013). Furthermore, both active surveillance and watchful waiting 
are meant for men with low risk and low grade prostate cancer with Gleason score 
and PSA less than 6 and 10 respectively. However, while watchful waiting is a viable 
option for older men, younger men less than 65 years with considerable life 
expectancy are likely to benefit from active surveillance (Miller et al., 2018). 
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Prostatectomy (surgical removal of part or whole of prostate gland) is the oldest means 
of treating confined and non-malignant and high risk prostate cancer to avert 
complications of urinary incontinence and advanced metastases (Meuleman and 
Mulders, 2003: Petrelli et al., 2014). There is usually a high rate of erectile dysfunction 
following post-prostatectomy though the aetiology and pathophysiology has not been 
fully established. However, Meuleman and Mulders, (2003) suggested that 
prostatectomy is not the core cause of erectile dysfunction, that erectile dysfunction 
following prostatectomy is a coincidental dysfunction often mistaken for already pre-
existed erectile dysfunction due to old age (since prostate cancer is diagnosed in 
between 6 to 8 decades of life). Radical prostatectomy in most cases is not used as a 
prostate cancer monotherapy because high-risk prostate cancer still require 
supplementary adjuvant treatment such as androgen deprivation therapy (ADT) and 
radiotherapy to avert metastasis. However, Petrelli et al., (2014) suggested that radical 
prostatectomy can be used as a single therapy only in patients with quality life 
expectancy without significant competing death challenges. Heidenreich et al., (2011) 
in line with leading guideline indicated that radical prostatectomy is non-beneficial to 
candidates with less than 10 years life expectancy; however, it is preferred to 
radiotherapy for patients with life expectancy from 10 years and above at the time of 
initial diagnosis. According to the surveillance epidemiology and end resort (SEER) 
database, radical prostatectomy has been reported to improve survival more than 
radiotherapy (Sun et al., 2013). 
Adjuvant radiotherapy is required to significantly minimise risks of disease 
reoccurrence and PSA relapse (biochemical recurrence) in patients who had radical 
prostatectomy of pathological advanced prostate cancer (Thompson et al., 2006). 
Radiotherapy involves the use of ionization radiation to kill or disable proliferation of 
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malignant cells. Two types of radiotherapy exist, they include; Brachy therapy (BT) 
which is employed for treatment of small and confined prostate tumours by radioactive 
capsule implantation right inside the prostate to kill tumour cells. External beam 
radiation therapy (ERT) employs high energy X-rays directed to the prostate to 
damage and quench cancer cell division while affected normal cells undergoes auto 
repair (Baskar et al., 2014; Bentzen, 2006). Incrocci et al., (2002) reported cases of 
84% and 51% of erectile dysfunctions following external beam radiotherapy and 
brachytherapy respectively. ERT in combination with hormone therapy is often a 
treatment of choice for men with high stage prostate cancer with PSA greater than 10 
ng/ml while either BT or radical prostatectomy could be beneficial to men with small 
prostate tumour who are below 70 years with PSA less than 10 ng/ml in the absence 
of other risk factors such as pulmonary and cardiovascular disease (Bolla et al., 1997; 
Incrocci et al., 2002).  
Androgen deprivation therapy was first used in 1941 to supress testosterone release 
from the hypothalamus in advanced prostate cancer patients. This is achieved either 
by surgical castration or by administration of diethylstilbestrol (DES) which inhibits the 
production of luteinizing hormone-releasing hormone (LHRH) from the brain 
(Perlmutter and Lepor, 2007; Huggins and Hodges, 1941). Androgen deprivation 
therapy (ADT) is often used as an adjuvant in combination with radical prostatectomy 
or radiotherapy for prostate cancer treatment to improve survival. For patients with 
locally advanced prostate cancer, long term ADT administration up to three years is 
recommended, while six months short term treatment is ideal for patients with localized 
prostate cancer (Bolla et al., 2009; Pisansky et al., 2015). ADT treatment accounts for 
about 90% sexual dysfunction and decreased libido in men receiving treatment, there 
is also detrimental effect of ADT treatment on mental and bone health, diabetes, 
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cardiovascular disease, cognition, erection and testicular size leading to distress and 
regret of treatment (Hadziselimovic et al., 1987; Haliloglu et al., 2007). 
Cryotherapy, a technique that involves the insertion of liquid nitrogen or argon gas to 
the prostate through a transurethral cryoprobe to ensure the death of localized 
prostate cancer by extremely low temperature (freezing). Cryotherapy was first 
introduced in 1966 by the American Urology Association (Han et al., 2003; Gonder et 
al., 1966). Third generation cryotherapy was established by monitoring the inserted 
cryoprobe and the temperature of the surrounding tissues through transrectal 
ultrasound control (Sverrisson et al., 2013). Principally, cryotherapy induces cell death 
by either apoptosis or coagulation necrosis through dehydration resulting to cell 
membrane protein denaturation and disruption by ice (Hoffmann and Bischof, 2002). 
Rodriguez et al., (2014) suggested that cryotherapy is a valid option treatment for men 
with localized tumours who have high surgical risk and complication from radiotherapy, 
beneficial effects of cryotherapy include: high survival cryosurgery, overall survival rate 
and rare cases of biochemical recurrence. However, it can be repeated after 
histological confirmation of biochemical relapse (Rodriguez et al., 2014). 
The contrast of cryotherapy is high intensity focussed ultrasound (HIFU). This is a non-
invasive approach that employs the use of high ultrasound energy (heat) delivered to 
the prostate gland (without damaging the surrounding tissue) to achieve cancer cell 
necrosis in the absence of surgical excision and radiation (Chaussy and Thuroff, 
2017). This technic is feasible because ultrasound beams transmission are capable of 
passing through a targeted solid tissue without surgical operation/excision or insertion 
of probes (Wu et al., 2001). Over the years they have been recorded success on the 
use of transrectal high intensity focused ultrasound for the treatment of prostate cancer 
and BPH (Nakamura et al., 1997). Blana et al., (2004) reported the efficacy of HIFU in 
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the treatment of confined prostate cancer with minimal morbidity and repeatable in 
cases of biochemical relapse. This procedure is a treatment alternative for men with 
prostate cancer who lack suitability for radical surgery.  
Apart from erectile dysfunction and urinary incontinence, other complications 
associated with prostate cancer treatment cannot be overlooked. These complications 
in some cases may lead to a lot of interventions such as surgery, rectal-anal and 
urologic interventions due to gastrointestinal or genitourinary haemorrhage, infections 
and urinary occlusion (Wallis et al., 2018). Studies suggest though radiotherapy has a 
minimal risk of invasive procedures yet radiotherapy is hugely associated with high 
and long term risk of secondary cancer, hospitalisation, major surgical and rectal-anal 
procedures (Nam et al., 2014; Wallis et al., 2015). Other complications of radiotherapy 
that is often associated with morbidity include; chronic tissue ischemia, bowel 
symptoms and urinary fistulae leading to urinary diversion (Bassett et al., 2016). 
Compared to watchful waiting, it has been reported that radical prostatectomy has low 
rate of urinary occlusion (Steineck et al., 2002). 
Research suggests that prostate cancer can be treated with metformin. Metformin is 
an anti-hyperglycaemic therapy used to lower blood glucose of type 2 diabetic patients 
(Shaw et al., 2005). Apart from the anti-hyperglycaemic property, metformin has been 
reported to possess the therapeutic advantage of retarding and preventing the risk of 
cancer growth including prostate cancer (Currie et al., 2012; Preston et al., 2014). 
Lipogenesis and androgen receptor pathway inhibition are the possible mechanisms 
via which metformin inhibits prostate cancer growth, proliferation and migration. 
Another suggested mechanism is by up regulation of PEDF (pigment epithelium 
derived factor) secreted in many tissues including prostate stromal and epithelial 
tissues (Wang et al., 2015; Chen et al., 2016). It has been reported that PEDF is 
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downregulated and under expressed during malignant prostate cell transformation. 
Therefore, Chen et al., (2016) hypothesized that the antitumorigenic effect of 
metformin is dependent on PEDF upregulation and overexpression. Chen and his 
research team also discovered that PEDF upregulation results to increased apoptosis, 
reduction in prostate cancer migration and invasion both in vivo and in vitro in a dose 
and time dependent manner of metformin.  
Cell biology, epidemiological and animal in vivo studies suggest the effectiveness of 
lycopene (which gives tomatoes its characteristic red colour) as an anti-cancer agent 
including in prostate cancer and also reduces the risks of cardiovascular diseases (Xin 
et al., 2016; Story et al., 2010). Epidemiological studies revealed that lycopene blood 
levels and its dietary intake are linked to prostate cancer reduced risk (Wang et al., 
2015). Research also suggests that the lycopene content of watermelon is greater 
than that in tomatoes. Numerous epidemiological studies have reported lower risk of 
prostate cancer in subjects with increased tomatoes intake than individuals with less 
tomato consumption (Chen et al., 2015; Rao 2004; Shahar et al., 2011; Salem et al., 
2011). Furthermore, Chen et al., 2015 reported that tomato consumption plays a 
preventive and protective role against prostate cancer while others reported negative 
correlation between tomato intake and prostate cancer risk (Diallo et al., 2016; Hadin 
and Witte, 2011; Takachi et al., 2010; Ambrosini and de Klerk, 2008). In a recent study 
by Xin et al., (2016), confirmed that there is a positive association between tomato 
intake and reduced risk of prostate cancer. 
The mechanism through which tomato exerts its protective role has been linked to the 
properties of lycopene which has been reported to supress prostate cancer 
proliferation and progression in many studies through ABCA1, LXRa and PPARy 
activation (Yang et al., 2012; Elgass et al., 2014). Furthermore, androgen- 
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independent prostate cancer (PC3, DU145) cell migration and adhesion was also 
inhibited by the tomato lycopene in a study by Elgass et al., 2014. In vivo studies 
reported a significant effect of dietary tomato and lycopene on mouse prostate 
carcinogenesis (Wan et al., 2014). In summary some natural products (such as 
lycopene) could provide opportunities for adjuvant therapy of prostate cancer. 
1.2 Alternative (differential) splicing and prostate cancer 
1.2.1 Pre-mRNA splicing 
Pre-mRNA splicing (figure 1.3) is a general term to represent the process which 
involves intron removal and joining of corresponding exons from pre-rnRNA to form a 
mature rnRNA capable of generating different kinds of protein from same gene needed 
for biological activities such as growth, differentiation and apoptosis (Johnson et al., 
2003).  Alternative splicing which I will discuss later, helps produce isoforms proteins 
from the same single gene (Wang et al., 2015). Pre-mRNA splicing is initiated by 
spliceosome machinery comprising of a large number of associated proteins and five 
small nuclear RNAs (snRNAs) (Wahl et al., 2009). Additional splicing factors such as 
Ser/Arg-rich (SR) proteins in combination with snRNPs are responsible for exon 
selection. The spliceosome machinery is recruited to the site of splicing aided by splice 
factors such as SRSF1 and SRSF2 binding to intronic or exonic splicing enhancers 
(ISE or ESE) (Malumbres et al., 2014). 
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Figure 1.3. Pre-mRNA splicing. In eukaryotic genes, cis-splicing is required to decode split genes. 
The thick lines denote introns while the rectangular boxes represent exons. While the introns are 
removed, the exons are joined together by the spliceosome to form a mature mRNA.  
 
1.2.2 Pre-mRNA splicing mechanism  
Splice sites (ss) are the intron – exon boundaries where the pre-mRNA are cut during 
splicing. An intron is surrounded by 5’ upstream ss and 3’ downstream ss (figure 1.4). 
The 5’ss joins with the 3’ss during splicing, thereby getting rid of the intervening intron. 
The process involves two transesterification reactions; in the first, the branchpoint A 
(located in the intron, upstream of the 3’ ss) provides a hydroxyl (-OH) groups that 
attacks the 5’ splice site creating a   phosphodiester bond through the process of trans-
esterification. Figure 1.4 shows the two primary reaction pathways/steps through 
which splicing occurs. During the first reaction step, the 2’ –OH groups of the branch 
point attack the 5’ ss leading to 2’-5’ new linkage resulting to lariat intermediate 
formation. This reaction releases the upstream exon with the terminal 3’ –OH group. 
In the second reaction step, the 3’-5’ phosphodiester bond which joins the 3’ ss and 
the intron is attacked by the 3’ –OH on the terminal of the upstream exon. The result 
of this reaction is the formation of brand new 3’-5’ phosphodiester bond linking the two 
exons and getting rid of the lariat intermediate and the intron (figure 1.4). Additional 
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pre-mRNA cis- acting elements are the exonic and intronic splicing silencers (ESSs 
and ISSs) or exonic and intronic splicing enhancers (ESEs and ISEs) which regulate 
alternative or constitutive splicing by binding to the modulatory proteins that either 
repress or stimulate spliceosomal assembly complexes. 
 
 
Figure 1.4. Pre-mRNA splicing mechanism and reaction. Pre-mRNA splicing are cut at the intron-
exon boundaries which constitute the splice sites. Surrounding the introns are 5’ splice site and 3’ splice 
site. The 5’ splice site joins with 3’ splice site to get rid of the intron at the middle. Trans-esterification 
reaction initiated by hydroxyl groups (-OH) occurs leading to the formation of phosphodiester bond. 
Lariat intermediate is formed when the 2’ –OH attacks the 5’ ss thereby creating a new 2’- 5’ linkage. 
3’- OH attack the 3’-5’ phosphodiester bond leading to the removal of the lariat intermediate with the 
intron. 
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If splicing does not occur correctly, incorrect isoform ratios or malfunctioning proteins 
may be produced (Wang et al., 2015).  Efficient splicing of pre-mRNA takes place in 
the spliceosome, a large macromolecular complex consisting of five small nuclear 
ribonucleoproteins (snRNPs), including U1, U2, U4/U6 and U5 and up to100 non-
snRNP splicing factors. The later are mainly RNA binding proteins (RBP) that include 
the SR (serine-arginine rich) proteins and hnRNP (heterogeneous ribonucleoprotein) 
(Kramer, 1996).  snRNPs are the essential spliceosome building block, the first 
primary step in the spliceosome cycle (assembly) is the association of proteins with 
newly transcribed RNA. Newly transcribed RNA associates with hnRNP proteins to 
form an H complex from RNA-protein interaction (Will and Lu, 2011). The second step 
is the early (E) complex formation via proteins binding to 5’ ss and 3’ ss and snRNPs. 
5’ ss forms a base pair with U1 which is strengthened and reinforced by U1 snRNP 
protein component known as U1C. Proteins such as U2AF65, U2AF35 and SF1 bind 
with the 3’ ss. U2AF65 interacts with the polypyrmidine tract, while the U2AF35 and 
SF1 interact with 3’ ss and branchpoint respectively. However, U2AF65 interacts with 
both U2AF35 and SF1.These three proteins tend to stabilize one another on 3’ ss (Shi, 
2017). 
The third step is the formation of A complex. At this stage there is displacement and 
subsequent replacement of SF1 by U2 via base-pairing with the pre-mRNA 
branchpoint. The branchpoint and U2 snRNP base-pairing does not perfectly match, 
this makes the branchpoint adenosine to puff up. The 2’ –OH group of the expanded 
or bulged out adenosine branchpoint kicks off the first splicing catalytic step. U2AF65 
interaction bound to the polypyrimidine tract helps to stabilize branchpoint binding to 
the U2 snRNP (Will and Luhrmann, 2011). 
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The next step is the pre-catalytic B complex formation by U5.U4/U6 tri-snRNP addition 
with its associated proteins. This leads to catalytically active spliceosome B* formation 
which is the fifth step. Here the snRNPs U1 and U4 are released from the spliceosome 
leading to the first catalytic splicing step. Upon formation of catalytically active B* 
spliceosome, a pre-formed nineteen complex (NTC) group of protein otherwise called 
Prp19 is added. The interaction between 5’ ss with U5 and U6 snRNP is stabilized by 
the nineteen complex protein. These rearrangements formulate the catalytic core for 
the splicing reaction first step occurring in the catalytically active B* complex. As 
explained earlier, in the first catalytic step a brand new 2’- 5’ phosphodiester bond is 
formed when the phosphodiester bond of the 5’ ss is attacked by the 2’ –OH group of 
the adenosine branchpoint (Lee and Rio, 2015). 
Next step is the splicing catalysis. This is the splicing catalytic second step which 
occurs in the spliceosome cycle called the C complex where the remaining snRNPs 
such as U2, U5 and U6 are contained and in excess of various proteins. Proteins such 
as U2AF65, U2AF35 and U1 components which are shelved in the earlier spliceosome 
cycle and are therefore not contained in this step. The next step is the post-splicing 
disassembly. When splicing attains completion, the spliceosome releases and exports 
the mRNA to the cytoplasm, the lariat product is discarded and the snRNPs are 
recycled for further use (Warf and Berglund, 2010). 
It is interesting to note that the proteins added at each stage of spliceosome reaction 
help to drive the spliceosome assembly forward (figure 1.5). Energy is also required 
in the form of ATP or GTP (depending on the neuclotide) at each major step especially 
after E complex.  It is also important to briefly highlight the specific role of these 
proteins in the spliceosome assembly. For instatnce, Prp5 plays the role of remodelling 
binding of U2 to branchpoint, SF1 is displaced by SUB2/UAP56, with Prp28 U1 is 
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released to enable U6 binding to 5’ ss, in the presence of Brr2 U4 is released, Snu114-
GTPase regulates Brr2 and also releases U4, Prp8 is a component of catalytic domain 
which also controls Brr2, with Prp2 complex B is remodelled into catalytically active B 
denoted with B*, spliceosome is remodelled into complex C with Prp16, and finally 
snRNPs are released from excised lariat with Prp43 (Lee and Rio, 2011; Will and 
Luhrmann, 2011). 
1.2.3 Functional role of spliceosome in pre-mRNA splicing 
The assembly of spliceosome occurs through an orderly snRNPs binding to the pre-
mRNA in a sequential order of U1, U2 and preformed tri-snRNP U4/U6.U5 (Will and 
Luhrmann, 2011). A commitment complex is formed when U1 binds to the 5’ ss via U1 
and 5’ ss base pairs (Seraphin and Rosbash, 1989). U1 binding to the pre-mRNA 
requires ATP. U2 through base-pairing binds to the branch point to form the pre-
spliceosome which is also ATP dependent. Following U2 binding and 5’ ss interaction, 
the tri-snRNP (U4/U6.U5) (figure 1.5) is recruited to the spliceosome. Upon formation 
of pre-spliceosome, the branch point-binding proteins (BBP) such as SF1 (splice factor 
1) is displaced by U2 in an ATP dependent manner (Rutz and Seraphin, 1999). 
Furthermore, after the U4/U6.U5 binding, spliceosome undergoes a series of 
conformational changes leading to U1 and U4 dissociation from the spliceosome 
(Lamond et al., 1988). To release U4 and U1, ATP is needed to disentangle U4/U6 
duplexes and disorganise U1-5’ ss base-pairing. Brr2 and Prp28 are responsible for 
the release of U4 and U1 respectively. Brr2 has been identified as a U5 component 
and has been implicated in the in vitro catalysis of unwinding U4/U6 duplexes 
(Raghunathan and Guthrie, 1998). In human, Prp28 has been linked with U4/U6.U5 
tri-snRNP which is dependent on SRPK2 phosphorylation (Mathew et al., 2008). 
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Though the mechanism is not yet entirely clear, genetic studies have suggested that 
Prp28 is needed to cause destabilisation of U1-5’ base-pairing (Staley and Guthrie, 
1999). 
New base-pair formation such as base-pairs between U6 and 5’ ss and between U6 
and U2 are made possible by the release of U1 and U4. The cross-link of Prp8 to 5’ 
ss and 3’ ss is an indication that its binding to the pre-mRNA would cause U5 base-
pairing stabilization with exon sequences (Wyatt et al., 1992). 
It has been known that Nine Teen Complex (NTC) is an active integral component of 
spliceosome which provides spliceosomal snRNP support. After U1 and U4 release, 
NTC is needed for activation of spliceosome. It has also been reported that the 
association of U5 and U6 is stabilized by NTC for the formation of active spliceosome, 
hence base-pairings of U5 and U6 are provided by the presence of NTC (Chan et al., 
2003). 
As shown in figure 1.5, the first spliceosomal catalytic step is grouped into two stages, 
the first group is the Prp2-ATP mediated stage with no chemical alterations to the RNA 
substrate, while the second stage is ATP-independent where additional protein factors 
are needed to speed up chemical reaction. In the first catalytic reaction, the Prp2 
function is unclear but is thought to be associated with the release of SF3a and b (U2 
snRNP subunits) from spliceosome (Lardelli et al., 2010). SF3b has been found to 
play essential role during spliceosome assembly by causing U2 branch site 
stabilization (Gozani et al., 1998). The second catalytic step is all about 3’ ss 
identification to align with 5’ ss for the ligation of exon. For exon alignment, U5 plays 
essential role by enabling exons interaction at the splice junction (Crotti et al., 2007). 
Same as the first catalytic step, the second catalytic step is also ATP-dependent 
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requiring Prp16 protein and ATP for transesterification reaction (Horowitz and 
Abelson, 1993). 
 
 
Figure 1.5 Spliceosome structure and function. Circles are used to indicate the snRNPs ordered 
interactions. Lines and boxes are used to indicate the intron and exon sequences respectively. Also 
indicated are the various stages of evolutionary conserved RNA ATPases or GTPases snu114, 
helicaxes such as Prp5, Prp28, sub2/UAP56, Prp2, Prp16, Prp22, Brr2 and Prp43. These ATPases and 
helicaxes function to enable conformational changes. 
 
1.2.4 Assembly of spliceosomes via intron and exon definition 
Intron and exon definitions occur at the very preliminary stages of spliceosome 
assembly and both are crucial for gene expression. Intron definition implies that the 
spliceosome first aggregates and clusters around the intron needed to be spliced. 
Though exons are first recognized by the spliceosome in higher eukaryotes and is 
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called exon definition. The first basic step in exon definition is the recognition and 
binding of exons within the pre-mRNA by the early or preliminary spliceosome 
components (De Conti et al., 2013). These early splicing factors act like punctuation 
marks informing the spliceosome the location of exons specifically at the 3’ ss binding 
by U2AF and 5’ ss binding by U1. U1 binding to to the 5’ ss on one exon extreme is 
stabilized by U2AF binding to the 3’ ss on the other extreme of the exon, and vice 
versa. Exon definition occurs at the early stages of spliceosome assembly while intron 
removal is associated with the later stages of spliceosome assembly interactions 
(Barget, 1995; Elliott and Ladomery, 2011). 
However, intron definition implies that early spliceosome factors first recognize and 
cluster around the intron to be removed. Here the molecular interaction between 
adjoining 5’ ss and 3’ ss occurs correctly within the intron to be removed. In other 
words, the intron to be removed is defined by the spliceosome (Elliott and Ladomery, 
2011). 
1.2.5 Types of alternative splicing 
Alternative pre-mRNA splicing is crucial in the regulation of gene expression as 94% 
of human genes are alternatively spliced (reviewed in Ladomery, 2013). There are four 
major types of alternative splicing which include: (i) exon skipping which is also called 
cassette exons (figure 1.6A); (ii) alternative 5’ and (iii) 3’ splice sites, which occurs at 
the end of the exon at two or more different positions (figure 1.6B and 1.6C 
respectively) (Kim and Goren, 2008). In alternative 5’ ss a choice of exon selection is 
made between 5’ ss position resulting to shorter or longer version of same exon being 
spliced into mRNA. (figure 1.6B).  Likewise, in the 3’ ss, a choice of exon selection is 
made between 3’ ss resulting to longer or shorter version of same exon being spliced 
50 
 
out into mRNA. The fourth type is intron retention, where an intron is retained (not 
spliced) in the mature mRNA (figure 1.6D). Another category is mutually exclusive 
exons (figure 1.6E). This is a case where options are made between exon(s) to be 
included. One is choosen in the place of the other. (Kim and Goren, 2008; Ghigna et 
al., 2008). 
 
Figure 1.6. Five major modes of alternative splicing. (A)  Cassette alternative exon (exon skipping) 
which is the most wide spread (˃30%) form of alternative splicing in vertebrates and invertebrates 
involving skipping of exon(s)   (B) Alternative 5’ splice site (5’ end of the splice junction is used while 
the 3’ end boundary of the upstream exon is changed). (C)Alternative 3’ splice site (use of 3’ end of the 
splice junction while the 5’ boundary of downstream exon is changed. (D) Intron retention. Though very 
rare in vertebrate and invertebrate (˂5%) (Kim et al., 2007), but the predominant form of alternative 
splicing in lower metazoans involving retention of one or more intron(s) which is an indication of mis-
splicing linked to weaker splice sites. (E) Mutually exclusive exons. This involves retention of 1 out of 
2 consecutive exons.   
An understanding of alternative splicing is crucial due to increasing numbers of human 
diseases being associated with aberrant splicing events. Likewise, frequently 
occurring hereditary diseases have been linked to splicing mutations in both exons 
and introns. Mutations of any sort could in most cases cause alterations in pre-mRNA 
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sequences and structures which will prevent the spliceosome from properly decoding 
the exon-intron boundaries (Faustino and Cooper, 2003; Will and Luhrmann, 2011).  
1.2.6 Alternative splicing mutation and disease development 
Alterations in the splicing programme also called aberrant or variant alternative 
splicing have been implicated in the several types of cancer and other diseases 
(Brinkman, 2004; Pajares et al., 2007; David and Manley, 2010; Ahn et al., 2011). 
Brinkman, (2004) suggested that since aberrant splicing is involved in many oncogenic 
disorders including prostate cancer, a better knowledge of the mechanism will provide 
opportunities for drug development. Apart from prostate cancer, aberrant splicing has 
also been investigated and documented in other malignant and non-malignant 
diseases such as lung cancer, cancer of the liver, colorectal cancer, breast cancer, 
ovarian cancer, and skin cancer, to mention but a few (Venables, 2004). Non-
malignant diseases include; neurodegenerative disorders, diabetes, aging and 
vascular diseases. Alternative splicing programme changes in breast and prostate 
tumours compared to normal tissues. Notably, most changes in alternative splicing 
correlate with changes to proteins linked with survival and increased proliferations 
(Venables et al., 2008). All mutations affecting pre-mRNA splicing  result in exon 
skipping, full length protein is not usually expressed (truncated protein) leading to 
varieties of human diseases such as Huntington's disease, muscular dystrophy, 
progeria and cancers of various types including prostate cancer (Duncan et al., 1997; 
Mavrou et al., 2014). Furthermore, many forms of genetic disease could result from 
mutations affecting the intronic and exonic splicing enhancers (ISE, ESE) (Lapuk et 
al., 2014).  
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It is still not entirely clear how aberrant splicing could initiate the development of cancer 
and its progression. However, there is an association between mutations of the 
splicing regulatory factors that alter splice site selection and cancer development. 
Mutations in the long run lead to the formation of non- functional tumour suppressor 
genes which causes cell exposure to cancer. The proportion of disease-causing 
mutations that affect splicing remains controversial. It has been postulated that this 
proportion is as high as 50%; a more conservative estimate is 15%; regardless of the 
correct percentage, the proportion is undoubtedly high (Reviewed in Ward and 
Cooper, 2010). Mutations can also occur at other points such as splice enhancers and 
silencers, branch points and pyrimidine tracts.  It has been reported that exonic 
splicing enhancer point mutation in the breast cancer gene BRCA1) could lead to 
breast cancer (Welcsh and King, 2001). BRCA1 encodes a specialised protein 
responsible for DNA repair; a point mutation in exon 18 causes exon skipping leading 
to breast cancer (Walsh et al., 2006; Tazi et al., 2012; Generali et al., 2007; Buleje et 
al., 2017.). It has also been reported that AA > AG mutation forms a pseudo 3’ ss 
which creates 11 additional neoclotides to the mRNA of BRCA1 resulting in truncated 
protein in breast cancer (Hoffman et al., 1998). This mutation causes alteration of the 
splice factor SRSF1 (ASF/SF2) binding site. SRSF1 itself has been referred to as 
proto-oncogene due to its overexpression in cancer (Karni et al., 2007). SRSF1 has 
many targets and affects the alternative splicing of numerous cancer-associated 
genes. Apart from the splice sites and splice factors (splicing regulators), mutations 
can also occur and affect the expressions and activities of the regulatory sequences 
of the core splicing machinery (Ward and Cooper, 2010). 
Also, point mutations in the gene encoding U4ATAC has been linked to a diseased 
condition known as microcephalic osteodysplastic primordial dwarfism as U4ATAC 
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constitutes part of the minor spliceosome machinery and exons identified by this minor 
spliceosome results in developmental impairments such as growth defects (He et al., 
2011). Furthermore, mutation in adenomatous polyposis coli (APC) gene at intron 4 
results to exon 4 skipping which is the leading cause of familial adenomatous polyposis 
(FAP) (Neklason et al., 2004). Point mutation (AT →GT) on intron 5 of estrogen 
receptor leads to pseudo 5′ ss formation in intron 5 (Wang et al., 1997). Double point 
mutation on exon 7 of neurofibromatosis 1 (NF1) causes in-frame deletion due to ASF 
and SF2 ESE binding site disruption (Colapietro et al., 2003). 
About 185 splicing mutations have been identified in cystic fibrosis transmembrane 
conductance regulator (CFTR) leading to its loss of function for mucus hydration which 
is the major cause of cystic fibrosis. 165 of these mutations are intron localized while 
20 are located in the exon. In healthy individuals, exon 9 and 12 are alternatively 
spliced though there are variations of ratio of exon inclusion per individual which 
explains the variations in the trans-acting elements concentration per individual. 
Complete skipping of these exons (9 and 12) due to mutation leads to full clinical 
manifestation of cystic fibrosis presenting with digestive and respirartory tract 
impairement. Also affected are the sweat gland, biliary, intestinal, male ganitalia and 
pancreatic systems. 
Spinal muscular atrophy (SMA) is a neurodegenerative disorder and the most common 
cause of infantile mortality due to loss of spinal cord alpha- motor neurons. SMA 
occurs during infantile stage of life due to mutation leading to the diminution of survival 
motor neuron gene 1 (SMN1) encoding SMN protein that modulates snRNP assembly 
(Zhang et al., 2008). 
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Tauopathies referes to numerous disorders of the CNS with abnormal accumulation 
of intracellular microtubule associated protein tau encoded by microtubule associated 
protein tau gene (MAPT) found on chromosome 17. About eight of sixteen exons of 
MAPT gene are alternatively spliced. Four and three microtubule repeats of this gene 
called 4R and 3R respectively are created by exon 10 inclusion and skipping 
respectively. An example of disease emalnating from dominant mutation of tau gene 
is frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP-17). A 
mutation in exon 10 called N279K which causes pre-mRNA alteration of 4R and 3R 
tau isoforms has been linked with FTDP-17 (Gallo et al., 2007; Andreadis, 2006). 
Research suggests that alterations between 4R and 3R tau isoform ratio due to 
mutation is the leading cause of FTDP-17 (Dawson et al., 2007). There is also a 
speculation that changes in the ratio between 4R and 3R tau isoforms could be found 
in other tauopathies such as Alzheimer’s disease. 
Furthermore, mutation leading to a disease condition could also occur at the intron. 
One of the intronic mutation diseases that activate pseudo splice site is Hutchinson-
Gilford progeria syndrome (HGPS). In Hutchinson Gilford progeria syndrome (HGPS), 
instead of splice site mutation, a brand new 5’ splice site is created within an exon 11 
in the LMNA gene encoding Lamin A/C. Lamin proteins are evenly distributed in the 
nucleoplasm and are responsible for DNA transcription, replication, nuclear assemble 
and disassemble. Individuals suffering from HGPS have accelerated aging with a 
maximum of thirteen years life span and frail features such as baldness, midface 
hypoplasia, loss of subcutaneous fat, osteoporosis, wizened skins and clogged 
arteries. In contrast, deletion of the entire LMNA gene gives rise to muscular dystrophy 
(Kim et al., 2011). 
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There is an association between hypercholesterolemia (leading to arteriosclerosis) 
and a mutation (single neuclotide polymorphism - SNP) at exon 12 of low-density 
lipoprotein receptor (LDLR). LDLR physiologically plays the role of removal of low-
density lipoprotein (LDL) that would cause hypercholesterolemia from the blood 
stream. This suggests that skipping of exon 12 by SNP is linked with cholesterol level 
in the blood (Zhu et al., 2007).  
A mutation at the 5’ ss leading to a disease called familial dysautonomia (FD) has 
been identified (Cooper et al., 2006). FD is generally caused by complete loss of i-
kappa-B kinase complex associated protein (IKBKAP) function leading to nervous 
system development impairment in children with symptoms of demyelination, volmiting 
crisis and reduced pain perception. The loss of (IKBKAP) is caused by a point mutation 
of 5’ ss at exon 20 where T replaces C at position 6 of inton 20 which causes the 
interruption of U1snRNA base-pairing. This mutation definitely prompts exon 20 
skipping as the intronic 5’ ss is being weakened (Carmel et al., 2004). 
Medium-chain acetyl-CoA dehydrogenase (MCAD) deficiency is another form of 
splicing mutation resulting to mitochondrial β-oxidation defect with symptpms of 
metabolic crisis such as high blood glucose, seizure and lethargy. Under normal 
physiological condition, this enzyme (MCAD) is responsible for medium chain length 
fatty acid degradation. Its deficiency is caused by missense mutation (362C->T) at 
exon 5 of MCAD gene leading to exon 5 skipping and mRNA degredation by NMD 
(Nielson et al., 2007). Some of the splicing mutation diseases and features are 
depicted in table 1.
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Table 1. Examples of splicing mutation diseases and features (Tazi et al., 2009; Anna and Monika, 2018) 
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Other diseases that may be affected by aberrant splicing due to mutation include: 
Myotonic dystrophy (DM), Leukaemia and sarcomas, Alzheimer disease (AD), 
paraneoplastic syndrome, stickler syndrome, retinitis pigmentosa, azoospermia, 
hepatocellular carcinoma, papillary renal cell carcinoma, fabry disease, X-linked 
spondyloepiphyseal dysplasia tarda, hay-wells syndrome, Ehlers-Danlos syndrome, 
androgen insensitivity syndrome, xeroderma pigmentosum and so on (Garcia-blanco 
et al., 2004; Anna and Monika, 2018). 
1.2.7 Regulation of alternative splicing by splice factors 
SR proteins are essentially involved in spliceosome maturation and are therefore 
required for efficient pre-mRNA splicing. Components of the SR proteins include RNA 
recognition motifs and RS domain otherwise known as the C- terminal domain rich in 
Arg-Ser repeats. In the RS domain, SR proteins are phosphorylated at many serines 
by SRPKs. Phosphorylation of the RS domain facilitates SR protein entry into the 
nucleus and also play crucial role in both mRNA export and alternative splicing 
(Mueller and Hertel, 2012; Ghosh and Adams, 2011). Serine – argenine rich proteins 
called SR proteins are members of nuclear factors with numerous essential roles in 
both constitutive and alternative RNA splicing. They participate in many stages of 
splicing regulations by binding exonic splicing enhancers (ESEs) via RNA recognition 
motifs (RRM) and by moderating protein-RNA and protein-protein interactions through 
their RS domain (Shen and Green, 2006; Busch and Hertel, 2012). Specific RNA 
binding proteins are identified and recognised by  splice factors. RNA recognition motif 
(RRM) is often encountered as the RNA binding domain. This motif identifies generally 
the targeted single stranded RNA sequences (Pedrotti et al., 2012).  
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In the past, several names have been given to same SR protein making it difficult to 
understand in literatures. For clarity, a more standardized nomenclature has been 
proposed for twelve core members of SR proteins. For instatnce, ASF/SF2 or 
SF2/ASF is presently named SRSF1; SC35 is now named SRSF2; SRp20 is renamed 
SRSF3; SRp75 is same as SRSF4; SRp40 equals SRSF5; SRp55 equals SRSF6 and 
9G8 is renamed SRSF7 (Manley and Krainer, 2010). These SR proteins are the key 
substrates of protein kinases activity which are vital in the regulation of alternative 
splicing (Amin et al., 2011; David and Manley, 2010). 
In constitutive splicing, SR proteins such as SRSF1 and SRSF2 play essential 
regulatory roles, for instatnce, SRSF1 and 2 facilitate binding of U1 snRNP to 5’ ss 
and U2 snRNP to 3’ ss and subsequently stop the association between the initial splice 
site recognition steps in the pre- and mature spliceosomes  (Cho te al., 2012). The 
best known function of SR protein is its ability to promote selection of splice site by 
binding to the ESEs. The choice of splice site regulation and selection is usually 
initiated and determined by the exonic and intronic splicing enhancers (ESEs, ISEs) 
for exons and introns respectively. Weak splice sites are actively promoted by the 
splice enhancers, conversely, strong splice sites are repressed by the splice silencers. 
Splice factors such as SR proteins and RNA binding proteins such as hnRNP are 
typical examples of splicing activators and suppressors respectively (Cooper et al., 
1997). Therefore, alternative splicing can be actively regulated by the interaction of 
the specific regulatory RNA sequences such as ESE or ISE and the binding splice 
factors. Regulatory sequences can also repress splicing; these are known as ESS and 
ISS (exonic and intronic splice silencers). A study suggest that SR proteins do not only 
enhance exon inclusion but also facilitate induction of exon skipping depending on the 
pre-mRNA interactions. For instatnce, binding of SR protein to exon promotes exon 
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inclusion while exon skipping is the resultant effect when SR protein binds to the 
intronic sequence (Erkelenz et al., 2013). In 2011, Han et al demonstrated that SR 
protein binding to a flanking exon resulted to internal alternative exon skipping where 
as exon inclusion is promoted when SR protein binds to the alternative exon (Han et 
al., 2011; Stanford et al., 2009). Other roles of SR proteins in splicing include: RNA 
stability regulation through nonsense mediated RNA decay (Zang and Krainer, 2004), 
chromatin interaction and nuclear export of mRNA ((Loomis et al., 2009; Huang and 
Steitz, 2005), transcription machinery coupling and translational control by 
cytoplasmic shuttling of SR proteins (Sanford et al., 2004; Michlewski et al., 2008). 
Another form of alternative splicing regulation is through promoters. This was indicated 
in a minigene construct where the type of promoter used typically influenced the 
expression of the splice isoforms ratio. Alternative splicing is regulated by promoters 
through the mechanism of transcriptional elongation speed by the RNA polymerase II. 
For instance, spliceosomes tend to choose stronger splice sites at fast transcription. 
However, weaker splice sites take more time to be recognised by spliceosomes when 
the transcription is slow. This was typically illustrated in 2003 by Mata et al in EDI exon 
skipping in the fibronectin gene due to faster transcriptional elongation initiated by 
RNA polymerase II. Increased exon inclusion was observed when a transfection to 
cause mutation and slow down the RNA polymerase II was initiated. Furthermore, 
alterations of RNA polymerase II elongation in different part of the gene affects the 
specificity of exons alternative splicing (Mata et al., 2003). 
For more information. It is worthy of note that alternative splicing factor; ASF/SF2) now 
called SRSF1) overexpression has been identified in numerous cancers due to its pro-
oncogenic potential (Das and Krainer, 2014). Upregulated SRSF1 is associated with 
increased cell transformation, proliferation and invasion (Olshavsky et al., 2010). 
60 
 
SRSF1 expression mediates switching of caspase 9 and BIN1 splicing to produce pro-
oncogenic isoform that supress apoptosis in many cancer cells including prostate 
cancer (Anczukow et al., 2012). In the RON and MNK2 genes, increased SRSF1 
levels was found to promote the pro-oncogenic isoforms thereby enhancing the 
invasive and migratory processes of cancer cells including prostate cancer. This is 
thought to occur due to the impairment of signalling pathways of mammalian target of 
rapamycin (mTOR) and p38-mitogen-activated protein kinase (MAPK) (Ghigna et al., 
2005; Maimon et al., 2014). 
1.2.8 SR protein kinases 
The first SR protein kinase was discovered in 1994 and named SR protein specific 
kinase 1 (SRPK1) (Gui et al., 1994). Other homologues such as SRPK2 and SRPK3 
were subsequently discovered in human and mice. While SRPK1 is generally 
expressed, SRPK2 and SRPK3 are majorly expressed in the nervous system and 
muscle cells respectively (Nakagawa et al., 2005; Wang et al., 1998), suggesting that 
individual members of SRPK family may possess unique function during development 
and in various cell types. 
Apart from SRPKs, there are several other kinases capable of phosphorylating SR 
proteins in vitro. Some of which include: Akt (Patel et al., 2005), protein kinase A 
(PKA), protein kinase C (PKC) (Colwill et al., 1996), dual-specificity tyrosine 
phosphorylation-regulated kinases (DYRKs) (Aranda et al., 2011) and cyclin-
dependent like kinases otherwise called CDC-like kinases (CLK1-4) (Duncan et al., 
1998). However, among these kinases, only CLKs and SRPKs are capable of in vivo 
phosphorylation of SR proteins as demonstrated through either direct chemical 
inhibition or genetic ablation (Zhong et al., 2009; Yomoda et al., 2008).  
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1.2.9 Regulation of splice factors (SR proteins) by splice factor kinases (SRPK 
and CLK) 
Over ten years ago, it was discovered that SR specific protein kinases such as SRPKs 
(SR protein kinases) and CLKs (CDC2-like protein kinases) are responsible for SR 
protein phosphorylation causing changes in SR protein functions and intracellular 
distribution. Studies have shown the implication of splicing factors in various forms of 
cancer. For instance, in colorectal cancer, SRSF1 expression is found to be 
upregulated. In breast, prostate, pancreatic, and colorectal cancers, splice factor 
kinases such as SRPK1 and CLK1 expressions are reported to be upregulated (Zhou 
et al., 2012). Mermoud et al., (1994) suggested that phosphorylation is an essential 
process for assembly of spliceosome whereas dephosphorylation is a critical catalytic 
process of spliceosome assembly. It is important to understand the phosphorylation 
mechanism especially how the SR proteins are recognised and phosphorylated by the 
SR protein kinase (Zhou and Zu, 2013). Structurally, an SR protein is composed of C- 
and N-terminals. The C-terminal is otherwise called the RS domain, and is rich in Arg-
Ser repeats. A representative example of this domain is ASF/SF2 now called SRSF1. 
RS domains of SR proteins are phosphorylated by protein kinases such as CDC-like 
kinases (CLKs) and serine-arginine protein kinases (SRPKs) thereby modulating their 
interactions with exonic or intronic splicing enhancers of pre-mRNAs as well as their 
subcellular localizations (Twyffels et al., 2011; Long and Caceres, 2009). The N-
terminal of SR proteins is composed of RNA recognition motifs (RRMs) which 
determine the targets of the SR proteins by binding sequences such as ESE splicing 
enhancers (Zuo et al., 1994) 
SR proteins can be phosphorylated or dephosphorylated at multiple sites in the SR 
domain leading to the functional alteration of the SR proteins. For instance, to ensure 
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the recognition of an appropriate splice site, the splice factor SRSF2 cooperates with 
U1 snRNP facilitating its interaction with the 5’ splice site and the interaction is 
phosphorylation dependent (Kohtz et al., 1994). Two of the best studied splice factor 
protein kinase families (CLK and SRPK) are responsible for RS domain 
phosphorylation thereby altering the cellular distribution of the SR proteins (Colwill et 
al., 1996). The impact of RS domain phosphorylation in alternative splicing has not 
been fully elucidated. The extent of RS domain phosphorylation in SRSF1 regulates 
the alternative splicing of apoptotic genes such as Bcl-x and caspase-9 favouring 
expression of their antiapoptotic isoforns (Massiello and Chalfant, 2006). Both families 
of kinases cooperate to regulate the function of the SR proteins in the cell. 
 
SRPK is diferent from CLK due to its subcellular localization. However, SRPK is 
detectable in both cytoplasm and nucleus (figure 1.7) with a greater proportion found 
in the cytoplasm. All members of CLK are nuclear localised and co-localized in the 
nuclear specles with SR proteins (figure 1.7) (Naro and Sette, 2013). These 
differences in SRPKs and CLKs localization suggest a synergic phosphorylation 
regulation partern of SR proteins. For instance, SRPKs in the cytoplasm play the role 
of initial phosphorylation of SR proteins to promote their nuclear import while the CLKs 
tune up and improve the SR protein phosphorylation state in the nucleus (figure 1.7). 
Therefore both SRPKs and CLKs work in a complementary and synergic manner to 
bring about splicing regulation by SR protein phosphorylation and other processes 
such as RNA export (Ghosh and Adams, 2011). 
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Stamm et al., 2008 suggested that splice factor activities can be regulated by 
phosphorylation through the following mechanisms: altering their RNA binding 
capacity or ability to interact with other proteins (i.e biochemical properties alteration) 
and or manipulating their intracellular localization. Splice factors are either nuclear or 
cytoplasmic localized. For instance, SRSF1 has both nuclear and cytoplasmic 
functions. It is imported into the nucleus when phosphorylated by the SR protein 
kinases (SRPKs), Phosphorylation of the SR proteins by the SR protein kinases 
causes increased nuclear concentration of the SR proteins which makes them 
available to participate in the splicing reaction (Duncan et al., 1997; Zhou et al., 2013; 
Araki et al., 2015), whereas its dephosphorylation by protein kinase inhibitor promotes 
its nuclear export (Giannakouros et al., 2011). SRSF1 accumulate in the nuclear 
speckles (splice factor storage site) and the CLK kinases otherwise called CDC2-like 
‘LAMMER’ kinases hyperphosphorylate SRSF1 in the nucleus (figure 1.7). The 
hyperphosphorylation of SRSF1 (and of other splice factors) by the CLK kinases 
facilitate its release from the nuclear speckles to the location where splicing takes 
place. 
To understand the biological importance of SRSF1 phosphorylation, it is worth noting 
that SRSF1 is involved in the alternative splicing regulation of vascular endothelial 
growth factor A (VEGFA). The two isoforms of VEGF-A that arise through alternative 
splicing are pro and antiangiogenic isoforms. The pro-angiogenic isoform is being 
promoted by SRSF1 due to the use of exon 8 (VEGFA terminal exon) 3’ proximal 
splice site. SRSF1 nuclear accumulation is due to high levels of SRPK1 leading to 
high expression of proangiogenic VEGFA. However, cytoplasmic accumulation of 
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SRSF1 results from chemical inhibition or knockdown of SRPK1 resulting in higher 
antiangiogenic VEGFA isoform expression (Amin et al., 2011). 
  
.   
 
Figure 1.7 Regulation of splice factor activities by splice factor kinases. SRPKs and CLKs families 
mediates the phosphorylation of splice factors (SRps SR- proteins) and other components of 
spliceosome. The SRPK located in the mammalian cytoplasmic cells mediates the transport of newly 
synthesized SRps into the nucleus by phosphorylating them. SRPKs are said to have dual localization 
due to their ability to also translocate into the nucleus during osmotic stress or G2/M cell cycle phase 
and therefore has the potential of phosphorylating SRps both in the cytoplasm and nucleus (Naro and 
Sette, 2013; Gui et al., 1994). Cytoplasmic phosphorylation of the SRPs by the SRPK ensures their 
nuclear import. While in the nucleus the SRPK mediates the SRps release from the nuclear speckles. 
The CLKs are localized with the SRps in the nucler speckles. Hyper phosphorylation of the SRps is 
initiated by the overexpression of CLKs which automatically leads to disassembly of the nuclear 
speckles (Ghosh and Adams, 2011). CLKs nuclear localization distinguishes it from SRPKs which is 
mostly localized in the cytoplasm. This localization difference makes it possible for their interaction to 
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regulate subcellular SRps localization. It has also been reported that CLKs have wider substrate 
specificity while SRPK’s substrate specificity is confined to phosphorylation of ser-arg-sites (Colwill et 
al., 1996). 
Both in vivo and in vitro studies suggest that CLK family have the ability to modulate 
splicing (Ninomiya et al., 2011; Araki et al., 2015; Muraki et al., 2004). Duncan et al. 
also investigated the role of CLKs on splicing and concluded that the CLK1 protein 
kinase specifically regulates alternative splicing by phosphorylation of the SR protein 
(within the nucleus, particularly in nuclear speckles (splice factor storage sites; Duncan 
et al., 1997). Ninomiya et al., (2011) carried research on the effect of the benzothiazole 
compound TG003 on the phosphorylation of SR proteins, specifically SRSF4, by 
CLK1. They discovered that TG003 administration to cultured cells causes 
dephosphorylation of SRSF4 after one hour and re-phosphorylation of SRSF4 
occurred after the removal of the compound. Furthermore, researchers have also 
looked at the effect of TG003 on viruses. TG003 inhibits proliferation of influenza virus 
both in vivo and in vitro (Karlas et al., 2010 and Nishida et al., 2011).  
These SR proteins are known to be localized within the nucleus where they play crucial 
role in the alternative splicing programme. These protein kinases are crucial factors 
that determine exon selection during splicing by binding to either exonic or intronic 
splicing enhancers of pre-mRNA (Naro and Sette, 2013). Notably, both over 
phosphorylation and under phosphorylation of SR proteins by the protein kinases 
serves as a regulatory function which can prevent splicing (Duncan et al., 1995). In 
addition to its active role in the pre-mRNA splicing in the nucleus, SR proteins also 
participate in posttranscriptional processes such as translation, nonsense-mediated 
mRNA decay (NMD) and nuclear export of the mature mRNA (Liu et al., 2013; Prasad 
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and Manley, 2003) and these additional activities are undoubtedly also affected by SR 
protein phosphorylation by CLKs.  
CLKs do not only phosphorylate the classical SR proteins. Other splice factors such 
as SPF45, overexpressed in cancer, are phosphorylated by CLK1. The inhibition of 
CLK1 drastically reduced SPF45 induced exon skipping (Liu et al., 2013). Chemical 
inhibitors of splice factor kinases have been developed by researchers. Such inhibitors 
include TG003, a specific CLK1 inhibitor and has also been reported to modulate 
alternative splicing of pre-mRNAs of CLK and SRSF2 (Muraki et al., 2004). Similarly, 
natural chemical compounds such as herboxidiene, spliceostatin A (SSA) and E7107 
has been reported as anti-tumour agents targeting core splicing components such as 
SF3B1 (Kotake et al., 2007; Webb et al., 2013). 
 
Araki et al., (2015) conducted investigation of the potential inhibitory effect on protein 
kinases on 870,000 known compounds at a concentration of 1 µM. About 319 of the 
compounds met the criteria to inhibit 30% of the in vitro kinase activity of protein 
kinases such as SRPK1. Three compounds identified as compound (Cpd1-3) were 
investigated in the in vitro kinase assay using CLKS and SRPKS. Cpd -1, Cpd-2 and 
Cpd-3 were identified to possess inhibitory effect at varying capacities against CLK1, 
CLK2 and SRPK1 respectively. Cellular activities of the above Cpds were also 
investigated using anti- pan- phospho- SR antibody. It was identified that the 
phosphorylation levels of SRSF4 (SRp75) was drastically reduced in a dose 
dependent manner by the three Cpds. Furthermore, TG003 is a chemical and specific 
inhibitor of CLK1, Chemical inhibition of CLK1 with TG003 reduced the 
phosphorylation levels of splice factors such as SRSF1 and SRSF4, in a dose 
dependent manner. Phosphorylation levels of all SR proteins was reduced upon 
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treatment of DU145 cells with alkaline phosphatase, whereas phosphatase inhibitor 
treatment of same cells had a minimal effect confirming that phosphorylated SR 
proteins was selectively detected by the anti-phospho SR antibody (Araki et al., 2015). 
 
The selection of splice site can be altered by many extra cellular factors such as 
osmotic shock, growth factors, cytokines, depolarization and UVC irradiation through 
phosphorylation causing changes in SR protein localization (Stamm, 2002). Although 
the full physiological role of the extensive phosphorylation of the RS domain of the SR 
proteins is not yet known (Gui et al., 1994), it is clear that the phosphorylation affects 
the protein-protein and protein-RNA interactions of the SR proteins (Xiao and Manley, 
1997). Several kinases including SRPK, CLK, hPRP4, LAMMER family kinases has 
been reported to phosphorylate SR proteins (Rossi et al., 1996; Kojima et al., 2001). 
(Nayler et al., 1997) reported in vitro and in vivo CLK family kinase phosphorylation of 
SR protein and SF2/ASF respectively. (Duncan et al., 1997) reported that CLKs over 
expression in disease (cancer for instance) interrupts pre-mRNA splicing site selection 
(of its own transcript and adenovirus E1A transcript). Though the signal, functional or 
biological pathway is not yet clear, but these findings have confirmed that alternative 
splicing is regulated by CLK family through phosphorylation of the SR proteins. 
 
1.2.10 Alternative splicing and epithelial mesenchymal transition (EMT) 
Interactions between epithelial and mesenchymal cells are essential in embryonic 
stages and in foetal organ development. The epithelial and the mesenchymal cells 
form two transitions (epithelial mesenchymal transition- EMT and mesenchymal 
epithelial transition - MET) both required for normal development (Larue and 
Bellacosa, 2005; Peng et al., 2014; Pei et al., 2019).  EMT has been linked to 
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metastatic disease development and this is linked to alternative splicing changes 
(Warzecha and Carstens, 2012). During EMT, several known genes with alternative 
splicing changes include: p120- catenin which controls activities of cadherin, MENA 
(ENAH) which is a cell motility regulator, CD44 which regulates cell adhesion, and the 
fibroblast growth factor receptor 2 (FGFR2) (Warzecha and Carstens, 2012, Xu et al., 
2015). 
1.2.11 Identification of mutations causing splicing defects  
DNA sequencing is a critical tool for the identification of disease-causing mutations 
(Foley et al., 2015; Mahdieh and Rabbani, 2013). Direct genetic comparison between 
normal and abnormal tissues through biopsy would have been the best mutation 
detection method but it is difficult to extract affected tissue for instance heart and brain 
tissues without harming the subject (Jung et al., 2013). 
When analysing mutations, software such as ESEfinder can be employed to determine 
if the mutation might affect an ESE or splice factor binding sites (Cartegni et al., 2003). 
Regardless of predictive software, it is important to assess the potential effect of the 
mutation on splicing directly by analysing patient RNA (Morlan et al., 2009). Minigenes 
derived from genomic DNA can also be employed in the analysis of mRNA splicing 
mutations. Minigenes with or without the mutations can be transfected into cell line 
models to determine the effect of the mutation on splicing. 
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1.3 Targeting the splicing machinery in prostate cancer 
1.3.1 Therapeutic manipulation of alternative splicing: 
There is a lot of interest nowadays in manipulating alternative splicing in a way that 
could be therapeutically useful (Hagen and Ladomery, 2012; Ghigna et al., 2008; 
Antonopoulou and Ladomery, 2018). RNA targeted therapies have been a growing 
and promising approach to curb the devastating effect of cancer including in prostate 
cancer (Bennett and Swayze, 2010, Havens et al., 2013).  There are several strategies 
that can be employed to manipulate alternative splicing towards therapy.  
Antisense oligonucleotides (ASOs) these are short oligonucleotides with 15 to 25 
bases targeting specific RNA transcripts. The functional mechanism of ASOs is the 
formation of Watson-Crick base pairs with targeted RNA. ASO directed to a splice site 
will inhibit access of the splicing factors to RNA sequence at that site thereby blocking 
splicing at that point. Splicing may also be redirected to another splice site. 
Conversely, splicing can either be promoted or blocked when trans-acting regulatory 
splicing factors are inhibited due to ASOs targeted to splicing silencers or enhancers. 
Furthermore, the ASOs specific sequence permits them to bind accurately and 
precisely at the endogenous RNA. More importantly, ASOs can be designed to target 
specifically to mutated genes. These qualities make ASOs a universal tool for targeting 
RNA expression for therapeutic purposes (Bennett and Swayze, 2010). The ultimate 
goal of utilising ASOs as a therapeutic potential is either to eliminate harmful proteins 
or restore the functional expression of a vital protein that is not expressed or made 
silent. Therefore, a functional protein that was lost due to mutation is restored  by ASO. 
ASOs restore a dormant or lost protein by either inhibiting the pseudo (cryptic) splice 
site or by blocking exon skipping via targeting regulatory splicing sequences. 
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Antisense oligonucleotides that modify splicing have been called ‘Splice-Switching 
Oligonucleotides’ (SSOs) (Gleave and Monia, 2005; Chan et al., 2006). 
Another strategy is targeting the alternative splicing regulatory machinery using 
compounds that specifically target and inhibit splice factors or components of the core 
spliceosome. Chromatin remodelling factors that are functionally involved in exon 
definition can also be chemically targeted.  Recently, trans-splicing otherwise called 
spliceosomal mediated RNA trans-splicing (SMaRT) has been subjected to detailed 
studies for development of specific therapies against diseases including prostate 
cancer (Wally et al., 2012). SMaRT is the most effective and efficient means of 
correcting gene expression with mutations at 5’ or 3’ splice sites. For example, 
mutations prevent U1 snRNA binding to 5’ss which in turn inhibit spliceosome 
assembly leading to splicing failure. In order to restore normal splicing, snRNAs 
(modified version of spliceosome) have been developed with sequence alterations to 
restore mutated 5’ss base-pairing (Schmid et al., 2012). 
Another promising approach is to target splice factor kinases; the inhibition of SRPK1 
with the compound SPHINX has been reported as potentially useful in blocking the 
growth of prostate cancer cells (Mavrou et al., 2015). Previously in 2011, Amin et al 
showed that SRPIN340, an earlier SRPK1 inhibitor also developed in the Hagiwara 
lab, blocks angiogenesis and therefore tumour growth in mouse xenografts. The 
mechanism of action is through altering SRSF1-regulated alternative splicing of 
VEGFA. Active, phosphor-SRSF1 promotes the expression of pro-angiogenic VEGFA. 
Whereas much attention has focused on the effects of SRPK1 inhibition, less is known 
about the potential of CLK inhibition. 
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1.3.2 CLK inhibition in prostate cancer 
CLKs otherwise called dual specificity protein kinases (CDC2-like protein kinases), as 
discussed, are major regulators of pre-mRNA splicing. During pre-mRNA processing, 
the CLKs phosphorylate the SR proteins in the nucleus triggering their release into the 
nucleoplasm where they can phosphorylate their substrates and contribute to splicing 
regulation (Aubol et al., 2014) 
The CLK family consists of four related genes named CLK1 to CLK4. Expression of 
CLK3 is seen in mature spermatozoa suggesting a role in fertilization; whereas CLK1, 
2 and 4 are widely expressed in several tissues (Menegay et al., 1999). The biological 
function of CLK1, 2 and 4 is not yet entirely clear. There is increasing evidence that 
CLKs are involved in cancer. It has been found that during malignant cell 
differentiations, some SRPKs and all members of the CLK family are overexpressed 
(Zhou et al., 2013).  
 As discussed previously, CLK1 substrates include non-SR proteins such as SPF45. 
Overexpression of SPF45 triggers cell proliferation, migration and invasion through 
exon skipping in many target mRNAs. Multidrug resistance was also reported following 
overexpression of SPF45 In both ovarian (A2780) and cervical (HeLa) cancer cells 
(Sampath et al., 2003). Interestingly, CLK1 mediated phosphorylation increases 
SPF45 protein expression while CLK1 inhibition stimulates SPF45 degradation 
(EIHady et al., 2017). CLKs are also likely involved in viral replication. Reducing CLK2 
activity causes reduction of HIV-1viral gag protein while overexpressed CLK1 
increases it (Wong et al., 2011). 
CLK1 and 4 maintain cell growth and viability in hypoxic cancer cells (Jakubauskiene 
et al., 2015; Eisenreich et al., 2013). It was found that hypoxia inducible factors (HIFs) 
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contribute to increased CLK1 and CLK4 expression. Bowler et al (2018) report that 
hypoxia causes upregulation of SRPK1, and also CLK1 and CLK3, but not CLK2 or 
CLK4 in hypoxic PC3 prostate cancer cells. 
EIHady et al., (2017) also observed a related cell growth retardation following CLK1 
inhibition. It was further reported that the chemistry behind the slow growth and anti -
cancer effect of CLK1 inhibition on tumour cells is because CLK1 inhibition leads to 
nonsense mediated decay of mRNAs of genes associated with cell viability, growth 
and survival. Therefore, treatment based on CLK1 inhibition could also work by 
preventing translation of mRNAs that promote cell proliferation (EIHady et al., 2017). 
EIHady et al., (2017) also verified the lack of cytotoxicity potential of CLK1 and -4 
inhibitors using normal cells such as human embryonic kidney cells (HEK293), normal 
peripheral blood lymphocytes (PBLs). There was no evidence of cytotoxic effect of 
CLK inhibitors on the proliferating and non-proliferating HEK293 and PBLs 
respectively.  
In search of chemical compounds that could target splice factor kinases, Muraki et al., 
in 2004 screened several compounds discovered TG003, an inhibitor of CLK1 and its 
close relative CLK4 (Muraki et al., 2004). Muraki et al, 2004, tested the specificity 
inhibitory effect of TG003, a benzothiazole, on CLK1/STY with other protein kinases 
such as SRPK1, SRPK2, PKC, PKA, CLK2 and CLK3, and discovered that TG003 
inhibits most efficiently CLK1 and its closest relative CLK4. 10nM of TG003 is able to 
inhibit IC50 of CLK1 activity (Li et al., 2013). 
 Apart from the benzothiazole TG003, other specific CLK1 inhibitors have been 
reported, they include: the indole KH-CB19 (IC50, 20 nM for CLK1) (Fedorov et al., 
2011), the quinazoline NCGC00010037 (IC50, 37 nM for CLK1) (Rosenthal et al., 
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2011). In vitro and in vivo studies have confirmed CLK1 inhibitors as antiviral agents 
against influenza virus (Zu et al., 2015). For the purposes of this study, and proof-of-
principle, and because it is a well established and widely used CLK inhibitor, and 
commercially available, we decided to focus on TG003. 
 
1.4 Aims and Objectives 
1.4.1 Hypothesis 
There is therapeutic potential in targeting CLKs such as CLK1 in the context of prostate 
cancer.  
1.4.2 Aims  
Aim 1. To gain a better understanding of the biological function of CLK1. 
Aim 2. To explore the potential benefit of targeting of CLK1 in vivo. 
1.4.3 Objectives 
Aim 1.  
(i) To study the effect of CLK1 inhibition with TG003 or knockdown with siRNA on 
cell proliferation and apoptosis in prostate cancer cell lines. 
(ii) To study the effect of CLK1 inhibition with TG003 or knockdown on alternative 
splicing of cancer-associated (eg apoptosis related) genes. 
(iii) To study the effect of CLK1 inhibition and knockdown on cell migration and 
invasion and EMT marker expression. 
Aim 2.   
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 (i)   To study the effect of CLK inhibition with TG003 on the growth of prostate 
cancer cells subcutaneously injected into nude mice. 
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Chapter 2 
 
2.0 Materials and Methods 
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2.1 Cell culture   
Prostate cell cancer lines (androgen independent PC3 and DU145 cells; and androgen 
dependent VCaP cells) and the immortalised normal prostate epithelium cell line PNT2 
obtained from ECACC were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) 
containing 5mM glucose and 5mM L-glutamine, 10% fetal bovine serum (FBS) and 
1% sodium pyruvate were added to make complete media. The PC3 cell lines and all 
the reagents mentioned above were purchased from Sigma Aldrich, USA. 
2.2 Cell treatments with TG003 
The benzothiazole compound TG003 that inhibits CLK1 was bought from Sigma 
Aldrich UK. 50mM stock solutions were prepared in dimethylsulfoxide (DMSO) solvent. 
1x106 Prostate cancer PC3 and DU145 cells were treated independently with various 
concentrations (10 nM -100 µM) of TG003 for 24-72 hours. Phase contrast microscopy 
(using a Nikon Inverter, Cat No. TE 300, UK) was used to check cell morphology. 
2.3 Adherent cell trypsinisation 
All adherent cells used in this study underwent trypsinisation as soon as they were 
about 80% confluent. This was important to avoid excess cell mass accumulation in 
T75 used for cell culture. In T75 culture flask containing 80% confluent adherent cells, 
5ml of phosphate buffer saline (PBS) was added and mechanically agitated to wash 
the cells. The process was repeated twice before 1ml of 1x trypsin EDTA (Sigma 
Aldrich) was added and rocked to cover the flask and incubated at 37oC for 5 minutes. 
This process detached the cells from the bottom of the flask and made them float; the 
flask was checked every 2 minutes to ensure complete detachment. 5 ml of fresh 
complete DMEM was added to the flask and the entire content of the flask was 
carefully pipetted into 15 ml tube. The 10% FBS content of the DMEM inactivated the 
77 
 
trypsin. Tubes containing the cell mixture was centrifuged at 1,000rpm for 5 minutes 
at room temperature using Beckman coulter Allegra x-22R centrifuge (Germany). The 
supernatant was discarded while the cell pellets were re-suspended in fresh DMEM 
for further use (counting or splitting). 
2.4 Cell cryopreservation 
Cells were preserved in liquid nitrogen to ensure availability of early passages. 
Confluent cells were trypsinised with 1x trypsin EDTA (Sigma-Aldrich) and incubated 
for 5 minutes until the adherent cells detached from T75 flask and floated. 5 ml of 
complete DMEM was added into the flask and the cell mixture pipetted into 15ml tube. 
The tube was centrifuged at room temperature at 1000 rpm for 5 minutes. The 
supernatant was discarded and the cell pellets were counted after being re-suspended 
in freezing media containing 20% (v/v) FBS, 10% (v/v) DMSO and 70% (v/v) 
Dulbecco’s Modified Eagle Medium (DMEM). Freezing media was adjusted to obtain 
a concentration of 1x106cell/ml. Aliquots of 1ml containing 1 million cells in cryovials 
were inserted into a cryopreserving chamber containing isopropanol and left overnight 
in -80oC before the cryovials were stored in a liquid nitrogen chamber for future use.  
2.5 Thawing cells from liquid nitrogen 
Cells stored in cryovials in liquid nitrogen were thawed in water baths under sterile 
conditions at 37oC. Thawed cells were transferred into T75 culture flask in 10ml of 
complete DMEM and incubated in CO2 incubator at 37oc. After 8 hours when the cells 
were already attached to the bottom of the flask, the media was removed and replaced 
with 10ml of fresh complete DMEM in order to get rid of DMSO (contained in the 
freezing media) as much as possible. The flask was incubated and split when 80% 
confluence was attained. 
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2.6 Cell proliferation measure via trypan blue assay  
Three hundred thousand (3x105) prostate cancer cells were independently seeded in 
six-well plates containing 4ml of Dulbecco’s Modified Eagle’s Medium (DMEM) with 
the following additives: 5 mM glucose and 1% L- glutamine, 10% fetal bovine serum 
(FBS) and 1% sodium pyruvate to make complete media. The reagents mentioned 
above were purchased from Sigma Aldrich, USA. The cells were treated with various 
concentrations of TG003 with controls and incubated in a 5% CO2 incubator for 24, 48 
and 72 h. At each time point, the cells were harvested and diluted with trypan blue. 
Trypsinised cells were counted in the haemocytometer after being re-suspended in an 
appropriate volume of media containing equal amounts of 0.4% (w/v) trypan blue. Cell 
survival and percentage viability of each of the prostate cancer cell lines were counted 
and determined using a haemocytometer (Neubauer chamber). Stained blue cells 
were considered dead, while the nucleus of live cells were not stained by the trypan 
blue.   
2.7 Cell proliferation by Ki67 assay 
Three hundred thousand (3.0x105) prostate cancer cells (PC3, DU145) and normal 
prostate epithelia cell line (PNT2) were seeded on cover slips in six-well plates and 
serum starved in 4ml of DMEM without fetal bovine serum for 8 hours. Starving media 
was carefully removed after 8 hours of starvation and subsequently replaced with 4ml 
of complete DMEM. Cells were immediately treated with chosen concentrations of 
TG003 (1 µM, 10 µM and 50 µM) and incubated with the controls in 5% CO2 incubator 
for 48 hours at 370C. After 48 hours incubation, media was removed from each of the 
wells and cells washed twice with 2 ml of warm PBS. Washed cells were fixed in 4% 
paraformaldehyde (PFA) for 10 minutes and permeabilized in 0.25% (v/v) triton in 
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PBS. Fixed cells were blocked in 10% FBS-PBS for 1 hour and incubated overnight at 
4oC in 1:1000 rabbit polyclonal anti-Ki67 primary antibody (Abcam, Cambridge, UK). 
After overnight incubation in primary Ki67 antibody, cells were washed 3 times for 5 
minutes each in PBS before incubation for 1 hour at 37oC in the secondary antibody- 
1:500 of Alexa flour 488/568 anti- rabbit. At this stage, cells were washed 3 times to 
remove residual secondary antibody for 5 minutes each. Cells were counterstained 
with DAPI (3 µl/mL) for 4 minutes and washed 2 times for 5 minutes each. Signal 
images were obtained using Image Proplus (Nikon TE 300 Japan). The percentage of 
proliferating cells was measured and calculated using Image J. 
2.8 Spectrophotometric measurement of colour changes and media depletion 
following TG003 treatment (indirect proliferation assay) 
Cells (1x106) were seeded and treated with TG003 in six-well plates. After 96 hours 
incubation in a 5% CO2 incubator at 37oC, the media from untreated, DMSO, 1µM, 10 
µM and 50µM wells was analysed in the spectrophotometer at 540nm wavelength 
using PBS and fresh DMEM as blanks and standards respectively. 
2.9 Acridine orange assay   
Cultured TG003 treated cells were thoroughly vortexed and about 150µl of 20,000 
cells in PBS suspension dispensed into a cytofunnel with ethanol cleaned slides and 
centrifuged in a Shandon Cytospin 4 (No. A78300101, Serial No. CY94701405, 
Thermo Scientific UK) at 1,500 rpm for 8 minutes. Slides were left to air dry completely 
after being removed from the Cytospin and then fixed in 90% methanol for 10 minutes. 
Phosphate buffer made from 0.66% w/v KH2PO4 and 0.32% w/v Na2HPO4 was freshly 
prepared and slides dipped into it for 2 seconds and stained in acridine orange solution 
(24 mg of acridine orange / 200 ml of phosphate buffer) for 45 seconds in a dark box. 
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Slides were removed from the stain solution and dipped into another dark box 
containing phosphate buffer for 10 minutes and 15 minutes respectively. Slides were 
analysed microscopically using a fluorescence microscope (Nikon Eclipse 80i-upright) 
with BG-12 excitation filter and 0-530 barrier filter. 
2.10 Caspase 3/7 apoptosis assay 
Three hundred thousand cells of human prostate cancer cell lines (PC3 and DU145) 
and normal prostate epithelia cell line (PNT2) were independently seeded in six-well 
plates containing 4 ml of complete DMEM. Cells were treated for 48 hours at 37oC in 
a 5% CO2 incubator with varying concentrations of TG003 ranging from 1 µM to 50 
µM, while the untreated received no treatment but DMSO alone was used as a solvent 
control. DMEM was removed from each well and replaced with 1 ml of warm PBS. 
Then two drops of caspase-3/7 green detection reagent cat 10723 bought from 
Thermofisher Scientific-UK were added to each well, plates wrapped with aluminium 
foil and left in the dark incubator at 37oC for 45 minutes. Images were obtained with a 
fluorescence microscope (using Image Proplus) usig the green channel (Flou-488). 
Matched images were obtained by switching to the light phase contrast microscope. 
The percentage of caspase 3/7 positive cells was determined using Image J software. 
2.11 RNA extraction  
RNA extraction was performed using the Absolutely RNA miniprep kit from Agilent 
technology Ltd, USA. The reagents include; RNase- Free DNase 1, high salt wash 
buffer, low-salt wash buffer, 70% ethanol, β-Mercaptoethanol (β-ME), lysis and elution 
buffers. These reagents were prepared and used according to the manufacturer’s 
protocol. Three hundred and fifty microliter (350 µl) of lysis buffer was mixed with 2.5 
µl of (β-ME) to lyse cell pellets containing between 1x106-5x106 cells. After cell lysis, 
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the procedures were followed strictly according to the kit protocols until the RNA was 
finally eluted in 30 µl of the elution buffer. 
2.12 RNA quality (assessed by nanodrop) 
RNA quality was checked on 1% agarose gels; the concentration and purity of the 
extracted RNA was determined using a nanodrop device (Spectrophotometric, UK). 
Firstly, the nanodrop sample dropping point was cleaned thoroughly with a wipe. The 
device was initialized with water and blanked with elution buffer before taking 
measurements. About 1.25 µl of the eluted RNAs were measured and the result was 
displayed on the screen. 
2.13 cDNA synthesis 
cDNA synthesis was performed using reverse transcriptase and a mixture of oligo (dT) 
and random primers bought from Promega company Ltd, USA. The procedures for 
cDNA synthesis, following manufacturer’s protocol, is summarised in Table 2. 
Table 2. protocol for cDNA synthesis 
 Untreated DMSO 10 
Nm 
100 
nM 
1 µM 10 
µM 
50 
µM 
100 
µM 
RNA 
concentration 
(ng/µl) 
        
3µg RNA (µl)         
0.5µl Oligo 0.5 0.5 0.5 0.5 0.50. 0.5 0.5 0.5 
0.5µlRandom 
Primers 
0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 
82 
 
Water (Make 
up to 5 µl) 
        
 
Three microliter (3 µl) RNA was mixed with 0.5 µl of the oligo and 0.5 µl random 
primers. The reaction was made up to 5.0µl with nuclease free water. The samples 
were placed in a heat block at 70oC for five minutes, chilled on ice for another five 
minutes and centrifuged at 12,000 rpm for 10 seconds. 
Table 3. The RT reaction mix was prepared as below on ice. 
Component For 1x reaction  
Goscript 5x reaction buffer 4.0 µl  
MgCl2 2.4 µl  
PCR Nucleotide Mix 
(dNTP) 
1.0 µl  
RNasin Ribonuclease 
inhibitor 
0.5 µl  
RT 1.0 µl  
Water 6.0 µl  
 
To each 5 µl RNA mix, 15 µl of RT mix was added. The mixtures were placed on a 
heat block at varying temperatures and time to fulfil the following conditions: annealing 
at 250C for 5 min, extension at 42oC for 1 hour and inactivation of the reverse 
transcriptase at 70oC for 15 min. 
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2.14 DNA quantitation 
During the DNA quantitation, the same procedures for RNA quality (nanodrop) were 
used with the same device. The only difference was that DNA parameters were 
selected from the drop down menu instead of RNA. 
2.15 CLK1 primer design 
CLK1 primers targeting exon 4 and intron 4. At exon 4, 1FB and 3RB (forward and 
reverse primers) were designed; see Appendix I. At the intron 4, 2FB and 3RA (forward 
and reverse primers) were used. The designed primers were purchased from Eurofins 
Ltd. 
Table 4. CLK1 primers 
 Forward 
primer  
(intron 4) 
Reverse 
primer 
 (intron 4) 
Forward 
primer  
(exon 4) 
Reverse 
primer  
(exon 4) 
Name 
 of primer 
2FB 3RA 1FB 3RB 
 
2FB = 5’-GGAGGTCACCTGATCTGTCAG-3’ 
3RA= 5’-CTGCTACATGTCTACCTCCCGC-3’ 
1FB=5’-CAAGGATGTGAACCTGGACATCGC-3’ 
3RB= 5’-CTCCTTCACCTAAAGTATCAAC-3’ 
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2.16 Gel extraction (DNA purification) 
For gel extractions the QIAquick gel extraction kit, USA was used. Using a clean sharp 
scalpel, the DNA fragment was excised from agarose gel and the sliced gel was 
weighed in a colourless eppendorf tube. Three volumes of QG buffer was added to 
one volume of gel. The tube containing the gel was incubated at 50oC on a heat block 
until the gel was completely dissolved. Isopropanol was added to one gel volume and 
the mixture was properly vortexed. The mixture was placed to a QIAquick spin column 
over a 2 ml collection tube and centrifuged at 13,000 rpm for 1 min until the samples 
have passed through the column. The flow-through was discarded and the QIAquick 
spin column replaced over the tube. To same QIAquick spin column, 0.5 ml of QG 
buffer was added and centrifuged as above. The flow-through was also discarded and 
the column replaced to the tube. The QIAquick column was washed with 0.75 ml of 
PE buffer, centrifuged and allowed to stand for 2-5 min. Over the 2 ml collection tube, 
the QIAquick spin column was centrifuged to remove traces of residual wash buffer. 
The QIAquick spin column was placed over 1.5 ml and 50µl of elution buffer (EB) was 
added at the center of the QIAquick membrane, centrifuged for 1 min and allowed to 
stand for 4 min. The purified DNA was analysed on agarose gel with a loading dye. 
2.17 DNA sequencing 
Purified PCR products were sent to Eurofins company Ltd. UK for sequencing. 
Sequencing reactions were assembled as per Eurofins instructions, Mix2Seq reads. 
Premixed samples were prepared consisting of 15 l template (1 ng/l) DNA plus 2 l 
of the relevant primers at 10 M. 
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2.18 RT-PCR  
cDNA was amplified with CLK1 primers (forward primers in exons 3 and 4, and reverse 
primers in exon 5). PCR cycles were as follows: 95oC for 2 minutes (initial 
denaturation), 95oC for 1 minute (denaturation), 59oC for 1 min (annealing), 72oC for 
1.5 min (extension), denaturation step repeated for 34 times followed by a final 
extension step at 72oC for 5 min. 
2.19 Protein isolation  
Cells were trypsinized, washed twice with phosphate buffer solution (PBS) and 
transferred to eppendorf tubes placed on ice. Two hundred microliters (200µl) of cold 
RIPA+PI buffer was added to the cells while still on ice for 20 min. The cells were 
freeze-thawed 3 times and spun down for 15 min at 13,000 rpm at 4oC. The 
supernatant (proteins) were recovered and quantified. 
2.20 Determination of protein concentrations using the Bradford assay 
Standard BSA protein concentration (2 mg:1 mg: 0.5mg: 0.25 mg: 0.125 mg) were 
prepared. Protein stock 50µl was diluted with equal volume of water. Twenty five 
microliter (25 µl) of the mixture was taken for protein concentration measurement 
according to BCA/ Bradford assays protocol (Fluostar Optima, BUG Labtech, UK). A 
standard protein curve was generated. 
2.21 SDS- PAGE 
Ten percent (10%) acrylamide (separating and stacking) gels were prepared 
according to table 5 below. 
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Table 5. Ten percent (10%) acrylamide gel preparation  
 Separating gel Stack gel 
Acrylamide concentration 10%  
MW Range (KDal) 16-70  
30% acrylamide mix (29:1 
acrylamide: bis- 
acrylamide) 
3.3 ml 0.67 ml 
Buffer A (1.5M Tris pH 
8.8) 
2.5 ml _ 
Buffer B (1.0M Tris pH 
6.8) 
_ 0.5 ml 
Water 4.1 ml 2.4 ml 
10% Ammonium 
persulfate 
100 µl 100 µl 
TEMED 40 µl 40 µl 
 
The separating gel was made first and gently poured into 1.5 mm gel tray in a vertical 
position. Isopropanol was overlaid on the gel to shield the gel from air which could 
inhibit polymerisation. When gel has polymerised, the isopropanol was rinsed off and 
drained out with water. The stack gel was overlaid on the separating gel and 10 well 
comb was inserted immediately. Twenty micrograms (20 µg) protein in 1:1 ratio of 
Laemlli buffer was denatured at 100OC for 5 min and cooled on ice. Samples (30µl 
each) were loaded to wells along with protein ladder and controls. Protein gels were 
run in 1x running buffer at 70V through the stack gel for 30 min, and 90V through the 
separating gel for 1 hour. 
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2.22 Buffer preparation 
To prepare 1 L of 10x running buffer, the following were added and made up to 1 L of 
deionised water: 250 mM Tris Base (pH 8.3), 1.9M glycine and 1% (w/v) SDS. While 
700 ml with 1x running buffer was made by adding 70 ml of 10x running buffer and 
630 ml of deionised water. 10x transfer buffer was prepared with same concentration 
and pH of tris Base and glycine as in 10x running buffer without SDS. However, 1 L of 
1x transfer buffer was made by adding 100ml of 10x transfer buffer to 200 ml of 
methanol and 700 ml of deionised water. 1 L of 10x TBS was made by adding the 
following and made up to 1 L with deionised water: 0.5 M Tris HCl (pH) 7.6 and 1.5 M 
NaCl 
2.23 Western blotting by wet transfer 
Six blotting papers and 1x PVDF membrane were cut to 9x6cm and the membrane 
marked for identification. The membrane was activated in methanol for 5 min and 
washed 3 times along with blotting papers and cassette sponges in ice cold transfer 
buffer. Stack gel was removed from the separating gel and the cassette assembled as 
follows: black side of cassette, sponge, 3x pads of blotting papers, gel, membrane, 3x 
pads of blotting papers, another sponge and red side of the cassette. This assemblage 
was run in a transfer tank with ice cold transfer buffer and freezer pack at 50v for 2 
hours. 
2.24 Antibodies 
Anti-CLK1 polyclonal antibody from rabbit bought from Sigma Aldrich (cat No. R1471-
1S) was used as primary antibody. Membrane was blocked in 5% blocking solution 
made from 1g of BSA and 20 ml of 1x TSB-T buffer and allowed on Stuart Gyro-rocker 
(SSL3, Biocote ltd, UK) for 1 hour. And incubated overnight with 1:5000 CLK1 primary 
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antibody. The secondary antibody is an anti-rabbit purchased from Sigma Aldrich (cat 
No. 7074S)   dissolved in 1:5000 blocking solution. The membrane was washed 3 
times for 5 min in 1x TBST and incubated in secondary antibody for 11/2 hour at room 
temperature on a shaking machine. Membranes were washed three times for 5 min in 
1X TBST before taken to the dark room for development. 
2.25 Film development 
Using tweezers, the membrane was picked from 1x TBST and the corners dripped 
onto filter or tissue paper to get rid of excess TBST. The membrane was placed on 
acetate paper, 2 ml of chemiluminescent substrate (Luminata forte, cat No. 
WBLUF0100, Millipore ltd, UK) was added and rocked for 2 minutes. Excess substrate 
was dripped from the corners of the membrane on paper. The membrane was 
transferred flat into the polypocket acetate sheet of cassette. Indications were made 
with a tick pen on the position of the molecular markers. Light was turned off and film 
purchased from Sigma Aldrich was laid over the membrane, the position of the 
markers noted and the cassette closed tightly for 5 minutes exposure. Film was rocked 
in a developer (Harman technology ltd, UK, cat No. 1757314) until bands were seen, 
dipped into water for 1 seconds and transferred to the fixer (Harman technology ltd, 
UK, cat No. 1758285) for 30 seconds and finally washed in water. Images were also 
captured using Li-Cor Odyssay (UK). 
2.26 Wound healing-scratch assay 
A yellow 200µl pipette tip guided by a clean glass slide was used to make a straight 
line scratch in a confluent prostate cancer cells seeded in six well plates. Floating 
scratched cells were gently removed with warm PBS while a complete DMEM 
containing TG003 treatment was used to incubate the cells in a 5% CO2 incubator at 
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37oC. A set lumascope was inserted in the incubator which records the extent of 
scratch closure every 2 hours for 72 hours. The time dependence of scratch closure 
was compared between TG003 treated cells and the untreated controls. Images were 
obtained every two hours using the phase contrast lumascope under x4 objective. 
Image j was used to analyse the length of scratch closure in both controls and TG003 
treated cells. 
2.27 Cell migration and invasion assay  
For invasion assay, prostate cancer (PC3) cells were treated for 48 hours with various 
concentrations of TG003 ranging from 1 µM to 50 µM in 10% foetal bovine serum 
medium after being subjected to 8 h pre-starvation in serum free DMEM. All equipment 
and reagents such as 24 well plates, Transwell chambers, serum free DMEM, pipette 
tips and micropipettes were kept overnight in a fridge prior to the assay. Stock 
7.9mg/ml extra cellular matrigel (ECM) (Sigma-Aldrich E6909) was defrosted 
overnight at 4oC. Serum free DMEM was used to dilute the stock matrigel and the 
transwell chambers suspended on 24 well plate were coated with100 µl of the mixture. 
The plate was kept for gelling overnight in incubator at 37oC. Into the lower chamber, 
500µl of complete DMEM containing 10% FBS were added as a chemoattractant, 
while 300µl containing 1.0x105cells/ml in a starving DMEM were added to the transwell 
chamber suspended on 24 well plate and incubated at 37oC for 24 h. The cells were 
washed twice in PBS after the media from each of the wells were removed with pipette. 
4% paraformaldehyde (PFA) was used to fix the cells at room temperature for 10 
minutes. Non-invasive cells that were still retained inside the insert were carefully 
scraped off with a swab. Cells were washed twice in PBS and permeabilized in 100% 
methanol for 20 minutes at room temperature and subsequently washed twice after 
methanol removal. A sterile scalpel guided with a forceps was used to cut the 
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membrane containing the invasive cell and turned upside down on clean slide. The 
slides were stained and incubated with Hoechst for 1 h on coverslip at room 
temperature in the dark. Invasive cells were imaged and counted using image proplus 
(Nikon TE 300 Japan). The same material and procedure was applied for cell migration 
assay, except that the transwell inserts were not coated with matrigel and the 
equipment were not refrigerated overnight.   
2.28 Heat shock assay 
Half a million prostate cancer cells (PC3, DU145) were seeded independently in a T25 
flask and allowed to settle overnight in incubator at 37oC. Cells were subjected to heat 
shock at 42°C for 1 h, 3 h and 6 h. RNA was made from the cell pellets and cDNA 
synthesized for PCR amplification. Protein from the portion of the pellets was 
quantified and run in a western blot to determine the effect of heat shock on CLK1 
protein levels. 
2.29 Osmotic stress induction and harmine treatment 
Induction of osmotic stress in prostate cancer cell line DU145 was achieved by cell 
line treatment with 200 and 400mM of sorbitol S0900 bought from Sigma Aldrich and 
incubated at 37oc for 3 hours. Untreated cells were used as control. For harmine 
treatment, 50% ethanol was used to dissolve 98% harmine bought from Sigma Aldrich, 
prostate cancer (DU145) cell lines were treated with 1, 3, and 5 µM of harmine 
concentration for 6 hours at 37oc while 10µM ethanol treated and untreated cells were 
used as controls. 
2.30 CLK1 siRNA knockdown 
PC3 cells (5.0x105) were seeded in six well plates with penicillin free DMEM and 
allowed to settle overnight. Eppendorf tubes were labelled A and B. Tube A according 
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to manual contains appropriate volume of Optimem minimal medium and 
lipofectamine RNAiMAX transfection reagent bought from Fisher Scientific UK Limited. 
Tube B according to manual contains appropriate volume of Optimem and diluted 
CLK1 siRNA bought from Santa cruz Biotechnology, USA. Contents of Tubes A and 
B were thoroughly mixed together and pre- incubated at room temperature on RT for 
20 minutes. The mixture was transferred to the cells, topped up to 1ml with Optimem 
and incubated for 4 hours at 37oC in a 5% CO2 incubator. After this step the mixture 
was topped up to 2ml with complete DMEM void of antibiotics such as penicillin and 
re –incubated in a 5% CO2 incubator at 37oC for 48 hours. Cells were lysed with 
RIPA+PI. Proteins were harvested and quantified using Bradford method and finally 
run in SDS PAGE. The same procedures were applicable to the scrambled- control 
siRNA bought from Santa Cruz, USA. 
 
2.31 EMT marker expression 
Three hundred thousand cells were seeded and treated with varying concentrations 
of TG003 on cover slips in six well plates and incubated in 5% CO2 incubator at 37oC 
for 48 hours. Cells were washed three times with warm PBS and fixed in 4% PFA. 
Cells were permebilized in 0.25% (v/v) Triton-PBS for 10min on RT after being washed 
three times in PBS. Cells were blocked on RT for 1 hour in 10% FBS/PBS. E-cadherin 
and vimentin primary antibodies were diluted 1:150 and 1:400 respectively in 10% 
FBS-PBS and incubated overnight on RT at 4oC. After three times wash with PBS, 
Goat anti-rabbit Alexa flour-568 1:750 dilution was used for E-cadherin secondary 
antibody, while anti-mouse Alexa flour-488 1:1000 dilution was used for vimentin 
secondary antibody and incubated at room temperature on RT for 1 hour. Cells were 
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washed three times in PBS and counterstained in Hoechst (1 µl/ml) for 10 min. Images 
were obtained using fluorescence microscope and analysed in image j. 
2.32 PC3 xenografts 
Xenograft experiments were conducted at the University of Exeter in collaborator Dr. 
Sebastian Oltean’s laboratory. Due to my lack of licence to work on live animals, Dr. 
Sebastian Oltean and Li Ling performed the entire experiment while I participated in 
tumour measurement. For treatment studies, PC3 human prostate cancer cells were 
detached from culture flasks and diluted in pre-cold PBS to a concentration of 
1x107/ml and placed on ice. 100 µl of cell suspension was subcutaneously injected 
into each right flank of CD1- nude mice (Charles River), 12 mice in total. Tumour 
sizes were measured by calliper two times per week.  When the tumour sizes 
reached 3mm x 3 mm, 50 µM TG003 or DMSO were injected intraperitoneally two 
times a week, 6 mice per treatment group. Mice were culled by cervical dislocation 
(Schedule 1) when the tumour size reached maximum (12 mm x 12 mm) and the 
tumours were extracted. Images of each tumours were taken and weighed. Tumours 
were flash frozen in liquid nitrogen for further analysis. Same procedures were 
repeated for 10 µM TG003. Tumour volumes were calculated using formula volume= 
[(length+width)/2]*length*width.  
 
2.33 Statistical analysis 
All results were subjected to statistical analysis using graph pad prism version 7.03 
after pre-testing data for normality of distribution and between data group homogeneity 
of variances. Parametric tests were applied for data with both normal distribution and 
of equal variances, taking sample sizes into consideration. One way variance analysis 
93 
 
(ANOVA) was used to determine the statistical differences among the means of 
independent groups (multiple comparison). In cases where the effect of two variable 
factors were to be determined both separately and as groups, two-way variance 
analysis was applied. Non-parametric tests such as Kruskal-Wallis were used for data 
showing non-normal distributions. Post hoc between data group pairwise comparisons 
were subsequently made by either 2-sample t-test, Tukey Kramer’s test, Mann 
Whitney U-test or Dunn’s test depending on data normality. The statistical package 
used for each data analyses are indicated in the respective figure legends, n.s depicts 
not significant, *=p≤0.05, **=p≤0.01, ***=p≤0.001, ****=p≤0.0001. 
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Chapter 3 
Regulation of CLK1 via alternative 
splicing through intron retention and 
exon skipping 
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3.1 Aim 
The importance of splice factor protein kinases in the regulation and control of 
alternative splicing is gradually gaining global recognition. The aim of this chapter is 
to examine CLK1 expression and alternative splicing through exon 4 skipping and 
intron 4 retention in a range of human cancer cell lines including prostate cancer. To 
address this aim we examined the effect of heat shock, osmotic shock and exposure 
to the drug harmine on CLK1 alternative splicing in prostate cancer cells. 
 
3.2 Design and evaluation of primers to measure CLK1 alternative splicing 
The CLK1 human is structurally very similar to the corresponding mouse gene which 
was previously analysed by Duncan et al., 1997 and Ninomiya et al., 2011. There are 
reports of alternative splicing of CLK1 related to mouse CLK1 (both skipping of exon 
4 and intron 4 retention; Ninomiya et al., 2011). The alternative splicing of the 
equivalent exon and intron of human gene has not been examined. We focused on 
human CLK1 exon 4 and intron 4 (figure 3.1A). Exon 4 is 91bp with a short intron 
(intron 4) separating it from exon 5. When exon 4 is skipped, CLK1 is truncated to a 
120 amino acid protein described by Duncan et al., (1997) as CLK1T which we refer 
to as CLKT1. However, intron 4 retention also results to truncated protein which we 
refer to as CLK1T2 (figure 3.1A and B). In summary, premature stop codons arising 
from exon 4 skipping and intron 4 retention result in truncated proteins which we call 
CLK1T1 and CLK1T2 respectively. 
 
We designed human specific primers (see the CLK1 alignment in the appendix I). The 
best combinations of primers were determined. To measure exon 4 inclusion rates we 
combined 1FB/3RB (5’-CAAGGATGTGAACCTGGACATCGC-3’/5’-
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CTCCTTCACCTAAAGTATCAAC-3’ forward and reverse primers respectively. To 
determine intron 4 retention the best combination was 2FB/3RA (5’-
GGAGGTCACCTGATCTGTCAG-3’/5’-CTGCTACATGTCTACCTCCCGC-3’ forward 
and reverse primers respectively). In order to check that the PCR products were 
correct, they were excised out of 2% gels and sent to Eurofins for sequencing. 
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Figure 3.1 A description of CLK1 alternative splicing of cassette exon 4 and retained intron 4. (A) A schematic of CLK1 splice isoforms depicting exon 4 
skipping and intron 4 retention. The position of the PCR primers used are indicated. (B) CLK1 protein structure indicating its splice isoforms. (C)  The sequence 
shows the position of putative potential exonic splice enhancers (green) in CLK1 exon 4 (capital letters) and an intronic splice silencer (red), predicted using 
SROOGLE (Schwartz et al., 2008). This figure is adapted from Uzor et al., (2018).
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3.3 Alternative splicing of human CLK1 in cancer cell lines 
CLK1 expression (in particular its alternative splicing) has not been studied in human 
cell lines. Here we considered whether or not human CLK1 is similarly alternatively 
spliced. Its alternative splicing was surveyed in a panel of cell lines (PC3, DU145 and 
VCaP prostate cancer), prostate epithelium cell line (PNT2), in leukemic cell lines 
(K562, TK6, HL60, CMK, MOLT4 and RPKV8226), cervical cancer cell line (HeLa) and 
foetal kidney cells (HEK293) (Figures 3.2A and B). It is clear that prostate, leukemic 
and other cancer cell lines (figures 3.2A and B) show varying degrees of intron 4 
retention and exon 4 skipping. Of interest there is more intron 4 retention in prostate 
cancer cell lines compared to leukemic cell lines. Among the prostate cancer cell lines 
there was less intron 4 retention in PC3 cells compared to DU145 and VCaP. CLK1 
alternative splicing was also visible with a higher degree of intron 4 retention in the 
normal prostate epithelia cells (PNT2). In foetal kidney and cervical cancer cell lines 
(HEK293 and HeLa respectively), we also observed alternative splicing of CLK1. CLK1 
alternative splicing was also observed in variety of leukemic cell lines with varying 
exon 4 skipping and intron 4 retention; the latter was at a lower level in acute 
lymphoblastic leukaemia cells (MOLT4) (figure 3.2B). In summary, although these 
PCR are semi-quantitative, there is evidence of alternative splicing of CLK1 in a range 
of cancer cell lines studied with various degrees of exon 4 skipping and intron 4 
retention. More accurate quantitative measurement, for example using qPCR are 
needed to measure the degree of alternative splicing precisely.
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Figure 3.2 CLK1 alternative splicing in a randomly selected cancer cell lines. To determine exon 4 skipping (E4S) E3F1 and E5R2 forward and reverse 
primers were used, while E4F1 and E5R1 forward and reverse primers were used to determine the extent of intron 4 retention (I4R). The position of the individual 
splice isoforms are indicated. (A) Alternative splicing of CLK1 in PC3, DU145 and VCaP (prostate cancer cell lines), for comparison PNT2 (normal prostate 
epithelium), HeLa (cervical cancer) and HEK293 (human embryonic kidney). (B) Alternative splicing of CLK1 in CMK (acute megakaryocytic leukaemia); MOLT4 
(acute lymphoblastic leukaemia; RPKV8226 (myeloma); K562 (chronic myelogenous leukaemia); HL60 (promyelocytic leukaemia); and TK6 (hereditary 
spherocytosis). These are leukemic cell lines. Indicated by the right corner are the PSI (percentage splice index) values of exon skipping and intron retention. 
N = 3 repeats. Individual error bars are indication of standard errors (SE). This figure is adapted from Uzor et al. (2018).
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3.4 Effect of environmental stress on CLK1 alternative Splicing. 
Based on previous work by Ninomiya et al., (2011) on CLK1 alternative splicing in 
mouse cells, we wished to determine if there is a similar effect driven on human CLK1 
alternative splicing. To do this, PCa (DU145) cells were heat-shocked at 42 °C for 1 
h, 3 h and 6 h. We observed that there is a simultaneous significant reduction of intron 
4 retention and exon 4 skipping after 1 h of heat shock treatment (figure 3.3A). We 
then performed western blot to determine if the increased CLK1 exon 4 inclusion and 
diminished intron 4 retention corresponds to changes in CLK1 protein levels. As 
expected CLK1 protein expression was increased due to increased exon 4 inclusion 
(figure 3.3B). We then subjected the PCa (DU145) cells to osmotic stress (200 mM 
and 400 mM sorbitol treatment). Here we also observed decreased CLK1 exon 4 
skipping and intron 4 retention disappearance (figure 3.3C). The same result was 
observed following alkaloid (harmine) treatment with 1 μM – 5 μM concentration for 3 
h (figure 3.3C). Hamine is a protein kinase (DYRK1A) specific inhibitor. DYRK1A 
overexpression has been linked with neuronal developmental impairment seen in 
down syndrome (Gockler et al., 2009). At 1 µM harmine concentration, there was 
complete loss of both CLK1 exon 4 skipping and intron 4 retention (figure 3.3C). We 
conclude that like in mouse CLK1 (Ninomiya et al., 2011), exposure of cells to heat 
shock, osmotic stress and alkaloid treatment results to production of full length 
catalytically CLK1 due to increased CLK1 exon 4 inclusion (decrease exon 4 skipping) 
and decreased intron 4 retentio
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Figure 3.3 Effect of environmental stress such as heat shock, osmotic shock and chemical treatment (harmine) on alternative splicing of CLK1. (A) 
Prostate cancer cells (DU145) were exposed to heat shock-treatment at 42 °C for 1 h, 3 h and 6 h. DU145 cells cultured at 37oC for 1 h, 3 h and 6 h were used 
104 
 
as controls. (B) a gel and graph showing CLK1 protein level in heat shock relative to GAPDH. (C) DU145 cells treated with 200 mM and 400 mM concentrations 
of sorbitol for 3 h, or treated with the alkaloid harmine (1–5 μM) concentration for 6 h. The PSI values for (A) showing rate of exon 4 and intron 4 retention is 
indicated by the right hand corner. N = 3, Kruskal-Wallis, *=p≤0.05. The error bars are indication of SE. This figure is adapted from Uzor et al., (2018).
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3.5 Effect of CLK1 inhibition with TG003 on alternative splicing 
Next, we looked at the effect of CLK1 inhibition on CLK1 alternative splicing. Prostate 
cancer cell lines (DU145 and PC3) were treated with various concentrations of TG003 
ranging from 10 nM to 100 µM for 48 h.  There was a clear and visible CLK1 alternative 
splicing starting from 100 nM (DU145) and 10 µM (PC3) TG003 treatment as shown 
in figures 3.4A for DU145 and 3.4C for PC3 cell lines respectively. There was clear 
reduction of exon 4 skipping and intron 4 retention in both cell lines at the highest 
concentration of TG003. In other words, results clearly show that CLK1 inhibition by 
TG003 causes both reduced intron 4 retention and increased exon 4 inclusion (Figures 
3 .4A, 3.4C). Both of these are consistent with generating ‘productive’ CLK1 mRNA 
leading to the translation of full-length CLK1, and this is confirmed by a higher level of 
CLK1 protein (Figure 3.4B). Furthermore, Bowler et al., (2018) have shown that CLK1 
might be involved in cellular adaptation to hypoxia as it is induced in hypoxic cells. In 
that study, CLK1 was also inhibited with TG003. One of the genes whose alternative 
splicing was altered in hypoxia and also affected by CLK1 inhibition is FGFR1OP 
(FOP). FGFR1OP is a fibroblast growth factor receptor 1 involved in myeloproliferative 
diseases. FGFR1OP alternative splicing was also determined in the same samples 
(figure 3.5). Consistent with previous findings (Bowler et al., 2018), here TG003 
induced exon skipping in the FGFR1OP gene (Figure 3.5).  
 
Having observed that there is a remarkably different rate of exon 4 skipping and intron 
4 retention in several cell lines, the next question was to see if, as was reported in 
mouse cells, CLK1 inhibition by TG003  results in increased expression of CLK1 
through altered splicing (in other words, indicating a potential auto-regulatory feedback 
mechanism). TG003, the compound used in the study is a synthetic specific CLK 
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kinase inhibitor developed by Hagiwara in 2005. Ninomiya et al., (2011) reported that 
the levels of CLK1 and CLK4 mature mRNAs are elevated with the administration of 
TG003. Interestingly they determined that the reason behind increased CLK1 
expression was reduced intron 4 retention and increased exon 4 inclusion. After 48 h 
of TG003 treatment, protein was extracted and observed by western blotting. Figure 
3.4B shows that there is an apparently increase in CLK1 protein following 48 h of 
TG003 treatment in PCa cells (DU145).
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Figure 3.4 Effect of benzothiazole TG003 (specific CLK1 inhibitor) on CLK1 alternative splicing. Prostate cancer cells (DU145) were treated with various 
concentrations of TG003 for 48 h. Untreated cells and cells treated with dimethylsulfoxide solvent (DMSO) were use as controls. (A, C) Effect of CLK1 inhibition 
on splice isoforms (intron 4 and exon 4 of prostate cancer cell lines-DU145 and PC3 respectively). (B) Effect on CLK1 protein levels: Western blot determination 
of CLK1 protein concentration in TG003 (10 nM, 100 nM, 1 µM, 10 µM, 50 µM and 100 µM) treated DU145 cells. Untreated and DMSO controls. The β- acting 
(loading control) is indicated. The PSI values of both intron 4 and exon 4 rate of inclusions and statistics are indicated by the right hand corner. N = 3, error bars 
are indication of SE. Kruskal-Wallis, *=p≤0.05, **=p≤0.01, ***=p≤0.001. Figure adapted from Uzor et al., (2018). 
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Figure 3.5. Effect of CLK1 inhibition on FGRF1 oncogene (FGFR10P) alternative splicing: Prostate cancer DU145 were treated with TG003 
concentrations ranging from 10 nM – 100 µM.  PCR products were optimised using FGRF1 forward and reverse primers. The position of exon skipping is 
indicated by the right hand coner.
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In summary, we have obtained evidence of extensive CLK1 alternative splicing in a 
range of human cancer cell lines with varying degrees of exon 4 skipping and intron 4 
retention. We found that exposure of cells to environmental stress such as heat shock, 
osmotic stress and harmine treatment favours the expression of CLK1 mRNAs that 
encode for full length catalytically active CLK1 as was also found in mouse CLK1 by 
Ninomiya et al., (2011). Treatment of prostate cancer cell line DU145 with 
benzothiazole compound (CLK1 specific inhibitor) also resulted to a significant decline 
in exon 4 skipping and intron 4 retention favouring full length CLK1 expression, an 
indication of CLK1 auto regulatory mechanism (figures 3.4 and 3.6). We observed that 
alternative splicing of FGFR1OP were also modified by TG003 treatment (figure3.5) 
(Uzor et al., 2018). 
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Figure 3.6 proposes a model for the autoregulation of CLK1 expression through modification of its own alternative splicing. The splice 
factors involved in the regulation of CLK1 alternative splicing (exon 4 skipping and intron 4 retention) are not yet known, but it is 
tempting to speculate that they will be affected directly by CLK1 phosphorylation. 
 
Figure 3.6. Summary of CLK1 auto-regulation: CLK1’s own productive splicing is suppressed under physiological condition through exon 4 skipping and 
intron 4 retention. However, pre-mRNA of CLK1 is more productively and efficiently spliced under heat shock treatment and exposure to other environmental 
stress such as osmotic shock, harmine (alkaloid) treatment and CLK1 inhibition via TG003 treatment (Uzor et al., 2018).
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Chapter 4 
 
 
Treatment of prostate cancer cell lines 
with TG003 induces apoptosis and 
decreases prostate cancer 
proliferation, migration and invasion 
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4.1 Aim of the chapter 
Having established that TG003 is exerting an effect by altering pre-mRNA splicing in 
prostate cancer cell lines, the aim of this chapter is to see if it has an effect on prostate 
cancer cell biology such as prostate cancer cell proliferation, apoptosis, migration, 
invasion and on scratch closure.   
4.2 The effect of TG003 treatment on SRSF protein phosphorylation 
We first wanted to confirm that CLK1 inhibition by TG003 could reduce splice factor 
phosphorylation. PC3 cells were treated with various concentrations of specific CLK1 
inhibitor for 48 h, after which protein from the treated and untreated controls was 
extracted and quantified using Bradford assay. SR phosphoprotein levels of both 
treated and controls were determined using western blotting with an antibody that 
specifically detects phosphorylated SR proteins. The SR phosphorylation levels (figure 
4.1) declined in a dose dependent manner following TG003 treatment. 
  
 
 
 
 
 
115 
 
 
Figure 4.1  Effect of CLK1 inhibition on SRSF protein phosphorylation. Western blot analysis 
showing the SRSF protein levels after TG003 48 h treatment, probed with pan phospho SRSF antibody 
and normalised with GAPDH. N=2 repeats. 
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4.3 Effect of TG003 on prostate cancer cell growth and proliferation 
3x105 of adherent PCa cells (PC3 and DU145) were initially seeded in six well plates. 
Before treatment with TG003, cells were allowed to adapt and settle eight hours after 
splitting. After 24-72 h of treatment with various concentrations of TG003 (1 µM- 50 
µM), the cells were washed with PBS and trypsinized. Live cell numbers were counted 
and determined using the trypan blue assay. Cell growth and proliferation was 
supressed in a TG003 dose and time dependent manner of treatment in both PC3 and 
DU145 prostate cancer cell lines (figure 4.2). The effect was particularly prominent in 
PC3 cells (figure 4.2A). Cells did not appear significantly affected at 24 h following 1 
µM TG003 treatment of both cell lines. However, at 48 to 72 h, there was evidence of 
apoptosis and decreased proliferation at concentrations ˃  1 µM. In contrast continuous 
growth and proliferation was observed in the untreated and DMSO solvent controls. 
At 24, 48 and 72 h, cell numbers increased approximately by 2.0x105 in the controls 
(untreated and DMSO) and there was a gradual reduction in cell number per TG003 
concentration with time, but not below the original seeded number of cells. At 48 h, 
continuous proliferation was seen in controls, but cell proliferation inhibition was 
observed in a TG003 dose-dependent manner up to 10 µM. This suggests that 
chemical treatment with TG003 over a prolonged period at higher concentrations up 
to 50 µM could induce cell death. However, at lower concentration (1 µM), the cells 
appear not to be proliferating. In contrast cell numbers increased to 1.0x106 in the 
controls (untreated and DMSO). 
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Figure (4.2) Prostate cancer (PC3, DU145) cell survival following 24-72 h TG003 treatment. PCa cells were treated with various concentrations of TG003 
(1 µM to 50 µM) for 24, 48 and 72 h. Live cells were determined by trypan blue assay. A and B PC3 and DU145 respectively cell survival after TG003 treatment 
at various TG003 concentrations. Time legends for 24, 48 and 72 h are indicated by the sides.  Untreated and DMSO are controls. N=5 repeats. Error bars are 
indication of SE.
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Percentage viability was also determined in both prostate cancer cell lines following 24 to 72 h TG003 treatment. The untreated and 
DMSO solvent controls resulted in increased percentage viability with time. However, percentage viability drastically decreased in a 
dose and time dependent manner suggesting that CLK1 inhibition with TG003 suppresses viability and survival of both PC3 and 
DU145 prostate cancer cells (figures 4.2, 4.3). 
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Figure 4.3. PCa (PC3, DU145) percentage viability after TG003 treatment. PCa PC3 and DU145 cells were treated with TG003 (1 µM to 50 µM) up to 72 h. 
Percentage viability of the PCa cell lines were determined with trypan blue assay with multiple repeats. Untreated (Unt) cells and cells treated with DMSO are 
controls.  N=5 repeats. Error bars are indication of SE. 
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As an indirect measurement of cell proliferation, the change in colour of the growth 
medium following TG003 treatment was measured (figure 4.4). The colour change 
was higher in the untreated and DMSO controls, probably due to continuous cell 
growth and proliferation in the controls leading to media depletion. The colour changes 
were measured spectophotometrically at 540 nm and graphically represented (figure 
4.4B). The colour changes effect decreased in a concentration dependent of TG003 
compared with the control media, an indication of less cell growth and proliferation in 
the treated cells especially 10 and 50 µM TG003 concentrations.  
  
  
Figure (4.4): Spectrophotometric measurement of colour changes and media depletion following 
TG003 treatment. (A) Spectrophotometric measurement of media colours for the untreated, DMSO, 1 
µM, 10 µM and 50 µM of TG003 was taken at 540 nm after 96 h incubation at 37oC. Untreated and 
DMSO are controls. (B) Graphical representation of colour changes and media depletion following 
TG003 treatment. N=3 repeats. One-way ANOVA, in all experiments n.s depicts not significant, 
*=p≤0.05, **=p≤0.01.Error bars are indication of SE. 
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To confirm the above results, and to be sure that CLK1 inhibition with TG003 causes 
reduction of prostate cancer cell proliferation, Ki67 analysis was performed. Ki67 is an 
antibody that binds only to the nucleus of proliferating cells. Eight hours serum starved 
3.0X105 PCa cells were treated with increasing doses of TG003 (1 µM to 50 µM) for 
48 h. 4% paraformaldehyde (PFA) was used to fix the treated cells for 10 minutes after 
being washed in warm PBS. Cells were permeabilized in 0.25% triton-PBS for 10 
minutes and incubated overnight with 1:1000 anti-KI67 antibody at +4⁰C. Goat anti- 
rabbit antibody (Alexa fluor 488) 1:750 was used as secondary antibody incubated at 
room temperature for 1 h. Cells were counterstained with DAPI for 10 minutes and 
matched images of both Ki67 and DAPI were obtained using image pro plus. Cell 
proliferation levels were measured using imageJ. Figure 4.5 shows that the 
proliferation levels of PCa cells were impaired following TG003 treatment especially at 
10 µM and 50 µM concentrations. 
 
Having examined and confirmed a decline in proliferation of prostate cancer cell lines 
(PC3 and DU145) following TG003 treatment, we also examined the proliferation of 
the normal prostate epithelium cell line (PNT2) subjected in the same conditions. In 
terms of proliferation PNT2 appeared to be less sensitive to TG003 (figure 4.5C). 
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Figure (4.5) TG003 Treatment induces cell proliferation reduction): 8 h serum starved PCa cells were treated with increasing doses of TG003 (1 µM to 50 
µM) for 48 h. Treated cells were  fixed in 4% paraformaldehyde (PFA) and   incubated overnight with Ki67 antibody at +4⁰C and subsequently anti- rabbit 
antibody (Alexa fluor 488)  . Cells were counterstained with DAPI for 10 minutes and washed three times in PBS. Images of both Ki67 and DAPI were
123 
 
obtained using image pro-plus and measured using imageJ. Graphical and representative images are shown above. A and B are representative images of 
prostate cancer cell lines (PC3 and DU145 respectively) treated with TG003 concentrations and stained with Ki67 antibody. DAPI images are controls. Their 
respective statistical analyses are indicated by the sides. N=3 (One-way ANOVA). In all experiments, *=p≤0.05, **=p≤0.01, ***=p≤0.001. (C) is the graphical 
representation of the proliferation analysis of prostate cancer cell lines (PC3 and DU145) compared with the normal prostate epithelium cell line (PNT2). N=3 
repeats (Two-ways ANOVA). Shown are the means of groups of data +/- 95% confidence interval. PC3 vs DU145 not significant, PC3 vs PNT2 p≤0.001, DU145 
vs PNT2 p≤0.05.  
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In summary, in both PC3 and DU145 cells, there was an evidence of cell growth and 
viability suppression in a dose (especially 10 µM and 50 µM) and time dependent 
manner of TG003 treatment. Significant decreased cell proliferation was also observed 
in both cell lines following TG003 treatment. However, a greater percentage Ki67 
positive cells were recorded in normal prostate epithelium cell line (PNT2) than the 
prostate cancer cell lines (DU145 and PC3) suggesting the reduced sensitivity of 
normal prostate cells to TG003. 
 
4.4 Effect of CLK1 inhibition on apoptosis 
The term apoptosis otherwise known as programmed cell death describes the process 
of deliberately eliminating damaged or unwanted cells (Formigli et al., 2000; Sperandio 
et al., 2000; Debnath et al., 2005). It is a normal homeostatic mechanism involved in 
the aging and developmental processes to sustain tissues’ cell populations. Apoptosis 
is a highly organised process regulated by many genes (Lowe and Lin 2000). 
Alterations of the alternative splicing of several regulatory genes results in 
deregulation of apoptosis leading to metastatic development and progression 
(Mercatante and Kole 2001). 
 
The Bclx apoptotic regulator is alternatively spliced into anti-apoptotic (BclxL) and 
proapoptotic (Bclxs) variants. BclxL is overexpressed in many cancers including 
prostate cancer and has been linked to chemoresistance and a vital target for cancer 
therapy. Increased prostate cancer metastasis is associated with over expression of 
BclxL (Mercatante et al., 2001) Apoptotic induction and increased chemosensitivity 
has been found in both breast and prostate cancer cells through redirection of BclxL 
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to Bclxs pre-mRNA splicing by blockade of the alternative 5’ splice site with an 
antisense oligonucleotide in Bclx intron 2 (Mercatante et al., 2001). Bclxs is a potential 
antagonist of BclxL and inhibits the pro-survival properties of BclxL to induce 
apoptosis. High levels of apoptotic Bclxs variant have been found in patients with 
stomach and colon cancers and in nude mice with breast cancer (Gryco et al., 2012). 
Many studies suggest that BclxL overexpression in cancer cells is a clear indication of 
oncogenic anti-apoptotic stimuli while the overexpression of the isoform Bclxs is an 
evidence of pro-apoptotic stimuli (Finch et al., 2006; Coluccia et al., 2004). Increased 
levels of BclxL are also found in cancer cells that tends to resist the chemotherapeutic 
effect of some agents (Shultz et al., 2012). Both transcriptional and post-transcriptional 
processes are needed for the regulation of BclxL expression. In the later, the Bclx 
gene through alternative splicing of exon 2 5’ splice site selection, produces either 
upstream 5’ss selection (proapoptotic) or downstream 5’ss selection (antiapoptotic) 
isoforms. However, in contrast to BclxL, many studies have suggested that the Bclxs 
isoform triggers apoptosis (Minn et al., 1996; Ban et al., 1998). 
PCa (PC3 and DU145) cells were treated for 48 h with TG003 and stained with 12% 
acridine orange in phosphate buffer solution. Slides were analysed microscopically 
using a fluorescence microscope with BG-12 excitation filter. Results suggest 
progressively increasing number of apoptotic cells in a TG003 dose dependent 
manner (figure 4.6). This suggests that chemical treatment of cells with TG003 induces 
apoptosis in prostate cancer cell lines. 
 
 
 
 
126 
 
 
 
Figure (4.6). TG003 induces apoptosis. PCa (DU145 and PC3) Cells were treated with TG003 
concentrations (1 µM to 50 µM) for 48 h. Treated cells were further stained with 12% acridine orange. 
2000 cells were scored per treatment, percentage apoptotic cells in the mix of other cells were also 
scored and recorded. The untreated and DMSO controls received no TG003 treatment. Representative 
sections are shown while, the arrows indicate representative apoptotic cells. N=3 repeats (One-way 
ANOVA). Shown are the means of groups of data +/- 95% confidence interval. In all experiments, 
*=p≤0.05, **=p≤0.01, ***=p≤0.001. 
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RNA was extracted from 48 h TG003 treated prostate cancer cells. RNA quality was 
ascertained using nanodrop technics before cDNA synthesis. cDNA from the treated 
and untreated (controls) cells were run in 2% agarose gel at 400A and 95V for one 
hour. PCR analysis were performed with apoptotic genes such as Bclx, caspase 9, 
Mcl1 and survivin (figure 4.7). There was increased expression of the pro-apoptotic 
variants (isoforms) following higher concentrations of TG003 which strongly correlate 
the results that CLK1 inhibition with TG003 induces apoptosis. 
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Figure 4.7. Study of CLK1 inhibition in apoptotic genes (BclX, Mcl1, Survivin and Caspase 9):  A, 
B, C and D are BclX, Mcl1, Surviving and Caspase 9 genes respectively. BclXL and BclXS are anti and 
pro-apoptotic isoforms of BclX respectively, Mcl1L and Mcl1S represent anti and pro-apoptotic isoforms 
of Mcl respectively, Survivin a and Survivin b represent anti and pro-apoptotic isoforms of Survivin 
respectively, Caspase 9a and Caspase 9b represent anti and pro-apoptotic isoforms of Caspase 9 
respectively. Figure adapted from Uzor et al., (2018). 
 
To obtain further evidence that TG003 treatment induces apoptosis, prostate cancer 
cell lines (PC3 and DU145) compared with normal prostate epithelia cell lines (PNT2) 
treated for 48 h with TG003 were stained with an apoptotic marker (caspase 3/7). A 
significant increase in apoptosis was recorded in a dose dependent manner, especially 
in high doses of TG003 treatment (figures 4.8A, B, C). Statistical analyses of the three 
cell lines suggest that prostate cancer cell lines (DU145 and PC3) displayed consistent 
induction of apoptosis in a dose dependent manner. The normal prostate epithelia cell 
lines (PNT2) displayed a much reduced induction of apoptosis (figure 4.8C). 
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Figure 4.8. TG003 treatment induces apoptosis. Apoptosis was meaured via caspase 3/7. TG003 
treated (48 h) PCa cell lines were stained with caspase 3/7 (green channel) for 45 minutes, matched 
images (green channel and bright field) of each treatment were obtained using fluorescent phase 
contrast microscope (image pro plus). Untreated and DMSO (solvent) are controls. TG003 
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concentrations for each treatment are indicated.  A, B and C are representative images of PC3, DU145 
and PNT2 cell lines respectively stained with caspase 3/7 immunofluorescence antibody. Their 
respective statistical analyses are indicated by the sides. For each experiment, N=3 repeats (Two-way 
ANOVA using Tukey’s multiple comparisons test). Shown are the means of groups of data +/- 95% 
confidence interval. In summary, at 10 µM TG003, DU145 vs PC3 p≤0.0001, DU145 vs PNT2 
p≤0.0001, PC3 vs PNT2 p≤0.01. At 50 µM TG003, DU145 vs PC3 p≤0.0001, DU145 vs PNT2 p≤0.0001, 
PC3 vs PNT2 p≤0.0001.
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4.5 Effect of CLK1 inhibition on prostate cancer cell migration and invasion 
It has been postulated that greater than 80% male mortality of prostate cancer is due 
to its invasiveness and rapid metastasis to the bone marrow (Coleman, 2006). The 
major target for prostate cancer metastasis is the bone; when this happens, poor 
prostate cancer prognosis is indicated and survival rate declines (Jin et al., 2013). The 
nature of the bone microenvironment and its interaction with malignant tumour cells 
makes it the most susceptible site of metastasis. In prostate cancer cases, about 68% 
incidence of prostate cancer bone metastasis has been reported (Suva et al., 2011).  
For prostate cancer cells to thrive in the bone marrow, it must interact with osteoclasts 
and osteoblasts which triggers and amplifies its overwhelming metastasis within the 
bone environment (Casimiro, et al., 2009). Furthermore, Wang et al., (2011) 
suggested that an essential therapeutic strategy for malignant prostate cancer that 
has spread to the bone is to inhibit cancer cell migration and osteoclast differentiation. 
Wang et al also found that lanthanides (Ln) and gadolinium (Gd) are examples of such 
compounds with the potential of inhibiting cell migration. They investigated the potency 
of GdCl3 in cell migration inhibition and obtained a statistically significant result (Wang 
et al., 2011). Another compound of interest capable of inhibiting prostate cancer cell 
migration, proliferation and invasion as found within the context of this study could be 
TG003. 
 
4.5.1 TG003 reduces cell migration and invasion (transwell assay). 
To determine cell migration using a transwell insert, half a million (0.5x106) PC3 cells 
were seeded in starving media for 8 h in a twenty-four well plate which was allowed 
under sterile conditions to warm up to room temperature. After eight hours starvation 
at 37oC, the starving media was replaced with a complete DMEM containing TG003 
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and re-incubated at 37oC for 48 h. The cells were washed twice with warm PBS, 
trypsinized, spun down and the supernatant removed and replaced with DMEM 
without FBS. Exactly 500 µL of DMEM containing 10% FBS (complete DMEM) was 
added to the lower chamber while 300 µl containing 1.0x105cells/ml in a starving 
DMEM was added to the transwell inserted over the 24 well plate and incubated for 
24 h at 37oC. Media from the transwell was carefully aspirated and the insert washed 
twice with PBS for 5 minutes. The cells were fixed in a clean well containing 225 µL of 
4%(w/v) paraformaldehyde (PFA) for 10 minutes. Non migrated cells were scraped off 
from the insert with cotton swab. The insert was washed twice with PBS for 5 minutes 
each and permeabilized with absolute methanol for 20 minutes at room temperature. 
Using a tweezer, the membrane was carefully removed and turned upside down on a 
clean slide and incubated for 1 h at room temperature with a drop of Hoechst under a 
coverslip. Cells were counted from random sight using a fluorescence microscope.  
The procedure to determine the effect of TG003 treatment on PC3 cell line invasion 
was same as that of cell migration except that the transwell chambers, 24 well plates, 
serum free DMEM, micropipettes and pipette tips were kept refrigerated overnight prior 
to the assay. Stock extra cellular matrix (ECM) matrigel was defrosted in 4oC 
refrigerator overnight and diluted with serum free DMEM. It was statistically confirmed 
that TG003 treatment slowed down prostate cancer (PC3) cell migration and invasion 
in a concentration-dependent manner especially at ≥ 10 µM TG003 concentrations 
(figure 4.9).
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Figure 4.9. PCa (PC3) cell migration (A) and invasion (B). 48 h PC3 cells were subjected to a migration and invasion assay using a transwell insert. Untreated 
and DMSO are the controls; TG003 was used at 1 µM, 10 µM, and 50 µM. N=3 repeats (Kruskal-Wallis). Shown are the means of groups of data +/- 95% 
confidence interval. In all experiments, **=p≤0.01, ***=p≤0.001.
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4.5.2 Effect of TG003 treatment on cell migration (scratch assay) 
Scratch assays were performed to further study the effect of TG003 on cell migration. 
A camera (lumascope) was inserted in a CO2 incubator to record the migration of PCa 
cell lines (PC3 and DU145 independently) over a scratch made with 200µL yellow 
pipette tip on fully confluent cells in six-well plates. Results show that the scratch 
closed completely on the controls after 72 h incubation in CO2 incubator at 37oC while 
the TG003 treated cells remain unclosed at 72 h incubation. TG003 treatment inhibited 
scratch closure in a concentration and time dependent manner in PCa PC3 (figure 
4.10) and DU145 (figure 4.11).
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Figure 4.10. TG003 treatment inhibits scratch closure in prostate cancer PC3 cell line.  (A) and (B) are scratch assays of PCa PC3 cell line. (A) is treated 
with 50 µM TG003 concentration and incubated in CO2 incubator at 37oC under lumascope from 0 h to 72 h. (B) is treated with various concentrations of TG003 
as indicated and incubated for 72 h at 37oC under lumascope. Untreated and DMSO are controls. Their respective statistical analyses are indicated beside 
each image. N=3 repeats (Kruskal- Wallis). Error bars are indication of SE. In all experiments *=p≤0.05, ***=p≤0.001. 
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Figure 4.11. TG003 treatment inhibits scratch closure in prostate cancer DU145 cell line.  (A) and (B) are scratch assays of PCa DU145 cell line. (A) is 
treated with 50 µM TG003 concentration and incubated in CO2 incubator at 37oC under lumascope from 0 h to 72 h. (B) is treated with various concentrations 
of TG003 as indicated and incubated for 72 h at 37oC under lumascope. Untreated and DMSO are controls. Their respective statistical analyses are indicated 
beside each image. N=3 repeats (Kruskal- Wallis). Error bars are indication of SE. In all experiments *=p≤0.05, **=p≤0.01 ***=p≤0.001.
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4.5.3 Effect of CLK1 inhibition (TG003 treatment) on EMT marker expression. 
During metastatic prostate cell progression, prostate tumour cells become invasive 
and degrade the basement membrane of the extracellular matrix (ECM) through a 
process known as epithelial-to-mesenchymal transition (EMT). EMT is involved in 
wound healing, neural crest formation and mesoderm development. However, in 
cancer, EMT is associated with increased migration and invasiveness, cell invasion is 
the migration of cells through tissue after overcoming the extracellular matrix barrier 
(Tiwari et al., 2012). Invasive prostate cancer cells are characterised by a loss of 
expression of crucial epithelial biomarkers including cell to cell tight junction and basal 
epical polarity (Kalluri and Weinberg, 2009). Apart from tumour progression, EMT also 
occurs during normal physiological development including wound healing. EMT 
prostate cell migration can be studied by investigating the extent of E-cadherin and 
vimentin expressions (Schaeffer et al., 2014) 
Cadherins are a group of transmembrane proteins with calcium ions dependent 
function and are important adhesion cell molecule that help cells interact with each 
other. Extracellular cadherin regulates cell-cell adhesion while the cadherin adhesome 
comprisese the cytoplasmic intracellular tail. E- Cadherin is a cell adhesion molecule 
highly dependent on calcium ion that determines embryonic epithelial development 
and adult homeostatic epithelium differentiation. Cadherins suppress tumour invasion. 
Aberrant cadherin expression has also been linked with aggressive and invasive form 
of prostate cancer with high Gleason scores (Bengaroll et al., 2016; Putzke et al., 
2011). 
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We continued to explore the effect of TG003 treatment on cell biology examining the 
EMT markers E-cadherin and vimentin. Prostate cancer cell lines (PC3 and DU145) 
were grown on cover slips in six well plates for 48 h with 4 ml of complete DMEM and 
TG003 treatments. Cells were washed twice with warm PBS and fixed with 4% (w/v) 
PFA for 10 minutes. PFA fixed cells on cover slips in 6-well plates were washed three 
times with PBS and permeabilized in 0.25% (v/v) triton at RT for 10 minutes. 
Permeabilized cells were blocked with 10% FBS in PBS for 1 h, after which E-cadherin 
and vimentin primary antibodies (from rabbit and mouse respectively) were incubated 
in the cells overnight in cold room. Cells were washed and counter stained with their 
respective secondary antibodies for one and half hour. The cover slips were mounted 
on slides with mounting media and images were viewed and obtained with image pro-
plus and analysed with image J. 
It was found that the untreated (PC3 and DU145 cells) continued to proliferate, migrate 
and invade the extra cellular matrix (ECM) matrigel with low E-cadherin (figure 4.12A 
and B) with a stronger vimentin signal (figure 4.12C and D). However, TG003 treated 
cells displayed higher E-cadherin positivity and lower vimentin (figure 4.12) in a dose 
dependent manner. 
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Figure 4.12. Epithelial – mesenchymal transition (EMT) marker expression in prostate cancer cell lines: A and B are representative images of 48 h 
TG003 (1 µM-50 µM) treated PC3 and DU145 cell lines respectively incubated with anti-E-cadherin antibody. C and D are representative images of PC3 and 
DU145 cell lines under same condition as in A and B above but incubated with anti-Vimentin antibody. Hoechst staining highlights the position of cells.  TG003 
concentrations are indicated. Untreated and DMSO are also shown. The percentage E-cadherin and vimentin for each cell lines were statistically analysed and 
are indicated graphically. Shown are the means of groups of data +/- the 95% confidence interval around the means in each case. N=3 repeats (One-way 
ANOVA). In all experiments, *=p≤0.05, **=p≤0.01, ***=p≤0.001.
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4.6 Summary 
As observed in (figure 4.1), the phosphorylation level of regulatory splice factors 
specifically SRSF4, SRSF6 and SRSF5 decrease in a concentration dependent of 
TG003 treatment. Interestingly, cell growth and proliferation is suppressed in both 
prostate cancer cell lines (PC3 and DU145) following TG003 treatment as found in 
trypan blue cell count (figure 4.2), cell viability assay (figure 4.3), indirect cell 
proliferation and ki67 assays (figures 4.4 and 4.5) respectively. Furthermore, there 
was increased apoptosis in both PCa (PC3 and DU145) cell lines in a dose dependent 
manner of TG003 treatment as observed in acridine orange, apoptotic gene 
polymerase chain reaction (PCR) and caspase 3/7 immunofluorescence staining 
(figures 4.6, 4.7 and 4.8) respectively. In this study, TG003 also reduces prostate 
cancer (PC3) cell migration and invasion in a concentration dependent manner 
(figures 4.9). TG003 effect was also tested on scratch closure of both PC3 and DU145 
prostate cancer cell lines. It is obvious that the scratch closure on both cell lines are 
inhibited in a dose and time dependent manner of TG003 treatment (figures 4.10 and 
4.11).  
Lastly, as observed in figure 4.12, there is a significant effect of TG003 on EMT 
markers expression. Here, there is increased E-cadherin and decreased vimentin 
expressions in dose dependent manner of TG003 treatment. However, it is interesting 
to note that the normal prostate epithelial cells are less sensitive to apoptosis and ki67 
proliferation markers(figures 4.8 and 4.5C respectively) as compared with PCa 
(DU145 and PC3) cell lines. 
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Chapter 5 
 
 
Effect of CLK1 inhibition on tumour 
growth (xenografts) 
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5.1 Aim 
Having observed that TG003 has a potent effect on prostate cancer cell line growth, 
proliferation, migration, invasion, scratch closure and apoptosis, we next examined its 
effect on xenograft growth in vivo. Before that we first performed an siRNA-mediated 
knockdown of CLK1 in prostate cancer PC3 cells knockdown to confirm that the effects 
observed with TG003 treatments are likely due to a reduction in CLK1 activity. 
  
5.2 CLK1 knock down recapitulates the effects of TG003  
To confirm that the effects of TG003 are due to CLK1 inhibition, and not because of 
the effect of TG003 on other protein kinases, we decided to knockdown CLK1 using 
standard siRNAs (figure 5.1A). The knockdown recapitulated the results observed with 
TG003. For instance, there was increased apoptosis with caspase 3/7 
immunofluorescence green detection (figure 5.1B), decreased cell proliferation with 
Ki67 (figure 5.2A) and decreased cell migration (scratch closure) (figure 5.2B) 
following CLK1 siRNA knockdown compared with controls.
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Figure 5.1. CLK1 siRNA knock down induces apoptosis: (A) Western blot of CLK1 siRNA knock 
down with the quantitation indicated by the side.  N=3 repeats (B) caspase 3/7 antibody staining 
(apoptotic cells) with the quantitation graphically indicated by the side. N = 3 repeats. Shown are the 
means of groups of data +/- the 95% confidence interval around the means in each case (One-way 
ANOVA). In all experiments, n.s depicts not significant, *=p≤0.05, **=p≤0.01. 
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Figure 5.2. CLK1 siRNA knock down inhibits prostate cancer cell proliferation and scratch 
closure: (A) ki67 staining (proliferation assay) following CLK1 siRNA knock down in PC3 cells. Ki67 
positive cells are stained in red while the control DAPI images are stained blue. N=3 repeats (One-way 
ANOVA). (B) Scratch assay following CLK1 knock down. Images were taken with lumascope inserted 
in CO2 incubator at 37oC every 2 h till 72 h. Their respective quantitation and statistical analyses are 
indicated by their sides. N=3 repeats (One-way ANOVA, Kruskal-Wallis). In both experiments (A and 
B), error bars are indication of SE, n.s depicts not significant, **=p≤0.01, ***=p≤0.001.  
 
5.3 TG003 treatment reduces xenograft growth 
Through a collaboration with Exeter University (Dr. Lin Ling and Dr. Sebastian 
Oltean), we looked at the impact of TG003 (a specific CLK1 inhibitor) on the growth 
of PC3 xenografts in standard nude mice. PC3 human prostate cancer cells were 
detached from culture flasks and diluted in cold PBS to a concentration of 1x107/ml 
and placed on ice. 100 µl of cell suspension, containing 1x106 cells was 
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subcutaneously injected into each right flank of CD1- nude mice (Charles River). 
Tumour sizes were measured by caliper twice per week.  When the tumour sizes 
reached 3mm x 3mm, 50µM TG003 or DMSO-containing vehicle were injected 
intraperitoneally two times a week, 6 mice per treatment group. Mice were culled by 
cervical dislocation (following Schedule 1 procedures) when the tumour size reached 
the maximum allowed (12mm x 12mm) and the tumours were extracted. Images of 
each tumours were taken, and the tumours weighed. Tumour volumes were 
calculated using formula volume=[(length+width)/2] *length*width. Quantitations of 
the tumour volumes were analysed by a two-way ANOVA using Prism software. 
 
There are several published studies on the effect of in vivo protein kinase inhibition, 
but no xenograft in vivo work has been reported specifically with TG003. For instance, 
in 2015 Mavrou et al reported that SRPK1 inhibition with the compound SPHINX in 
prostate cancer cell line xenografts drastically reduced tumour volume in vivo. In 2012, 
Oltean et al claimed that SRPK1 inhibition is a potential manipulator of pro and anti-
angiogenic VEGF-A alternative splicing was altered in xenografts towards the anti-
angiogenic isoforms, thereby preventing abnormal blood vessels formation that could 
fuel cancer growth including prostate cancer. In mouse models, SRPK1 inhibition has 
also been performed to treat retinopathy by diminishing abnormal in vivo 
neovascularisation formation (Gammons et al., 2013; Gammons et al., 2013). 
 
The xenograft experiments with TG003 show tumour volume reduction in both 10 µM 
and 50 µM TG003 treatments (figure 5.3 A and C) with clear statistical difference seen 
in 50 µM TG003 treatments (figures 5.3B, D; p˂0.0001). The excised tumours from 
both 50µM TG003 treatments and DMSO control were weighed (figure 5.3 E). It is 
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important to note that the mice appeared otherwise normal throughout the 
experimental process until the tumours were excised. It is also worthy of note that 
DMSO had no effect on xenograft growth. 
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Figure (5.3). TG003 reduces tumour volume in vivo (In vivo xenograft of TG003 treated mice): (A) Mice treated with 10 µM TG003 after tumour growth. 
The controls are also indicated. (B) and (D) are quantitation of the tumour volume of 10 µM and 50 µM TG003 treatment respectively compared with their 
controls. (C) Mice treated with 50 µM TG003, the excised tumours from the 50 µM TG003 treatment and their controls are also indicated.  (E) Quantitation of 
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the tumour weight of both 50 µM TG003 treatment and DMSO control. Shown are the means of groups of data +/- the 95% confidence interval around the 
means in each case.  N=6 repeats (Two-Ways ANOVA). p≤0.0001, but for tumour weight p≤0.01. 
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5.4 Summary 
It was observed that CLK1 knockdown on PCa PC3 cell line recapitulated the effect of 
TG003 on same cell line in terms of increased apoptosis, decreased proliferation and 
scratch closure (figures 5.1 and 5.2) in a dose dependent manner of TG003. This is 
an indication that the effect of TG003 is as a result of CLK1 inhibition. Figure 5.3 shows 
that TG003 reduces tumour volume in an in vivo xenograft.
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Chapter 6 
 
Discussion 
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6.1 Ongoing research on CLK1 function and the consequences of its inhibition 
Other groups are exploring the biological roles and the consequences of targeting CLK 
protein kinases; in agreement with this growing body of literature, the work presented 
in this thesis confirms that CLK1 inhibition results in reproducible and potent effects 
on cell biology and proliferation. For example, Liu et al., (2013) demonstrated that in 
vitro protein kinase phosphorylation of SR proteins regulates cell adhesion and 
proliferation; and that CLK1 regulates not just the activity but also the expression of 
key splice factors through alternative splicing mechanisms. Whereas CLK1-dependent 
phosphorylation of the splice factor SPF45 promotes its expression, CLK1 inhibition 
with TG003 lowered SPF45 expression by inducing exon 6 exclusion (Liu et al., 2013). 
It has been shown that overexpression of SPF45 promotes cell invasion and migration 
depending on the regulatory function of the CLK1 (Liu et al., 2013; Araki et al., 2015).  
Muraki et al., (2004) reported that TG003 treatment of prostate cancer cell line 
potentiated SR protein phosphorylation suppression and nuclear speckles 
dissociation.  In 2008, Yomoda and colleagues discovered the impact of active CLK1 
in the phosphorylation of SR proteins. They reported that dephosphorylation of SR 
proteins occur one hour after administration of TG003 to cultured cells and 
rephosphorylation occurred immediately after removal of TG003.  
 
Yun et al (1994) suggest that CLK family plays a crucial role during embryonic 
development, this is evidenced in the observed mutation in the Drosophila 
melanogaster homologue of CLK which resulted in differentiation, segmentation and 
general neuronal development defects. This is also supported by the finding of Myers 
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et al., (1994) that CLK1 expression in PC12 cells is required for neuronal 
differentiation. In Xenopus leavis, excess CLK1 activation causes neuronal defects 
and is rescued by the administration of a specific CLK1 inhibitor - TG003 (Zhoa et al., 
2012). 
  
Araki et al., 2015 reported that TG003 treatment of S6K cells caused significant 
reduction of SR protein phosphorylation and increased numbers of nuclear speckles 
in the cells. Similarly, we found that treatment of PC3 cells with TG003 diminished SR 
protein phosphorylation of three SR splice factors (SRSF4, SRSF5 and SRSF6) (figure 
4.1).  It is important to note as demonstrated by Araki and his colleagues that inhibition 
of CLK1 suppressed cell growth and induced apoptosis through splicing alterations in 
genes involved in cell growth and survival (Araki et al., 2015). Cell growth inhibition in 
TG003 concentration dependent manner was also observed in our results (figures 4.2 
and 4.3). 
 
6.2 Alternative splicing of human CLK1 
We have confirmed alternative splicing of CLK1 previously reported in mouse cells, 
also in human prostate cancer cell lines (PC3, DU145 and VCaP), prostate epithelium 
cell line (PNT2) and leukemic cell lines (K562, TK6, MOLT4 and HL60) using intron 
and exon 4 primers. It is clear that both prostate and leukemic cell lines show various 
degrees of intron 4 retention and exon 4 skipping (figure 3.2A and B). There is more 
intron 4 retention in prostate cancer cell lines than leukemic cell lines. PC3 tends to 
possess less intron 4 retention than the rest of the prostate cancer cell lines. In 
summary there is evidence of differential rates of CLK1 exon 4 inclusion and intron 4 
retention in a wide panel of human cell lines.  
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Knippschild et al., (2014) reported that CLK1 expression is highly dependent on the 
type of cell and some other factors such as treatment with inhibitors, viral 
transformation, stimulation with insulin and irradiation. It is now apparent that its 
alternative splicing is also highly variable. Here we show that administration of TG003 
to cultured prostate cancer cells causes more efficient CLK1 splicing leading to more 
CLK1 protein (figure 3.4B) via reduction in exon 4 skipping and intron 4 retention 
(figure 3.4A and C). The same effect is seen on exposure of prostate cancer DU145 
cells to adverse environmental stress such as osmotic shock, heat shock and alkaloid 
treatments (figures 3.3A, B and C). This is in agreement with the findings of Ninomiya 
et al., 2011 who reported that exposure of cells to a specific CLK1 inhibitor caused 
elevation of CLK1 mature mRNA by promoting splicing of the intron retaining RNAs. 
Ninomiya et al., (2011), Duncan et al., (1997), Duncan et al., (1995) also noted that 
intron 4 retaining CLK1 RNA is located in the nucleus. They were able to investigate 
the nucleus localization of the CLK1 intron retaining RNA by the application of in situ 
hybridization. Herein TG003 treatment of human cell lines (figure 3.4A and C) also 
reduced exon 4 skipping in a dose dependent manner (10 nM-100 µM). This finding is 
consistent with the result of (Nishida et al., 2011). 
 
A study shows that CLK hyper-phosphorylate SR proteins and induce their release 
from the nuclear speckles (Naro and Sette, 2013). It is also important to note that 
dephosphorylation of splice factors (SR proteins) is required for efficient splicing 
processes. In this study, we examined the effect of CLK1 inhibition via TG003 on SR 
protein phosphorylation using pan phosphor-SR antibody (1H4). We observe 
progressive dephosphorylation of splice factors (SR proteins) in a dose-dependent 
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manner of TG003 (figure 4.1). Araki et al., 2015 also observed decreased 
phosphorylation of SR proteins with CLK1 inhibition detected using the same 1H4 
phospho-SR antibody. 
 
In summary we have confirmed that, as initially reported in mouse cells, human CLK1 
inhibition also results in higher CLK1 protein expression presumably through a 
feedback mechanism that involves its alternative splicing. It will be interesting to 
determine how this feedback mechanism works (for example, which splice factors are 
specifically involved in regulating exon 4 skipping and intron 4 retention). 
 
6.3 Effect of TG003 on PCa cell growth and proliferation 
Having confirmed that TG003 causes reduced phosphorylation of SR proteins in 
prostate cancer cells we decided to test the effect on prostate cancer cell growth and 
proliferation using trypan blue and Ki67 assays. Ki67 is an established proliferation 
marker and has been currently recommended by researchers as a biomarker of choice 
for tumour proliferation. Ki67 was first discovered in the early 80s as nuclear histone 
proteins by Gerdes et al., 1984. For the purpose of evaluation as a tumour proliferation 
marker, Ki67 was found to be overexpressed in proliferating cells and absent in non-
proliferating cells (Lopez et al., 1991). The precise function of Ki67 is not yet known 
but is thought to be involved in ribosomal RNA synthesis (Rahmanzadeh et al., 2007). 
Prognostic and predictive values of Ki67 has been shown in breast cancer cells (Viale, 
2011; Romero et al., 2014 
The Ki67 antigen is therefore implicated in cell proliferation and has proved to be a 
useful tool in predicting human tumour development. It has been reported that the Ki67 
antigen is detectable in the nucleus during interphase, whereas majority of the antigen 
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translocates to the surface of chromosomes during mitosis. Ki67 antigen is absent in 
G0 phase and present in mitosis and all active stages of cell cycle (G1, S, G2), this 
quality has made Ki67 a potential excellent biomarker for determining the proliferating 
fraction of both normal and abnormal cells (Scholzen and Gerdes, 2000). As an 
excellent marker of cell growth and proliferation, Ki67 has been recommended for 
clinical use in monitoring and evaluation of cancer patients (Chen et al., 2018). 
Berney et al., 2009 reported Ki67 a better promising biomarker in prostate cancer with 
more prognostic information than Gleason scare and serum PSA after 808 patients 
diagnosed with prostate cancer between 1990 and 1996 were treated and Ki67 was 
used to measure the rate of proliferation in response to treatment. 
Immunohistochemical staining demonstrates that Ki67 is a cell cycle regulatory protein 
(Jalava et al., 2006) and highly expressed in all proliferative phases of cell cycle 
(Jalava et al., 2006).  
 
The heterogeneity of cancer is one of the limitations of biomarker integration into 
clinical practice. The heterogeneity of Ki67 as a marker has been described in other 
forms of cancers including breast and liver cancer but has not been sufficiently studied 
in prostate cancer (Dowsett et al., 2011). Mesko et al., 2013 studied Ki67 
heterogeneity in prostate cancer. They analysed 77 prostate cancer cores and 
observed that both inter and intraprostatic Ki67 heterogeneity is significantly higher in 
high risk cancer patients, and is therefore recommended for clinical use.Desmeules et 
al., 2015 also investigated the quantitative consistency of prostate cancer Ki67 
microscopic virtual scoring with that of digital image analysis. The emergence of Ki67 
as a tool to distinguish aggressive from non-aggressive prostate cancer, will aid better 
evaluation of prognosis. 
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Here the administration of TG003 to cultured cells suppressed cells growth and 
proliferation in a dose dependent manner (figures 4.2, 4.3, and 4.4). This is consistent 
with the reports of Karlas et al., 2010 and Nishida et al., 2011 that administration of 
TG003 suppresses influenza virus proliferation and affects splicing both in vitro and in 
vivo. We confirm a significant decrease in prostate cancer cell proliferation in a dose 
dependent manner (figure 4.5). We also examined the effect of TG003 treatment on 
prostate cancer cell growth and viability (figure 4.3). Consistent growth was observed 
in untreated cells and in DMSO-treated controls while there was a significant 
decreased cell growth in a concentration dependent manner of TG003 treatment 
(figure 4.2)  The same was observed in the percentage viability analysis of prostate 
cancer cell lines (PC3 and DU145) treated with TG003 (figure 4.3). There was about 
50% reduction in cell survival in both prostate cancer cell lines (PC3 and DU145) at 
50 µM TG003 concentrations. We also noticed that the growth media (DMEM) in PCa 
cell lines treated with TG003 changed colour after 72 h to 96 h incubation in a CO2 
incubator at 37oC (figure 4.4). The colour change was measured 
spectrophotometrically, the result of the untreated controls and TG003 treated cells 
were matched with the control media. There was a significant difference between 
TG003 medium and the control media (figure 4.4), but there was no statistically 
significant difference between untreated controls including DMSO and the control 
medium. This suggest that there was medial depletion due to progressive growth and 
multiplication of prostate cancer cells in the untreated controls which was not same in 
the TG003 treated cells in the media. In summary, TG003 treatment decreases 
prostate cancer cell growth and proliferation in a concentration dependent manner. 
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We also considered the effect of TG003 on a normal prostate cell line (PNT2) 
compared with the prostate cancer cell lines (PC3 and DU145). Our results examining 
cell proliferation using Ki67 show that PNT2 (normal prostate epithelia cell line) is less 
sensitive to Ki67 than prostate cancer cell line (PC3 and DU145) (figure 4.5C).  
 
6.4 Effect of TG003 on PCa cell apoptosis 
Having observed that TG003 treatment inhibits prostate cancer cell growth, viability 
and proliferation, we examined the effect on apoptosis. Apoptosis (programmed cell 
death) occurs in response to severe cell damage (Norbury and Hickson, 2001). 
Apoptosis refers to a coordinated cascade of events and energy dependent processes 
leading to cysteine proteases (caspases) activation. Interestingly, cells respond and 
react differently to pathological and physiological apoptotic stimulating agents. For 
instance, corticosteroid hormones may trigger apoptosis in some cells such as 
thymocytes while other cells are unaffected. Cancer therapeutic drugs and irradiation 
results in DNA damage which can trigger apoptotic cell death in a TP53-dependent 
pathway. Apoptosis can also be triggered by TNF or Fas expressed by some cells. 
However, necrosis should not be mistaken for apoptosis as both processes result in 
cell death which may occur simultaneously, independently and sequentially depending 
on the degree, duration and type of stimulating agent (Zeiss, 2003). In most cases, it 
is the nature and the intensity of stimuli that determines whether a cell dies by necrosis 
or apoptosis. For instance, apoptosis may occur at low doses of heat shock, hypoxia, 
radiation and anticancer cytotoxic drugs; however, the same stimuli at increased 
doses can induce necrosis. 
At the early stages of apoptosis, there is evidence of visible pyknosis and cell 
shrinkage. Pyknosis is due to chromatin condensation and is one of the major features 
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of apoptosis. Features of cell shrinkage include: smaller sized cells, dense cytoplasm 
and tightly packed organelles (Hacker, 2000; Kerr et al., 1972). Histologically, eosin 
and haematoxylin stains identify apoptotic cells as a purple nuclear fragment with a 
spherical dark eosinophilic cytoplasm. 
Apoptosis involves two major pathways: (a) the death receptor pathway otherwise 
called the extrinsic pathway (b) the intrinsic or mitochondrial pathway. Research 
indicates that the two pathways are interlinked such that molecules from one pathway 
can influence the other. Another form of the intrinsic pathway is the granzyme/perforin 
which is a T-cell mediated cytotoxicity pathway (Igney and Krammer, 2002). The latter 
pathway can trigger apoptosis through granzyme A or B. The above pathways 
converge at the execution pathway initiated by caspase-3 and the whole process 
finally results to fragmentation of DNA, cytoskeletal and nuclear protein degeneration, 
protein cross linking apoptotic bodies formation, ligands expression for phagocytic cell 
receptors and uptake by phagocytic cells. 
 
The Bclx apoptotic regulator is alternatively spliced into anti-apoptotic (BclxL) and 
proapoptotic (BclxS) variants. BclxL is overexpressed in many cancers including 
prostate cancer and has been linked to chemoresistance and a vital target for cancer 
therapy. Increased prostate cancer metastasis is associated with over expression of 
BclxL (Mercatante et al., 2001). Apoptotic induction and increased chemosensitivity 
has been found in both breast and prostate cancer cells through redirection of BclxL 
to BclxS pre-mRNA splicing by blockade of the alternative 5’ splice site with an 
antisense oligonucleotide in Bclx intron 2 (Mercatante et al., 2001). BclxS is a potential 
antagonist of BclxL and inhibits the pro-survival properties of BclxL to induce 
apoptosis. High level of apoptotic BclxSvariant has been found in patients with 
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resolving stomach and colon cancers and in nude mice with breast cancer (Gryco et 
al., 2012). 
  
Using acridine orange staining, we investigated the effect of TG003 on apoptosis. We 
observed apoptotic bodies in cells treated with increasing concentrations of TG003 
compared with the controls (figure 4.6). There was a statistically significant percentage 
apoptotic difference between control and TG003 treated prostate cancer cells 
especially at concentrations ≥10 µM of TG003. We proceeded to consolidate our 
results by staining both TG003 treated cells and untreated controls with caspase 3/7 
antibody. There was a significant increase in apoptosis especially following higher 
doses of TG003 compared with the control (figure 4.8). We also tested for apoptosis 
using apoptotic genes such as caspase 9, Bclx, Survivin and Mcl1 genes. In each of 
these genes, the pro-apoptotic isoforms were expressed in an increasing order of 
TG003 concentrations (figure 4.7). In summary, our findings suggest that chemical 
treatment with TG003 induces apoptosis as well as inhibiting cell proliferation.  
 
Other groups have also reported similar findings. Marcel et al., (2014) reported 
increased apoptosis in TG003 treated cells. Araki et al., 2015 also reported that TG003 
treatment increased apoptosis.  
We also examined the effect of TG003 on apoptosis in PNT2, normal prostate 
epithelium cells. Caspase 3/7 apoptotic immunofluorescence staining suggested that 
less apoptosis was induced in PNT2 cells compared to PC3 and DU145 prostate 
cancer cell lines (figure 4.8). 
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6.5 Effect of TG003 treatment on prostate cancer cell biology 
6.5.1. Effect of TG003 on cell migration and invasion 
Having shown that CLK1 inhibition via TG003 induces apoptosis, suppresses growth 
and proliferation of prostate cancer cell lines, we then investigated the effect of CLK1 
inhibition on cell biology such as cell migration and invasion, wound healing scratch 
assays of prostate cancer cell lines (figures 4.9, 4.10, respectively). Results show that 
TG003 inhibits prostate cancer cell (PC3) migration and invasion (figure 4.9 A and B) 
in transwell inserts in a dose dependent manner. There was a statistically significant 
difference between controls and 10- 50 µM TG003 treatments in scratch assays in a 
time and dose dependent manner particularly in PC3 cells (figure 4.10, 4.11).  
6.5.2 Effect of TG003 on the expression of E-cadherin  
In prostate cancer, E-cadherin has been implicated as a possible prognostic indicator 
because of its decreased expression in higher-grade tumours associated with poor 
outcome. Loss of E-cadherin is associated with the prostate cancer transition to the 
mesenchymal phenotype associated with cancer aggressiveness, migration and 
invasion (Putzke et al., 2011). 
We therefore examined E-cadherin expression in treated cell lines (figure 4.12A and 
B). In untreated cells we could see clear vimentin expression and low E-cadherin 
(consistent with a mesenchymal phenotype) but this was reversed following TG003 
treatment (figure 4.12C and D). E-cadherin expression is an important prostate cancer 
prognostic indicator (Umbas et al., 1992; Umbas et al., 1994). For instance, using 
monoclonal E-cadherin antibody and frozen snap prostate tissues, Umbas et al., 
reported high E-cadherin expression in a low Gleason score cancer from 4-7, while at 
the same time they observed low or almost complete absence of E-cadherin 
expression in metastatic advanced high grade prostate cancers with high Gleason 
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scores from 10 -13. In other words, they reported increased E-cadherin expression in 
a decreasing Gleason prostate tumour scores (Umbas et al., 1992; Wang et al., 2017). 
Furthermore, in 2017, Wang et al., reported that E-cadherin downregulation promotes 
prostate cancer chemoresistance (Wang et al., 2017). Fan et.al, 2012 proposed that 
prostate cancer metastasis is enhanced by loss of E-cadherin expression through 
metastasis- associated-1- gene (MTA-1) upregulation. Our findings therefore suggest 
that TG003 reverses the mesenchymal phenotype and this is consistent with the 
observed reduction in cell migration and invasion. This is also in agreement with the 
work of Deep et al., (2011) who also reported increased E-cadherin expression in the 
context of anti-invasion and anti-migration silibinin treatments of prostate cancer cells 
(Deep et al., 2011). 
6.5.3 Effect of TG003 on the expression of vimentin  
Increased vimentin expression is associated with prostate cancer metastasis, 
increased migration and invasion (Wei et al., 2008) consistent with the properties of 
PC3 cells, a highly proliferative and tumorigenic cell line that readily metastasizes. 
Other studies have also demonstrated high vimentin expression in metastatic and 
invasive prostate cancer cells (Craven et al., 2006; Singh et al., 2003; Vasko et al., 
2007; Liu et al., 2003; Sateli and Li 2011; Vuoriluoto et al., 2010). It was suggested 
that vimentin is more expressed in motile or migratory and highly invasive prostate 
cancer cells, but down-regulated in non-motile or degreased migration and invasive 
prostate cancer cells (Lang et al., 2002). Based on this, it has been suggested that 
high vimentin expression is a poor prognostic marker in prostate cancer (Sateli and Li, 
2011). Singh et al., (2003) also reported that upregulation of vimentin fuels the 
invasiveness of androgen independent prostate cancers. We noted a clear decrease 
in vimentin expression via immunofluorescence staining following TG003 exposure 
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(figure 4.12C, D). Additional experiments, however are needed to measure accurately 
the effect of TG003 on the expression of vimentin using more quantitative methods 
such as realtime PCR. 
 
6.5.4 The importance of EMT in prostate cancer 
The chemoresistance of prostate cancer (PCa) is invariably associated with the 
aggressiveness and metastasis of this disease. New emerging evidence indicates that 
the epithelial-to mesenchymal transition (EMT) may play pivotal roles in the 
development of chemoresistance and metastasis. 
EMT is characterised by downregulation of an epithelial marker known as E- cadherin 
and upregulation of vimentin, N-cadherin and Snail which are known mesenchymal 
markers (Nakamura andTokura, 2011). E-cadherin expression suggests epithelial 
phenotype while loss of it suggests a complete EMT and is associated with metastasis 
(Bougen et al., 2013). Studies suggest that EMT is not only associated with 
aggravated prostate cancer invasion and metastasis but also a leading cause of 
prostate cancer chemoresistace (Duran et al., 2015; Li et al., 2014).  
Rubin et al., (2001) systematically evaluated the role of decreased expression of E-
cadherin on prostate cancer progression in a broad range of prostate tissue including 
clinically localised prostate cancer, benign prostate tumour and hormone-refractory 
metastatic prostate cancer. These prostate tissues were analysed using high-density 
tissue microarrays (TMA) under same condition. After analysing 1,220 prostate TMA 
samples, Rubin et al discovered that 87% E-cadherin expression in benign samples 
and clinically localised prostate cancers, while there was a statistically significant 
correlation between aberrant E-cadherin and higher Gleason score, large tumour size 
and PSA failure prostate cancer suggesting that loss of E-cadherin expression is 
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linked with aggressive, invasive and metastatic forms of prostate cancer. In general, 
aberrant E-cadherin is associated with advance form of cancers including prostate 
cancer. Furthermore, in several clinical studies, E-cadherin has been reported to be 
silenced, downregulated or aberrantly expressed in many cancer types (Sharma and 
Lichtenstein, 2009). Fan et al. (2012) showed the knockdown of E-cadherin results in 
increased expression of the MTA-1 gene. Overexpression of MTA-1, (metastatis-
associated gene encoding a protein involved in chromatin remodelling) is associated 
with invasion, metastasis and high grade prostate cancer (Dannenmann et al., 2008; 
Ryu et al., 2008). Toh and Nicolson, (2009) reported that MTA-1 is capable of 
potentiating the conversion of cancer cells including prostate cancer into a devastating 
aggressive prostate cancer when factors such as hypoxia‑inducible factor‑1α (HIF‑1α), 
oestrogen receptor α (ERα) and p53 protein are repressed. It is now very clear that 
MTA-1 and E-cadherin are deeply involved in the EMT process, however, it has not 
been investigated whether E-cadherin has any effect on MTA-1 expression (Radaelli 
et al., 2009).  
 
Another EMT factor that play a role in the aetiology and pathogenesis of prostate 
cancer progression, migration, invasion, metastasis and aggressiveness is the 
vimentin. Vimentin is a 57KDa protein and a major component of intermediate filament 
(IF) widely expressed only in mesenchymal cells. One of the crucial roles of vimentin 
is to maintain cellular integrity and resists cellular stress (Satelli and Li., 2011). 
Overexpression of vimentin has been reported in prostate cancer epithelial as well as 
epithelial of other cancer types such as CNS tumour, GIT tumour, breast cancer, lung 
cancer, malignant melanoma and others. Overexpression of vimentin in prostate 
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cancer correlate with poor prognosis, rapid tumour growth, migration, invasion and 
prostate cancer aggressiveness. 
Evaluation of vimentin expression in normal and malignant tissues is an essential tool 
in prostate and other cancers diagnosis and prognosis. During prostate cancer 
progression, vimentin expression is detectable in mobile cancers especially in bone 
metastasis and poorly differentiated prostate cancer (Zhao et al., 2008). 
Downregulation of vimentin in prostate cancer cells is associated with less tumour 
motility which also suggests decreased tumour migration and invasion. While the 
reverse is the case of vimentin overexpression. Many authors support the assertion 
that vimentin is upregulated in most aggressive prostate cancer and contributes to 
prostate cancer progression, migration and invasiveness (Sethi et al., 2010). 
Therefore, vimentin expression does not only serve the purpose of prostate cancer 
detection but also involved in the development and progression of prostate cancer. 
Vimentin is also expressed in other cancers such as breast, lung, gastrointestinal tract, 
renal and cervical cancers. Others include malignant melanoma, CNS tumour, thyroid 
and endometrial carcinomas (Satelli and Li., 2011; Coppola et al., 1998). Gilles et al., 
(2003) reported increased vimentin expression in many aggressive breast cancers 
which also correlate with increased invasion and migration of such cancers. 
There is a growing interest by cell biologists on how to explore the therapeutic 
potentials of targeting vimentin E in the contest of human prostate cancer. This interest 
arose from the fact that vimentin E has been found to be overexpressed during 
malignant prostate cell transformation resulting in aggravated prostate cancer risk 
thereby presenting vimentin E as an excellent target for therapy (Klein et al., 2011). 
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In the current study, we have shown that TG003 (a potential and specific CLK1 
inhibitor) exhibited a potential anti-migratory and anti-invasive properties in prostate 
cancer cells as evidenced by series of experiments such as migration, invasion and 
scratch assays. TG003 also caused a significant suppression of highly metastatic and 
invasive prostate cancer cells (PC3) (figure 4.9). We also demonstrated that TG003 
exhibited an inhibitory function in both PC3 and DU145 prostate cancer cell motility 
which is closely related to cell migration (figure 4.10), this effect is more prominent in 
PC3 cell lines as demonstrated in scratch assays. However, the mechanism of the 
anti- migration and invasion of TG003 in metastatic prostate cancer cell lines is yet to 
be understood. The preliminary findings reported here, namely that TG003 reduces E-
cadherin while increasing vimentin could be highly significant, given the importance of 
EMT in prostate cancer. 
 
6.6 Effect of TG003 treatment on tumour volume in vivo 
Drastic significant reduction of tumour volume was observed on administration of 50 
µM of TG003 intraperitoneally in PC3 xenografts grown subcutaneously in nude mice 
in vivo (figure 5.3). In comparison, Moreira et al., (2018) have used the SRPK1 inhibitor 
SRPIN340 showing a significant decline of melanoma cell migration and invasion in 
vitro, and reduction of melanoma metastasis in vivo with no apparent sign of obvious 
toxicity to normal cells (Moreira et al., 2018). Gammons et al., (2014) also reported 
reduced growth of human melanoma in vivo by both SRPK1 knockdown and its 
pharmacological inhibition independently. Furthermore, in 2015, Mavrou et al., 
reported a decreased PC3 tumour growth in vivo on nude mice treated with SRPK1 
inhibitor, and then proposed that SRPK1 inhibition could pose a future therapeutic 
strategy against prostate cancer. In regards to CLK inhibition, it is already known that 
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its inhibition could be useful in treatment of other pathologies such as viral 
infection.The in vivo inhibition of CLK1 which inhibits influenza viral replication as 
CLK1 is majorly involved in the alternative splicing of M2 gene responsible for 
influenza viral proliferation and multiplication (Zu et al., 2015).  In the context of cancer, 
interestingly, recent work has highlighted the potential utility of targeting CLK1 and 
CLK2 in triple negative breast cancer cell lines (Zhu et al, 2018). Work presented here 
further strengthens the idea that CLK inhibition, either as an alternative to or in 
combination with SRPK1 inhibition, could offer additional benefit in the development 
of therapies for treatment of prostate, breast and potentially many other types of 
cancer. 
 
6.7 Summary of key findings 
In conclusion, accumulated evidence suggests that chemical inhibition of CLK1 with 
TG003 treatment suppresses growth, proliferation, migration and invasion at 
increased concentrations and induced apoptosis in prostate cancer cell lines. 
Administration of TG003 to cultured prostate cancer cells causes CLK1 inhibition 
resulting to efficient CLK1 splicing leading to more CLK1 protein. We now know that 
alternative splicing of CLK1 itself regulates how much CLK1 protein is made. There is 
evidence of differently CLK1 splicing in a panel of human cell lines. TG003 treatment 
changes splicing and induced mutated exon 4 skipping in a dose dependent manner 
(10nM-100µM). There is evidence of feedback loop in which CLK1 actively regulates 
its own splicing. We also discovered that normal prostate cell line treated with TG003 
are less sensitive to proliferation and apoptosis assays compared to its counterpart 
cancer cell lines. 
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In summary, TG003 treatment may be a valuable tool for alternative splicing 
modulation and potentially for the development of a novel anticancer therapy. However 
further work is necessary to determine the mechanism through which CLK1 inhibition 
modifies alternative splicing.  
 
6.8 Concluding remarks 
It is very clear that TG003 inhibits growth of prostate cancer cell lines, though the 
detailed underlying mechanism of the anti-cancer effect of TG003 is yet to be studied. 
In this report, TG003 treatment significantly inhibited prostate cancer cells proliferation 
in a time and dose dependent manner. TG003 also markedly suppressed prostate 
cancer cell migration and invasion, significantly induced apoptosis and reduced 
tumour volume in xenografts grown in nude mice. These investigations provide a novel 
insight into the molecular activities of TG003 and present it, and CLK inhibition more 
generally, as novel antitumour approach. Further studies are needed to investigate in 
more detail the therapeutic potential of CLK inhibition in the context of not only prostate 
but surely many other types of cancer.                                                   
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6.9 Future work 
6.9.1 siRNA knockdown in vivo 
SiRNA-mediated RNA interference of CLK1 worked in in vitro assays confirming the 
effect of TG003 on cell proliferation, apoptosis and wound healing assays in PC3 cells. 
It would be useful to repeat CLK1 siRNA knockdowns in other prostate cancer cell 
lines, attempting additional assays including measurement of EMT markers, and 
transwell migration and invasion assays. We have also established that TG003 
treatment reduces PC3 tumour xenograft growth in vivo. It would be of interest to 
establish an shRNA mediated stable or inducible knockdown of CLK1 in PC3 and other 
prostate cancer cell lines and to perform additional xenograft assays. 
6.9.2 Determination of the effect of TG003 on normal tissues 
In common with most drug treatments it is of course possible that TG003 cause 
widespread side effects. Within the scope of the experiments conducted so far, with 
50µM TG003 injections there was no visible adverse effect on the mice. It would be 
useful to investigate this in more detail and examine the effect of TG003 on critical 
organs such as the liver and kidneys, sites of drug metabolism, for any toxic effects.  
6.9.3 Testing novel CLK inhibitors in prostate and other cancer cell lines 
This project was focused on CLK splice factor kinase inhibition, particularly CLK1, 
using a well-studied inhibitor, TG003. However, clearly more specific CLK inhibitors 
are needed, and we have begun a collaboration with the University of Strathclyde, 
Scotland, to test novel and ideally more specific CLK inhibitors. We will be repeating 
the assays describe herein examining alternative splicing, cell line proliferation, 
apoptosis, migration and invasion, and xenograft work. Similar experiments could also 
be conducted in other cell line models; there is a wide choice. One possible avenue, 
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in line with recent literature, could be to turn attention to triple negative breast cancer 
for which there are very limited treatment options. 
6.9.4 Determination of the splice factors involved in the autoregulatory mechanism of 
CLK1 inhibition 
We have confirmed that inhibition of human CLK1 results in increased CLK1 protein 
expression probably through an autoregulatory or feedback mechanism that involves 
its alternative splicing. It will be interesting to determine how this feedback mechanism 
works (for example, which splice factors are specifically involved in regulating exon 4 
skipping and intron 4 retention). Presumably a specific set of splice factors bind to 
regulatory sequences within cassette exon 4, and surrounding intronic sequences, 
including intron 4. It could be speculated that in normal physiological conditions, for 
example, exon 4 inclusion is not maximised due to a trans-acting repressor of splicing, 
but that in cellular stress responses the repressor’s activity is diminished. Conversely, 
an activator of exon 4 inclusion becomes more active in response to cellular stress. 
Future work will address these possibilities, identifying the splice factors involved. It 
will also be of interest to determine whether exon 4 inclusion and intron 4 retention are 
coordinately regulated, or if their regulation is through entirely different mechanisms. 
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APPENDICES 
APPENDIX I: Alignment of human and mouse CLK1 mRNAs showing the 
position of designed primers 
Note that R primers were designed as the antiparallel sequence. The position of exons 
is shown on the mouse: human alignment. 
 
Clk1 exon 1FA        Unmodified DNA Oligo                                  
                     5'-CTGGTAGAAGTGGAAGAAGTAG-3' 
                     0.01 
 
Clk1 exon 1FB        Unmodified DNA Oligo                                  
                     5'-CAAGGATGTGAACCTGGACATCGC-3'  
                     0.01 
 
Clk1 exon 2FA        Unmodified DNA Oligo                                  
                     5'-AGGAGTGTAGAGGATGATGAGG-3'  
                     0.01 
 
Clk1 exon 2FB        Unmodified DNA Oligo                                  
                     5'-GGAGGGTCACCTGATCTGTCAG-3'   
                     0.01 
 
Clk1 exon 3RA        Unmodified DNA Oligo                                  
                     5'-CTGCTACATGTCTACCTCCCGC-3'   
                     0.01 
 
Clk1 exon 3RB        Unmodified DNA Oligo                                  
                     5'-CTCCTTCACCTAAAGTATCAAC-3'   
                     0.01 
 
VEGF 165b F          Unmodified DNA Oligo                                  
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                     5'-GGCAGCTTGAGTTAAACGAACG-3'   
                     0.01 
 
VEGF 165b R          Unmodified DNA Oligo                                  
                     5'-ATGGATCCGTATCAGTCTTTCCTGG-3'   
                     0.01 
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MouseCLK1       GGTATAGGCCCCGCCCATC-----------------TACGTCACCAGTTTTTCCGAGAAG 43 
HumanCLK1       -GTGCATGACCCGCCCCGCGGCGGAGACGCGCTCGCTGCGTCATCAGTGTTTTCGAGACG 59 
                 **. * *.*******. *                 *.***** **** *** *****.* 
 
MouseCLK1       AAGCTCG-CACTGCGTCTGTCCGCACCATTTTGTGTTGGGAGATCGTCGTAATCGTTTGC 102 
HumanCLK1       AGTCTCGACGCAGCAGCTGTCAGCTCCATTTTGTTGTTGGTGCGCGACGCAGTCAGCTGC 119 
                *. **** *.*:**. *****.**:*********  * **:*. **:** *.**.  *** 
                      Exon1 
MouseCLK1       AGACTTCTCGCCGTCGCCTTGTAAGCTTTGTCT---TCGCCTTGCAAGCTTTGTCTTCAG 159 
HumanCLK1       GTGATTCCCGTGATTGCGTTACAAGCTTTGTCTCCTTCGACTTGGAGTCTTTGTC--CAG 177 
                . ..*** **  .* ** **. ***********   ***.**** *. *******  *** 
                         ●  Exon 2 
MouseCLK1       GGTTGGAAAGATGAGACATTCAAAGAGAACTTACTGTCCTGACTGGGATGAAAGAGACTG 219 
HumanCLK1       G------ACGATGAGACACTCAAAGAGAACTTACTGTCCTGATTGGGATGACAAGGATTG 231 
                *      *.********* *********************** ********.*..** ** 
 
MouseCLK1       GGATTATGGAACATGGAGAAGCAGCAGCAGTCACAAAAGAAAGAAGAGATCACATAGCAG 279 
HumanCLK1       GGATTATGGAAAATGGAGGAGCAGCAGCAGTCATAAAAGAAGGAAGAGATCACATAGCAG 291 
                ***********.******.************** *******.****************** 
                                                                  ● 
MouseCLK1       CGCCCGTGAGCAAAAGCGCTGCAGGTACGATCACTCCAAAACGACAGACAGCTATTATCT 339 
HumanCLK1       TGCCCAGGAGAACAAGCGCTGCAAATACAATCACTCTAAAATGTGTGATAGCCATTATTT 351 
                 ****. ***.*.**********..***.******* **** *: :** *** ***** * 
                    Exon 3 
MouseCLK1       GGAAAGCAGATCCATAAATGAGAAAGCTTATCATAGTCGACGCTATGTTGATGAATACAG 399 
HumanCLK1       GGAAAGCAGGTCTATAAATGAGAAAGATTATCATAGTCGACGCTACATTGATGAGTACAG 411 
                *********.** *************.****************** .*******.***** 
 
MouseCLK1       GAATGACTACAT---GGGCTACGAGCCAGGGCATCCCTATGGAGAACCTGGAAGCAGATA 456 
HumanCLK1       AAATGACTACACTCAAGGATGTGAACCTGGACATCGCCAAAGAGACCATGAAAGCCGGTA 471 
                             CAAGGATGTGAACCTGGACATCGC 1FB 
                .**********    .**.*. **.**:**.**** * *:.****.*.**.****.*.** 
 
MouseCLK1       CCAGATGCATAGTAGCAAGTCCTCTGGTAGGAGTGGAAGAAGCAGTTACAAAAGTAAACA 516 
HumanCLK1       TCAGAACCATAGTAGCAAGTCTTCTGGTAGAAGTGGAAGAAGTAGTTATAAAAGCAAACA 531 
                                       CTGGTAGAAGTGGAAGAAGTAG 1FA 
                 ****: ************** ********.*********** ***** ***** ***** 
 
                                                       ●       Exon 4 
MouseCLK1       CAGGAGTCGCCACCACACTTCGCAGCACCATTCACACGGGAAGAGTCACCGAAGGAAAAG 576 
HumanCLK1       CAGGATTCACCACAGTACTTCACATCGTCGTTCACATGGGAAGAGTCACCGAAGGAAAAG 591 
                ***** **.****.. *****.** *. *.****** *********************** 
 
MouseCLK1       ATCGAGGAGTGTAGAGGATGATGAGGAGGGTCACCTGATCTGTCAGAGTGGAGACGTACT 636 
HumanCLK1       AACCAGGAGTGTAGAGGATGATGAGGAGGGTCACCTGATCTGTCAGAGTGGAGACGTACT 651 
                                        GGAGGGTCACCTGATCTGTCAG 2FB 
                    AGGAGTGTAGAGGATGATGAGG 2FA 
                *:* ******************************************************** 
 
                          ●             Exon 5 
MouseCLK1       AAGTGCAAGATATGAAATTGTTGATACTTTAGGTGAAGGTGCTTTCGGAAAAGTGGTGGA 696 
HumanCLK1       AAGTGCAAGATATGAAATTGTTGATACTTTAGGTGAAGGAGCTTTTGGAAAAGTTGTGGA 711 
                                   GTTGATACTTTAGGTGAAGGAG 3RB 
                ***************************************:***** ******** ***** 
 
MouseCLK1       ATGCATCGATCATAAAGTGGGAGGTAGACGTGTAGCAGTAAAAATAGTTAAAAATGTGGA 756 
HumanCLK1       GTGCATCGATCATAAAGCGGGAGGTAGACATGTAGCAGTAAAAATAGTTAAAAATGTGGA 771 
                                GCGGGAGGTAGACATGTAGCAG 3RA 
                .**************** ***********.****************************** 
 
MouseCLK1       TAGATACTGTGAAGCTGCTCAATCGGAAATACAAGTTTTGGAACACTTGAATACAACAGA 816 
HumanCLK1       TAGATACTGTGAAGCTGCTCGCTCAGAAATACAAGTTCTGGAACATCTGAATACAACAGA 831 
                ********************..**.************ *******  ************* 
                              ●   Exon 6 
MouseCLK1       CCCCCATAGTACTTTCCGTTGTGTCCAGATGTTGGAGTGGTTTGAGCATCGAGGTCACAT 876 
HumanCLK1       CCCCAACAGTACTTTCCGCTGTGTCCAGATGTTGGAATGGTTTGAGCATCATGGTCACAT 891 
                ****.* *********** *****************.*************.:******** 
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MouseCLK1       TTGCATTGTGTTTGAACTTCTGGGGCTTAGTACTTATGATTTCATTAAGGAAAACAGTTT 936 
HumanCLK1       TTGCATTGTTTTTGAACTATTGGGACTTAGTACTTACGACTTCATTAAAGAAAATGGTTT 951 
                ********* ********: ****.*********** ** ********.***** .**** 
 
MouseCLK1       TCTGCCGTTTCGAATGGATCATATCAGGAAGATGGCATATCAAATATGCAAATCTGTAAA 996 
HumanCLK1       TCTACCATTTCGACTGGATCATATCAGAAAGATGGCATATCAGATATGCAAGTCTGTGAA 1011 
                ***.**.******.*************.**************.********.*****.** 
 
                 ● 
MouseCLK1       CTTTTTGCATAGTAATAAATTGACTCATACAGACTTGAAGCCTGAAAACATCTTATTTGT 1056 
HumanCLK1       TTTTTTGCACAGTAATAAGTTGACTCACACAGACTTAAAGCCTGAAAACATCTTATTTGT 1071 
                 ******** ********.******** ********.*********************** 
 
MouseCLK1       GAAGTCTGACTACACAGAGGCTTATAATCCCAAAATGAAACGTGATGAACGTACTATAGT 1116 
HumanCLK1       GCAGTCTGACTACACAGAGGCGTATAATCCCAAAATAAAACGTGATGAACGCACCTTAAT 1131 
                *.******************* **************.************** ** :**.* 
 
MouseCLK1       AAATCCAGATATTAAAGTGGTGGACTTTGGAAGTGCAACATATGATGATGAACACCACAG 1176 
HumanCLK1       AAATCCAGATATTAAAGTTGTAGACTTTGGTAGTGCAACATATGATGACGAACATCACAG 1191 
                ****************** **.********:***************** ***** ***** 
 
MouseCLK1       CACATTGGTATCTACAAGACATTATAGAGCACCGGAAGTTATTTTAGCCCTCGGGTGGTC 1236 
HumanCLK1       TACATTGGTATCTACAAGACATTATAGAGCACCTGAAGTTATTTTAGCCCTAGGGTGGTC 1251 
                 ******************************** *****************.******** 
 
MouseCLK1       ACAGCCATGTGATGTCTGGAGCATAGGATGTATTCTTATCGAGTATTATCTTGGATTTAC 1296 
HumanCLK1       CCAACCATGTGATGTCTGGAGCATAGGATGCATTCTTATTGAATACTATCTTGGGTTTAC 1311 
                .**.************************** ******** **.** ********.***** 
 
MouseCLK1       AGTTTTTCCGACTCATGATAGCAGGGAACATTTAGCAATGATGGAAAGGATTCTTGGACC 1356 
HumanCLK1       CGTATTTCCAACACACGATAGTAAGGAGCATTTAGCAATGATGGAAAGGATTCTTGGACC 1371 
                .**:*****.**:** ***** *.***.******************************** 
 
MouseCLK1       ACTACCAAAGCACATGATACAGAAAACCAGGAAACGCAGATATTTCCATCATGATCGATT 1416 
HumanCLK1       TCTACCAAAACATATGATACAGAAAACCAGGAAACGTAAATATTTTCACCACGATCGATT 1431 
                :********.** *********************** *.****** ** ** ******** 
 
MouseCLK1       AGATTGGGATGAACACAGTTCTGCTGGCAGATATGTTTCTCGGCGCTGTAAACCTCTGAA 1476 
HumanCLK1       AGACTGGGATGAACACAGTTCTGCCGGCAGATATGTTTCAAGACGCTGTAAACCTCTGAA 1491 
                *** ******************** **************:.*.***************** 
 
MouseCLK1       GGAGTTTATGCTATCTCAGGATGCCGAACATGAGCTTCTCTTTGACCTCATTGGGAAAAT 1536 
HumanCLK1       GGAATTTATGCTTTCTCAAGATGTTGAACATGAGCGTCTCTTTGACCTCATTCAGAAAAT 1551 
                ***.********:*****.****  ********** **************** .****** 
 
MouseCLK1       GTTGGAGTATGATCCCGCCAAAAGAATTACTCTCAAAGAAGCCCTAAAGCATCCTTTCTT 1596 
HumanCLK1       GTTGGAGTATGATCCAGCCAAAAGAATTACTCTCAGAGAAGCCTTAAAGCATCCTTTCTT 1611 
                ***************.*******************.******* **************** 
 
MouseCLK1       TTACCCACTTAAAAAGCATACGTG-ATTTATAAAC--ACAGTGCTCTGAAAGGAATCTTA 1653 
HumanCLK1       TGACCTTCTGAAGAAAAGTATATAGATCTGTAATTGGACAGCTCTCTCGAAGAGATCTTA 1671 
                * *** :** **.**...** .*. ** *.***:   ****  **** .***..****** 
 
MouseCLK1       CAGACTGTATCAGTCTAGCTTTTAATT---AAGTTATTTTGTATAGCTT---AATTTGTA 1707 
HumanCLK1       CAGACTGTATCAGTCTAATTTTTAAATTTTAAGTTATTTTGTACAGCTTTGTAAATTCTT 1731 
                *****************. ******:*   ************* *****   **:** *: 
 
MouseCLK1       AAACATTTTATGTT----------TTTT---------AGATGCTTTATTAAATACATGGC 1748 
HumanCLK1       AACATTTTTATATTGCCATGTTTATTTTGTTTGGGTAATTTGGTTCATTAAGTACATAGC 1791 
                **..:******.**          ****         * :** ** *****.*****.** 
 
MouseCLK1       CAAACCAAATAACATCTTT--CAGTAATTATAGAATGATTTATTTGGAATAAAATTT--G 1804 
HumanCLK1       TAAGGTAATGAACATCTTTTTCAGTAATTGTAAAGTGATTTATTCAGAATAAATTTTTTG 1851 
                 **.  **: *********  ********.**.*.********* .*******:***  * 
 
MouseCLK1       TGCTTATGAA----------------------TGTATAAAGGTCTATA------------ 1830 
HumanCLK1       TGCTTATGAAGTTGATATGTATCTGAACAGTTTGTTCTAAGTACCATTTTTCTTCCTACT 1911 
                **********                      ***: :*** :* **:             
258 
 
 
MouseCLK1       ---------------------- 
HumanCLK1       TCTATTAAAGAATGGACATAGA 1933 
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